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Abstract
Patients with diabetes exhibit hyperglucagonemia, or excess glucagon secretion. The
glucagonocentric hypothesis of diabetes states that hyperglucagonemia, rather than
hypoinsulinemia, may be the underlying mechanism of hyperglycemia of diabetes. Thus,
uncovering mechanisms that regulate glucagon secretion from pancreatic α-cells is
crucial for developing treatments for hyperglycemia. One clue to the regulation of
glucagon secretion may lie in the proteins that interact with glucagon in α-cell’s secretory
pathway, primarily within the secretory granule. The purpose of my work was to identify
proteins that interact with glucagon within the secretory granule and characterize a
candidate protein within this network that regulates the intracellular trafficking of
glucagon to control its secretion.
To identify secretory granule proteins that interact with glucagon, I purified secretory
granules from α-TC1-6 cells. I then used affinity purification using tagged glucagon to
isolate protein complexes that interact with glucagon, and identified these proteins
through liquid chromatography/mass spectrometry. In this way, I identified a glucagon
“interactome” within the α-cell secretory granule. I found that components of the
interactome changed in response to different glucose concentrations, and to treatment
with the paracrine inhibitors insulin and GABA.
Next, I characterized the function of one interactome protein, the neuronal cytoskeletal
protein stathmin-2, in glucagon secretion. Through overexpression and siRNA-mediated
silencing of stathmin-2 in α-TC1-6 cells, I showed that stathmin-2 is a tonic inhibitor of
glucagon secretion. Using confocal high-resolution immunofluorescence microscopy, I
found that stathmin-2 exerts its regulatory role by trafficking of glucagon to the
endolysosomal system.
Finally, I examined how the trafficking role of stathmin-2 is altered in the
hyperglucagonemia of diabetes. Using isolated islets from a mouse model of diabetes, I
showed that the increase in cellular glucagon was accompanied by a reduction in
stathmin-2 levels. Confocal microscopy analysis indicated that, in diabetes, there is a
switch from the anterograde trafficking of glucagon towards the lysosome to retrograde
i

trafficking towards secretory granules, possibility mediated by the endosomal protein
Rab7.
In summary, my thesis describes the discovery of a regulatory mechanism for glucagon
secretion from α-cells that may operate in hyperglucagonemia. These findings have
clinical application for treatment of hyperglycemia of diabetes.

Keywords
Keywords: glucagon, secretory granule, glucagon secretion. proteomics, stathmin-2,
diabetes, endolysosome
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Summary for Lay Audience
People with diabetes have an abnormal amount of a hormone called “glucagon” in their
blood, which seriously increases blood sugar. Glucagon is released from a cell called
“alpha cell”, which is in the gland of the pancreas. My research was to discover some
proteins within a special structure in alpha cells called “secretory granule” that control
the release of glucagon. I found that the type and numbers of proteins within the secretory
granule changed when I exposed alpha cells to suppressors of glucagon secretion (insulin
or GABA). This would mean that those proteins are candidates for decreasing glucagon
secretion (stathmin-2 being one of the proteins). I found that both glucagon and stathmin2 are located within the secretory granule of a mouse’s pancreas in a close distance from
each other. By using a genetic technique, I removed stathmin-2 from the alpha cell and
found that cells released a lot of glucagon. On the other hand, when alpha cells produced
a lot of stathmin-2, they did not secrete glucagon. There is a structure within alpha cells
called “endolysosome”. I found that when there is a lot of stathmin-2 within the alpha
cell, it directs glucagon into the endolysosome, where it is destroyed. However, when
there is a lack of stathmin-2 in alpha cells, glucagon is not destroyed in the
endolysosome. These mean that stathmin-2 controls glucagon secretion through
endolysosome. I then proposed that, in diabetes, glucagon is not destroyed in the
endolysosome. This is the reason for high glucagon secretion from the pancreas. To test
this idea, I found that, in diabetic mice, there was very little stathmin-2 versus lots of
glucagon in its pancreas. Then, by using advanced microscopic studies, I found that both
glucagon and stathmin-2 were not destroyed in the endolysosome of alpha cells in the
diabetic mouse. I found that stathmin-2 collected into a structure called “late endosome”,
and at the same time, alpha cells showed an increase in glucagon secretion. Therefore,
stathmin-2 is a novel molecule that can control glucagon secretion. In future studies, it
could be used to decrease high blood sugar in people with diabetes.
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Chapter 1
1.1

Introduction

Diabetes as a widespread disease affects around half a billion people worldwide and is
mainly categorized to type 1 and type 2 diabetes (1). Based on World Health
Organization projections, diabetes will be affecting around 2 billion people by 2040,
which would have a severe impact on global health. According to the Public Health
Agency of Canada (www.canada.ca/en/public-health), diabetes affected 3.4 million
Canadians in 2015 (9.3% of the population). Based on this report, the prevalence was 1 in
300 for younger people (≤ 19 years old) and 1 in 10 for those over 20 years of age. The
prevalence of diabetes in Canada is predicted to grow to 5 million (12.1% of the
population) by 2025, a 44% increase compared to 2015 (2).
The β-cell of pancreatic islet secretes insulin, which reduces high blood glucose levels
and the α-cell secretes glucagon that counteracts insulin actions and increases blood
glucose levels. Thus, euglycemia is achieved when there is a fine balance between
functions of these two hormones. However, diabetes disrupts this balance, resulting in
fasting hyperglycemia that is characteristic of diabetes (3–5). Preclinical and clinical
findings in all diabetic models and clinical cases of diabetes also show a level of
hyperglucagonemia, even in well-controlled diabetes (6). In particular, people with type 2
diabetes have fasting hyperglucagonemia and defects in postprandial glucagon
suppression (4). This hyperglucagonemia exacerbates the pathological consequences of
diabetes such as hyperglycemia, hyperaminoacidemia, obesity, and cardiovascular
diseases. Therefore, the impact of consistent hyperglucagonemia in diabetes has brought
up questions up on how hyperglucagonemia exacerbates the pathophysiology of diabetes,
and the development of potential pharmacological interventions targeting
hyperglucagonemia for the treatment of diabetes (4,7). Uncovering the molecular
mechanisms of glucagon secretion and action as the key to understanding the
pathogenesis of hyperglucagonemia has been a relatively recent focus in diabetes
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research. In fact, some recent findings have suggested that glucagon secretion should also
be a main target for the treatment of diabetes(4,8).
In this Introduction, I have first described the physiological actions of glucagon. I then
discuss the role of glucagon in the development and pathophysiology of diabetes. I have
specifically focused on hyperglucagonemia as the underlying mechanism of
hyperglycemia in diabetes. I have reviewed the current literature on the cellular pathways
governing normal and abnormal glucagon secretion, and emphasized what the latest
proteomic studies have revealed on the alterations in the α-cell secretory pathway in
relation to diabetes. This provided a rationale for my study to interrogate a protein within
the secretory granule, which regulate glucagon secretion.

1.2

Glucagon and its general function in metabolism

Glucagon, a 29 amino acid peptide, is a product of the post-translational processing of
proglucagon by the enzyme prohormone convertase 2 (PC2) within the secretory pathway
of pancreatic α-cells(9–11). Glucagon is then stored within secretory granules and
secreted in response to nutritional, hormonal and neural factors. It is the major glucose
counter-regulatory hormone, and also functions in lipid and protein metabolism and
energy expenditure. In a general view, glucagon increases hepatic gluconeogenesis and
glycogenolysis and by this means regulates glycemia. In terms of lipid metabolism, it
increases lipolysis and ketogenesis. Regarding protein metabolism, it increases both
ureagenesis and uptake of amino acids by the liver. In addition, by reducing the level of
food intake and increasing energy expenditure it participates in energy metabolism (12).

1.2.1

Glucagon and glucose metabolism

Glucagon is the major glucose counter-regulatory hormone. In healthy individuals,
following an overnight fast, blood glucose levels fall to 3.8 mmol/L, which potently
stimulates glucagon secretion to increase blood glucose level towards its normal range (45.4 mol/L). Then, when blood glucose levels reach above the normal level, glucagon
secretion will be suppressed (13–15). Glucagon exerts it actions by binding to the
glucagon receptor, a class B seven- transmembrane G-protein coupled receptor that is
highly expressed in the liver. It is also present in the central nervous system, kidney,
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gastrointestinal tract and pancreas. Following the binding of glucagon with its receptor, it
triggers Gαs-coupled proteins, which activates downstream adenylate cyclase, and
production of cAMP. The increased level of cAMP activates both protein kinase A
(PKA) and cAMP response element-binding (CREB) protein. CREB enhances
gluconeogenesis through increasing transcription of both glucose 6-phosphatase and
phosphoenolpyruvate carboxykinase (PEPCK). At the same time, PKA activates fructose
2, 6-bisphosphatease and inactivates phospho-fructokinase 2, increasing levels of fructose
6-phosphate and potentiation of gluconeogenesis and suppression of glycolysis. PKA also
increases fructose 1,6-bisphosphate and decreases pyruvate levels, which consequently
suppresses glycolysis. In addition, PKA activates phosphorylase kinase that results in
glycogenolysis and improved levels of glucose 1-phosphate and simultaneously
suppression of glycogen synthase (16).
However, in the absence of glucagon action, the counter-regulation of glucose
metabolism still occurs. Inducing glucagon deficiency by either blocking glucagon
action through anti-glucagon antibodies or deleting the glucagon receptor in mice did not
result in hypoglycemia. In the absence of glucagon, glucose counter-regulation can occur
through the glucocorticoid hormone cortisol, (17), and through the actions of the
catecholamines, norepinephrine and epinephrine (18,19).Taken together, all of these
hormones target the liver to release glucose, with catecholamines, especially epinephrine,
playing a redundant role in glucose counter-regulation(19).

1.2.2

Glucagon and lipid metabolism

In hepatocytes, glucagon reduces hepatic fatty acid biosynthesis and simultaneously
increases fatty acid oxidation. Glucagon receptor signaling through cAMP results in
inhibition of acetyl-CoA carboxylase (ACC), prevention of malonyl-CoA formation and
suppression of fatty acid biosynthesis; 2) increases the AMP/ATP ratio, which activates
5' AMP-activated protein kinase (AMPK), inhibits ACC and suppresses fatty acid
biosynthesis and enhancing β-oxidation of fatty acids; and 3) activates CREB,
peroxisome proliferator-activated receptor-α (PPAR-α) and forkhead transcription factor
A2 (FoxA2), which enhance transcription of target genes controlling β-oxidation (20).
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Triggering fatty acid oxidation is a protective mechanism that provides energy for the
fight-or-flight response. However, whether glucagon exerts its lipolytic actions directly
on human adipose tissue is a matter of some debate. Even though glucagon induces
lipolysis in rodent adipose tissue, there are ambiguities about its role in human adipose
tissue (20). In vitro experiments show that glucagon increases lipolysis in human
adipocytes at both physiological (3 ng/kg) and pharmacological (0.5 – 1 mg) doses
(21,22). However, physiological concentrations of glucagon did not affect lipolysis in
both healthy people and people with type 1 diabetes (23). In a recently published review
article, it was extensively discussed that pharmacological levels of glucagon (in the range
of 6×10-11 – 10-8 M) has lipolytic effects on rat, bird, rabbit and human adipocytes in
vitro, but that physiological concentrations of glucagon (1-40 pM) did not increase
lipolysis in human adipocytes (20). These controversies about a direct effect of glucagon
on adipocytes also extend to detection of the glucagon receptor on adipocytes. While
following treatment of rat adipocytes with glucagon there was an increased level of Gcgr
mRNA, alteration at the protein level was not shown for the receptor (24). In fact,
determination of glucagon receptor in adipocytes is severely hampered by a lack of a
specific antibody (25). Thus, further molecular research on glucagon action in adipocytes
awaits another technique for detecting the glucagon receptor.

1.2.3

Glucagon and metabolism of protein and amino acids

Glucagon plays crucial roles in amino acids and protein metabolism. In neuroendocrine
of glucagonoma, all affected people show hypoaminoacidemia (26). In contrast, there is a
marked hyperaminoacidemia following total pancreatectomy (27). These effects are
mirrored in experimental animal models, as direct administration of glucagon decreased
blood amino acid levels and increased hepatic ureagenesis (26,28,29), and blocking
glucagon action with anti-glucagon receptor antibodies or silencing of the Gcgr gene
increased amino acid levels. Blocking the hepatic glucagon receptor also brought about
α-cell proliferation (30–32), prompting the description of a hepatic-α-cell axis (32).
Mechanistically, glucagon receptor signaling through cAMP in hepatocytes increases the
transcription of genes encoding amino acid transporters and enzymes involved in
ureagenesis (16), thereby promoting amino acid clearance and metabolism.
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Interestingly, blocking the hepatic glucagon receptor results not only in
hyperaminoacidemia, but also α-cell hyperplasia. Kim et al (2017) showed that after
blocking glucagon action on mouse hepatocytes, there was an increase in expression of
slc38a5, which encodes the neutral amino acid transporter in α-cells. When slc38a5 was
depleted, blocking glucagon action on liver had a very mild effect on α-cell proliferation
(33), indicating that specific amino acids that were transported by SLC38A5, such as
glutamine, functioned in α-cell hyperplasia. Glutamine may promote α-cell hyperplasia
through activation of the nutrient sensor mammalian target of rapamycin complex 1
(mTORC1), since blocking mTORC1 by rapamycin suppresses both induction of slc38a5
and α-cell proliferation (34). Other signaling processes may also mediate the effects of
glutamine on α-cell proliferation (35). Additionally, Dean et al (2017) showed that serum
of the Gcgr-/- mouse enhanced expression of a proliferation marker, Ki67, in α-cells.
They treated intact mouse islets with the serum of Gcgr-/- or Gcgr+/+ mouse, and then
dispersed the islets and prepared primary cell culture. Further analysis showed that serum
fraction of <10 KDa had proliferative effect on α-cells, which contained amino acids, in
particular glutamine (32).
Altogether, these findings suggest a crucial role for glucagon in amino acids and protein
homeostasis.

1.2.4

Glucagon and energy metabolism

In healthy individuals, it was shown that glucagon administration brings about an
increase oxygen consumption and weight loss; however, there are controversies about its
effect in non-diabetic animal models(36,37). Mechanistically, it is proposed that
glucagon increases energy expenditure through its receptor on brown adipose tissue
(BAT). Glucagon’s acute effect on energy expenditure through BAT immediately
appears following its administration, with a rapid up-regulation of FGF21 in BAT of
mice and humans (38), increases in oxygen consumption and changes in the expression of
genes linked to thermogenesis and mitochondrial function in ex vivo BAT of mice (39).
However, depletion of GCGR in BAT does not affect whole body energy expenditure,
suggesting a BAT-independent pathway for glucagon’s effect on energy expenditure. In
humans, glucagon can also mediate its effects on energy expenditure by increasing blood
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cortisol levels (40), which results in higher energy expenditure through increasing the
levels of BAT UCP1 at both the gene and protein levels (41,42).

1.3

The glucagonocentric hypothesis of diabetes

The increased blood glucose levels in diabetes is attributed to β-cell dysfunction
(defective insulin secretion) and insulin resistance in peripheral tissues. The pathogenesis
of diabetes, which includes decreased glucose utilization, increased lipolysis, increased
proteolysis, increased hepatic glycogenolysis, increased ketogenesis and decreased
glycogen synthesis, has historically been attributed to a lack of insulin (43). In the 1970s,
new findings about role of glucagon in metabolism and energy homeostasis led to the
discovery of other mechanisms based on the action of glucagon that could be responsible
for the pathogenesis of diabetes. These findings that led an α-cell research team to
propose a novel theory on pathogenesis of diabetes.
In 1975, Roger Unger and Lelio Orci proposed the “bi-hormonal theory of abnormalities
in diabetes”, which profoundly changed views on pathophysiology of diabetes (41).
Based on this theory, people with diabetes suffer from both a lack of insulin and
excessive glucagon. They described that some diabetes abnormalities are due to lack of
insulin, such as decreased glucose utilization, increased lipolysis and increased
proteolysis, while some other abnormalities such as increased hepatic glycogenolysis,
increased hepatic gluconeogenesis, increased ketogenesis and decreased glycogen
synthesis are caused by excess glucagon levels (44).
Over the next several decades, further research by Unger’s group and other researchers
revealed more biological effects of glucagon on the pathogenesis of diabetes. In 2012,
Unger and Cherrington proposed a “glucagonocentric hypothesis of abnormalities in
diabetes” to describe the pathogenesis of diabetes (3). This hypothesis states that
blockade of glucagon action will reduce hyperglycemia even in case of insulin
deficiency. It was shown that glucagon receptor knockout mice (Gcgr -/- ) were resistant
to STZ-induced diabetes (45) and normalization of hyperglucagonemia in rodent models
of uncontrolled diabetes reversed ketosis (3,44,46), decreased hepatic glucose production
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and mitigated hyperglycemia (3). Thus, hyperglucagonemia plays a crucial, and perhaps
the primary, role in the development of diabetic hyperglycemia (47).
There is a range of relative to absolute hyperglucagonemia in diabetes, which contributes
to both fasting and postprandial hyperglycemia. People with diabetes always have at least
a relative hyperglucagonemia; however, in patients with type 2 diabetes often there is an
absolute hyperglucagonemia. In this state, a carbohydrate meal or glucose load does not
suppress glucagon secretion; instead it paradoxically increases glucagon secretion, thus
reflecting a degree of α-cell dysfunction. Furthermore, in the presence of
hyperglucagonemia, a protein meal often exacerbates glucagon secretion regardless of
blood glucose concentrations. Malfunctioning of α-cells can be due to resistance of αcells to insulin, postprandial disturbance in interaction between glucagon and insulin,
defect in glucose-induced suppression of glucagon secretion, malfunctioning β-cells or
reduced numbers of β-cells, and lack of GLP-1(48,49), all of which lead to exacerbation
of hyperglycemia. Therefore, combating hyperglucagonemia has been spotlighted in
diabetes research over the past few years.
There are two strategies to combat hyperglucagonemia: 1) blocking glucagon action at
target organs; or 2) inhibition of glucagon secretion from α-cells. Blocking glucagon
action can be achieved through: i) glucagon receptor antagonists, in particular small
molecule antagonists, which can allosterically or competitively inhibit glucagon action
(50); ii) Glucagon receptor neutralizing antibody (51); and iii) Antisense oligonucleotides
against the glucagon receptor (52). However, many of the compounds that target the
glucagon receptor have been discontinued at different phases of clinical trials, since they
only have short-term beneficial effects towards reducing blood glucose levels. Their
long-term administration can be accompanied by the following consequences : i) severe
α-cell hyperplasia (20,30,53,54); ii) elevation of hepatic and serum transaminases
(20,29,55); iii) increased risk of hypoglycemia (55–57); iv) increased hepatic glycogen
storage (16); v) increased risk of hyperlipidemia; (58); and vi) increased body weight
(54,57,59).
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1.4
Understanding the mechanisms and
consequences of hyperglucagonemia
In order to understand the mechanisms that underlie hyperglucagonemia, we should know
about the cellular and molecular mechanisms thar regulate glucagon secretion. These
mechanisms have not been as widely studied as insulin secretion from β-cells, as a result,
there are conflicting hypotheses.
Inhibition of glucagon secretion from α-cells is a long-standing puzzle in islet biology. In
fact, there is no single factor to govern glucagon secretion or alter its secretion rate.
Glucagon secretion is simultaneously under the control of nutritional, neural and
hormonal factors, which interact with each other to making a complex set of pathways for
governing glucagon secretion (60). The following three theories have been proposed as
governing mechanisms for glucagon secretion from α-cells; i) Intrinsic mechanism, ii)
Paracrine mechanisms and iii) Extrinsic mechanism (which is not going to be discussed
here).

1.4.1

Intrinsic mechanism of glucagon secretion

This hypothesis states that glucose is the key regulator of glucagon secretion from the αcell. One argument in favour of this hypothesis is that glucagon secretion from isolated
non-diabetic α-cells can respond directly to glucose in the absence of paracrine inputs.
A) Pattern of glucagon secretion from dispersed α-cells and intact islets
1) Glucagon secretion from dispersed α-cells: Isolated non-diabetic mouse pancreatic
α-cells, clonal hamster In-R1-G9 cells(14,61), and non-diabetic human dispersed αcells(62) show a bimodal V-shaped curve in response to increasing glucose
concentrations. Increasing glucose concentrations from 1 to ~7 mM suppresses glucagon
secretion in a dose-dependent manner. On the other hand, increasing glucose
concentrations from 7-20 mM increases glucagon secretion dose-dependently (Figure 11). This profile of secretion suggests that α-cells are equipped with intrinsic mechanism
for regulating glucagon secretion which are effective in the range of 1-7 mM of glucose,
and these mechanisms are ineffective at higher glucose concentrations. It is noteworthy to
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mention that in this context, there is an argument as to whether if glucose- regulated
glucagon secretion in isolated α-cells follow a V shape curve or a dose pattern. A dose
dependent increase in glucagon secretion was shown in FACS sorted rat α-cells(63).

Glucose (mM)

Figure 1-1. V-shape curve of glucagon secretion in response to glucose in
dispersed human non-diabetic α-cells (black line). Red line denotes
response of islets from patients with T2D, which is discussed in the
related section in 1.6.3. The Figure was extracted from reference 62
under the Creative Commons Attribution License
(http://creativecommons.org/Licenses/by/4.0/).

2) Glucagon secretion from α-cells within intact islets: It was shown that increasing
Figure 1-2. Cross-talk among α, β, and δ-cells towards inhibition of
glucose concentration from 1 to 7 mM dose dependently decreases glucagon secretion
glucagon secretion. The Figure was extracted from reference 113 under
from mouse α-cells within intact islets (64) and human intact islets (62). However, by
the Creative Commons Attribution License
increasing glucose concentration from 7 mM to 20 mM glucagon secretion remains low
(http://creativecommons.org/Licenses/by/4.0/).Figure 1-3. V-shape curve
(Figure 1- 2). A U shape curve was shown for glucagon secretion when glucose
of glucagon secretion in response to glucose in dispersed human nonconcentration gradually increased up to 30 mM (61). In other words, 7-20 mM glucose
diabetic α-cells (black line). Red line denotes response of islets from
suppresses glucagon secretion when α-cells are located in their normal anatomical
patients with T2D, which is discussed in the related section in 1.6.3. The
positions within the islet and subject to paracrine regulation from other islet cells.
Figure was extracted from reference 62 under the Creative Commons
Attribution License (http://creativecommons.org/Licenses/by/4.0/).
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Figure 1-2. Glucagon secretion from intact mouse islets. The
Figure was extracted from reference 64 under the license of
https://www.asbmb.org/journals-news/editorial-policies.

B) Mechanisms of glucose-regulated glucagon secretion: Human α-cells transport
glucose into the cell via the glucose transporter GLUT1 and sodium-dependent glucose
transporters SGLT1 and SGLT2. Glucose then has direct effects on glucagon secretion
via the following mechanisms:
1) Effect of glucose on KATP channel conductance: Glucose is subsequently metabolized
to generate ATP which binds to and closes KATP channels at the plasma membrane. (65)
As a result, voltage-dependent Ca2+ channels close, which decreases Ca2+ influx into the
cytosol, thus reducing SNARE protein-mediated docking and fusion of secretory granules
to the plasma membrane (66).
2) Effect of glucose on store-operated current (SOC): While α-cells have potent voltagedependent Ca2+ channels, SOC through Orai1 Ca2+-release-activated channel (CRAC)
also plays an important role in regulation of glucagon secretion from α-cells(67). Under
low glucose conditions, the Ca2+ depletion of the ER causes the translocation of stromal
interaction molecule 1 (STIM1) from the ER to the subplasmalemmal junctions leading
to clustering with Orai1, resulting in SOC activation. It is believed that SOC plays a
central role in glucose inhibition of glucagon secretion and epinephrine-stimulated
10

glucagon secretion(68). It is mentioned that α-cells have a low membrane conductance,
which confers high sensitivity to SOC-induced current(14). In contrast, exposure of αcells to high glucose conditions and subsequent high ATP levels activate the
sarcoendoplasmic reticulum calcium transport ATPase (SERCA) pump, which results in
Ca2+ sequestration from the cytoplasm into the ER. Filling the store with Ca2+ inhibits the
translocation of STIM1, turns off CRAC channel subunit, reduces VDCC activity and
suppresses glucagon secretion (68,69).
3) Effect of glucose on cytosolic levels of cAMP: When high glucose levels strongly
suppress glucagon secretion, there is only a moderate (or temporary) reduction in the
cytoplasmic Ca2+ levels, suggesting the presence of an alternate regulator for glucagon
secretion. Low glucose levels regulate glucagon secretion through increasing cytoplasmic
levels of cAMP, which activates the Epac signaling pathway, stimulating L-type Ca2+
channels and increasing glucagon secretion. Furthermore, it was emphasized that
increased cAMP is accompanied by mobilization of secretory granules into the “readily
releasable pool”, which potentiates glucagon secretion. High glucose levels lower
cytoplasmic levels of cAMP, resulting in PKA-mediated inhibition of N-type or P/Q type
Ca2+ channel and suppression of glucagon secretion (66,70).

1.5
Paracrine and autocrine regulation of glucagon
secretion
1.5.1

Released factors from β-cells

1) Insulin: Insulin plays a key role in the paracrine regulation of glucagon secretion.
Insulin binds to its receptor on the α-cell and suppresses glucagon secretion through
several mechanisms. Insulin receptor signaling through PI3 kinase reduces KATP-channel
activity, causing plasma membrane hyperpolarization and reduced activity of the P/Q
type Ca2+ channel which results in reduced glucagon secretion (71). Insulin receptor
activation also results in the translocation of GABAA receptors from the cytoplasm to the
plasma membrane which activates GABA signaling pathway towards suppression of
glucagon secretion(72). In fact, all of these findings demonstrate that insulin directly
suppresses glucagon secretion from α-cells (73).
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In addition to direct effects on the α-cell, insulin can also inhibit glucagon secretion
through promoting the secretion of somatostatin from δ-cells. Although initial work
failed to find the insulin receptor on δ-cells (74), it has recently been shown that insulin
binds to its receptor on δ-cells and stimulates somatostatin secretion. Then somatostatin
binds to its receptor on α-cells and potently inhibits glucagon secretion (75) (discussed
below).
2) Gamma amino butyric acid (GABA): GABA is a potent suppressor of glucagon
secretion from α-cells (76,77). Activating the GABAA receptor in α-cells results in Clinflux into the cells which hyperpolarizes the membrane and reduces glucagon secretion
(78). As well, there is coordination between insulin and GABAA receptor activity, as
insulin action leads to the translocation of GABAA receptor to the cell membrane(79). In
addition, GABA also inhibits mTOR activity to suppress α-cell proliferation. In type 1
diabetes, due to destruction of β-cells, the amount of secreted GABA is also reduced,
resulting in the activation of mTOR and cell proliferation(80). It has been shown that
activation of GABAA receptor may trans-differentiate adult α- cells to β-like cells(81–
83), in a way that cell secretory granules will pack insulin and respond to glucose.
3) Serotonin: In human islets, serotonin can suppress glucagon secretion in two ways:
through a stimulatory autocrine effect on β-cells to increase insulin secretion and by this
way indirectly suppress glucagon secretion, or by a direct paracrine effect on α-cells
(84,85). Direct effects are mediated by activation of the serotonin receptor, 5-HT1FR, on
α-cells, which reduces intracellular cAMP to suppress glucagon secretion. In patients
with long-standing T2D, the proportion of α-cells expressing 5-HT1FR is decreased,
suggesting that reduced serotonin action on α-cells may play a role in hyperglucagonemia
of diabetes. In STZ-treated mice, administration of the 5-HT1FR agonist LY344864
alleviated hyperglucagonemia and hyperglycemia. However, insulin-induced
hypoglycemia was worsened, suggesting that the effects of serotonin are glucoseindependent. (84). Therefore, while α-cell HT1FR may be a potential target for the
treatment of hyperglucagonemia, it may not be an ideal target.
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4) Amylin: Amylin, a 39 amino acid peptide, is a major component of the islet amyloid
deposit in patients with type 2 diabetes. It is co-released with insulin in response to
nutritional stimuli (86) and is an inhibitor of glucagon secretion. Exogenous
administration of amylin and its agonists potently and profoundly suppresses glucagon
secretion in intact animals or subjects (87). However, there are controversies about
underlying mechanism of Amylin’s effect on glucagon secretion. Some researchers
proposed that Amylin just suppresses glucagon secretion in vivo, and does not have effect
on glucagon secretion in isolated islets and perfused pancreas (88). On the other hand,
some other researchers oppose this idea and believe that Amylin binds to its receptor on
α-cells and its action suppresses glucagon secretion in both in vitro and in vivo conditions
(89). As another proposed mechanism, amylin modulates vagus nerve signals in pancreas,
which inhibits post-meal glucagon secretion (90).
5) Adenosine: There are some controversies about the source of adenosine. One
hypothesis states that the ATP that is co-secreted with insulin is converted to adenosine in
the interstitial matrix of islet (91). However, there are species-related variations in
expression of 5'-ectonucleotidase (92). Adenosine may also be secreted directly with
insulin. Pharmacological concentrations of adenosine may stimulate glucagon secretion
(92), but physiologically, adenosine secreted from β-cells has an inhibitory effect on
glucagon secretion (93). The effects of adenosine are mediated by the adenosine A1
receptor (Adora1), in which activation is coupled to opening of KATP channels,
hyperpolarization of the cell membrane and prevention of granule exocytosis. In NOD
mice, human autoantibody-positive and people with long-term T1D, α-cells gradually
lose Adora1 expression, suggesting that the hyperglucagonemia of diabetes is associated
with a loss of adenosine action (93).
6) Zn2+: The Zn2+ transporter, Slc30A/ZnT8, is a causative gene for T2D, and ZnT8 is
located in the secretory granule membrane of both α-and β-cells. There is a direct
relationship between expression of the proglucagon gene and Slc30A in α-cells (94).
However, there are conflicting findings about the effects of Zn2+ on glucagon secretion
(94). There are reports that, in isolated mouse islets and α-cells, Zn2+ administration
decreases glucagon secretion (95), or has no effect (96). In contrast, treatment of isolated
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human islets with similar concentrations of Zn2+ enhanced glucagon secretion (97). The
reason for these discordant results is not clear; it may be that exogenously administered
Zn2+ or Zn2+ secreted from the β-cell does not have a direct role in glucagon secretion in
normal physiology. Interestingly, in mice lacking Slc30A/ZnT8 specifically in α-cells,
there is a heightened secretory response to 1 mM glucose (98), and overexpression of
ZnT8 specifically in α-cells restricted glucagon secretion in response to 1 mM glucose
(99), suggesting paracrine regulation by Zn2+.

1.5.2

Released factors from α-cells

1) Acetylcholine: In addition to cholinergic innervation of islets from parasympathetic
nerve endings, a cholinergic system is also contained within α-cells: the vesicular
acetylcholine transporter is present on α-cells, and choline acetyltransferase co-localizes
with glucagon in human pancreatic islets (131). Acetylcholine is secreted upon low
glucose stimulation, whereby it acts on M3 muscarinic receptors on β-cells and sensitizes
β-cells for insulin secretion (100). Acetylcholine has an important role in minimizing
blood glucose volatility and potentially aids in survival of β-cells (100,101). Therefore, αcells are equipped with a unique cholinergic-based system that responds to daily
variations in blood glucose.
2) Glutamate: The α-cell contains its own glutaminergic system that regulates glucagon
secretion in an autocrine manner. α-cells express the vesicular glutamate transporter,
VGLUT2, on secretory granules, enabling the transport and storage of glutamate within
the α-cell secretory granules. Both metabotropic and ionotropic glutamate receptors are
present on α-cells, but only ionotropic AMPA/kainite receptor activation was coupled to
glucagon secretion (102,103). Following α-cell exposure to low glucose, a glutamate
feedback loop is activated, which further increases the glucagon secretory response to
low glucose. In this way, the α-cell glutaminergic system guarantees that enough
glucagon is secreted in case of need, which prevents blood glucose
volatility(34,102,104). As well, the secreted glutamate may also activate α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on β and δ-cells , thus
participating in an intra-islet glutaminergic system that finely controls glucose
homeostasis(105). In both patients with diabetes and diabetic mice, glutamate levels are
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significantly increased. It was proposed that glutamate takes a role in development of
diabetes through exaggerated activation of N-methyl-D-aspartate (NMDA) receptors in
β-cells that may result in dysfunction and apoptosis of β-cells(106).
3) Glucagon: Secreted glucagon from α-cells can stimulate its secretion through an
autocrine effect. It has been shown that glucagon stimulates glucagon secretion from the
rat and mouse isolated α-cells in an autocrine manner through glucagon receptorstimulated cAMP signaling (107). Both biosynthesis and secretion of glucagon in human
and mouse α-cells is augmented due to the autocrine effect of glucagon. Thus, targeting
autocrine and paracrine effectors of glucagon secretion, including glucagon, has been
proposed as therapeutic strategies in patients with diabetes(108).
4) Other α-cell proteins: The role of proteins, in particular proteins of secretory granule,
may be new factors that regulate the secretion of glucagon from α-cells. It was shown
that brefeldin A-inhibited guanine nucleotide exchange protein 3 (BIG3) is a conserved
secretory granule protein in α-cells, and negatively regulates glucagon secretion (109). Li
et al (2015) showed that levels of glucagon within the secretory granule were increased in
different animal models of diabetes, in pancreatic islets and isolated α-cells, which may
contribute to higher glucagon secretion in diabetes. Therefore, the α-cell secretory
granule itself may contain other proteins that play a role in the regulation of glucagon
secretion.

1.5.3

Released factors from δ-cells

Somatostatin is a well-known inhibitor of glucagon secretion. Somatostatin binds to its
receptor, SSTR2, on α-cells, activates adenylate cyclase and generates cAMP. In the
downstream process, cAMP activates the serine/threonine protein phosphatase
calcineurin, which results in de-priming of the secretory granule (14). Notably, secretion
of somatostatin and inhibition of glucagon secretion potently occurs at 3mM glucose,
while this level of glucose does not have stimulatory effect on insulin secretion,
indicating that the α-cell response to low glucose may be mediated by somatostatin (110).
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Circulating and pancreatic somatostatin, together with SST mRNA, are elevated in
diabetes. However, expression of SSTR2 on α-cells is decreased in T2D, which makes αcells resistant to somatostatin; together with α-cell insulin resistance, this could be a
reason for paradoxical high glucagon secretion in hyperglycemic condition of
diabetes(62).

1.5.4

Cross-talk among β and δ and α-cells and glucagon
secretion

In gross histology, rodents’ islets are composed of β-cells in the core and non-β-cells in
the periphery. However, in human islets, non-β-cells are intermingled within β-cells(111)
and appear to be organized as “superclusters” of islets(112). Recently, Briant et al (2018)
applied optogenetic techniques to study temporal and spatial cross-talk among mouse
islet cells (Figure 1-3). By this approach, they demonstrated that, under high glucose
conditions, insulin secreted from β-cells suppresses glucagon secretion through insulin
receptor signaling , and through actions on δ-cells mediated by gap junctions (113). As
shown in Figure 1-3, high glucose levels stimulate glycolysis in β-cells to generate ATP,
which closes KATP channels, causing membrane depolarization, Ca2+ influx through the
voltage-dependent Ca2+ channels (VDCC), and insulin secretion (113). Additionally,
following Ca2+ influx into the β-cells, this Ca2+ is transported via gap junction proteins
into δ-cells, causing depolarization of the δ-cell membrane and initiating Ca2+ influx into
the cell through the VDCCs, which results in somatostatin secretion (113). At the same
time, entrance of glucose into the δ-cell and generation of ATP could activate δ-cells
through the KATP channels to release somatostatin (as mentioned in section 1.3.1)(114).
Somatostatin then binds to SSTR2 on α-cells, triggering Gαi and activating G-protein
coupled inwardly rectifying K+ (GIRK) channels, hyperpolarizing the α-cell membrane
and suppressing glucagon secretion(113).
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Figure 1-3. Cross-talk among α, β, and δ-cells towards inhibition of glucagon
secretion. The Figure was extracted from reference 113 under the Creative
Commons Attribution License (http://creativecommons.org/Licenses/by/4.0/).
It has been shown that eliminating insulin receptor on δ-cells completely abolishes the
glucagonostatic effect of insulin, which proposes an indirect glucagonostatic effect for
Figure 1-4. Kinetic model for trafficking of secretory granules in α-cells.
insulin through cell-cell junction. Additionally, the ability of insulin to inhibit glucagon
R(reserve pool); P0(primed pool); F (fused pool); r1(forward resupply rate); rsecretion was lost when either SSTR2 or the sodium-glucose co-transporter 2 (SGLT2)
1(backward resupply rate); Kon(binding rate); Koff (unbinding rate); γ (fusion
were blocked. (75).Thus these findings highlight a central role for δ-cells in the context
rate); r0(granule formation); rF( granule release). The Figure was extracted from
of intra-islet regulation of glucagon secretion, and may have implications for designing
reference 157 according to the Creative Commons Attribution License
drugs for the treatment of hyperglucagonemia of diabetes. Glucagon may also play a role
(http://creativecommons.org/Licenses/by/4.0/).Figure 1-5. Cross-talk among α, β,
in the intra-islet regulation of insulin secretion. In a mouse specifically engineered to
and δ-cells towards inhibition of glucagon secretion. The Figure was extracted
investigate intra-islet regulation, selectively shutting off glucagon secretion resulted in
from reference 113 under the Creative Commons Attribution License
impairment of the insulin secretory response to glucose, resulting in hyperglycemia and
(http://creativecommons.org/Licenses/by/4.0/).
glucose intolerance. Furthermore, it was demonstrated that these actions of glucagon
were mediated through the GLP-1 receptor on β-cells (115). Further studies confirmed
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insulinotropic role of glucagon through the β-cell GLP-1 receptor, in a way that in the fed
state, glucagon cooperates with insulin towards glucose homeostasis instead of
counteracting insulin’s action (116).
In case of diabetes, α-cells do not respond to elevated levels of glucose in a physiological
way, instead paradoxically secreting higher amounts of glucagon. The loss of response to
hyperglycemia may be due to either β-cell secretory defects or α-cell insulin or
somatostatin resistance (117,118). In spite of these proposed mechanisms, the underlying
events of paradoxical glucagon hypersecretion in hyperglycemic condition has not been
fully uncovered.

1.6

Chronic inflammation and diabetes

In the pancreatic islet of people with diabetes, in particular type 2 diabetes, there is a
remarkable reduction in the beta cell population due to the presence of a chronic
inflammation. This chronic inflammation is due to an increased levels of cytokines and
chemokines that affect whole islets (119). In fact, activation of immune system in islets,
triggers proinflammatory response and release of cytokines. Cytokines will be secreted
by both innate immune cells and all parenchymal cells of islets(120). It was shown that in
both human and rodent animal models there is an increase in macrophage infiltration in
islets, which produces and secretes Interleukin-1 (IL-1). To this end, IL-1β plays a master
role in development of inflammation within islets in a way that in the downstream
induces expression of some proinflammatory factors ( such as IL-6, IL-8, IL-1β, CXCL1,
CCL2, and TNF-α)(119). These inflammatory factors bring about ER stress, oxidative
stress, dysfunction of mitochondria, and apoptosis, which result in cell dysfunction.
Furthermore, these adverse effects trigger up-regulation of more inflammatory mediators
(such as CCL2, CXCL1, iNOS and Fas), which amplify inflammatory response, and
exacerbate loss of β-cells (121). In addition, long-term exposure of islets to glucose
induces Fas expression and increases secretion of IL-1β from resident immune cells
within islets. This phenomenon activates amyloid system in islets, which results in
initiation of inflammation. Thus, inflammation, brings about dysfunction in the cell-cell
interaction within islets through inducing malfunction in β-cells, which will be resulted in
dysfunction of δ and α-cells.
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1.7

GLP-1: Intra-islet or intestinal?

In addition to the pancreatic α-cell, proglucagon is also expressed in the intestinal L cell,
where it is post-translationally processed to glucagon-like peptide (GLP)-1 and GLP-2.
GLP-1 is an incretin hormone, secreted following meal ingestion and stimulates insulin
secretion in a glucose-dependent manner. GLP-1 also suppresses glucagon secretion in
both healthy people and people with type 2 diabetes (122), leading to the development of
GLP-1 receptor agonists for the treatment of T2D. The glucagonostatic actions of GLP-1,
the glucagonotropic actions of GLP-2 (123,124) and another incretin, glucose-dependent
insulinotropic polypeptide (GIP) (125,126) all regulate post-prandial blood glucose
levels. This balance is disrupted in diabetes, in particular type 2 diabetes, which results
in dysregulated glucagon secretion and hyperglucagonemia (126).
It has been believed that proglucagon processing to GLP-1 does not occur in pancreatic
α-cells under normal circumstances, due to the relative lack of the processing enzyme
PC1/3 (127). However, this hypothesis has been very recently overturned by a study
showing that there is a substantial subpopulation of α-cells (40%) within the non-diabetic
human pancreatic islets that potently secretes GLP-1(128), and that this subpopulation
increases in T2D. It has previously been shown that, when α-cells encounter metabolic
stress, such as in both T1D and T2D and hyperplasia, the abundance and activity of
PC1/3 increases, cleaving proglucagon to generate GLP-1 (129,130). Therefore, the αcell has a degree of plasticity which allows it to respond to sustained metabolic stress
(131).
It has been postulated that islet-derived GLP-1 may act on β-cells to promote β- cell
regeneration and thus ameliorate hyperglycemia and loss of β-cell mass By considering
generation of GLP-1 in both gut and islet, there is a debate on which source of GLP-1
suppresses glucagon secretion from pancreatic α-cells. Chambers et al (2017) generated
a Gcg knockout mouse and then by reactivation of Gcg in L-cells or α-cells, showed that
islet-generated GLP-1 was primarily responsible for glucose homeostasis by promoting
glucose-stimulated insulin secretion and suppressing glucagon secretion (118). The gut19

derived GLP-1 binds to its receptor on local afferent vagal nerve terminals, which
ultimately signals for satiety, delaying gastric emptying and suppression of hepatic
glucose release (129,132).
How GLP-1 exerts its actions on α-cells is a matter of debate. The search for a GLP-1
receptor on α-cells has been hampered by a lack of a reliable GLP-1 receptor antibody
(127,133). However, GLP-1 appears to mildly reduce action potentials in the α-cell
membrane at 1 mM glucose in isolated mouse α-cells, and this effect is blocked by the
GLP-1R antagonist exendin (9-39), therefore suggesting the presence of GLP-1R,
perhaps at a very low density, on a small proportion of α-cells (122).
It is known that GLP-1 acts on α-cells to trigger signaling through cAMP, which
stimulates PKA-dependent activation of N-type Ca2+ channels, blocking Ca2+ influx and
suppressing glucagon secretion. Notably, GLP-1 inhibits glucagon secretion in both basal
status and in case of diabetes. It is noteworthy to mention that the low level of GLP-1R
expression is crucial for GLP-1 inhibitory effect on glucagon secretion (134). It has also
been shown that GLP-1R may be expressed on rat δ-cells, which, when activated,
stimulates somatostatin secretion, which results in suppression of glucagon secretion
from α-cells (127,135). However, this area needs further future research through
designing a δ-cell-specific GLP-1R knockout.
As I have discussed so far, glucagon secretion from the pancreatic α-cell is regulated by
multiple inputs from outside and within the α-cell. However, the entire picture of how
glucagon secretion is regulated is far from clear (71). All of the factors I have thus far
discussed ultimately converge on components of the regulated secretory pathway in the
α-cell. In particular, the secretory granule, which stores mature glucagon, is the
compartment that responds to factors that either stimulate or inhibit glucagon secretion.
In the next section, I will outline the regulated secretory pathway of the α-cell, and
propose that proteins contained within the secretory granule can regulate glucagon
secretion.
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1.8

Biogenesis of the regulated secretory pathway

The α-cell secretory pathway begins with the synthesis of proglucagon in the
endoplasmic reticulum. It is then transported through the Golgi to the trans-Golgi
network (TGN). Budding immature secretory granules from the TGN contain
proglucagon, its processing enzymes and many other proteins (136). Two models have
been proposed as underlying mechanisms for secretory granule biogenesis: “sorting for
entry” and “sorting by retention”(137).

1.8.1

Molecular mechanisms of sorting glucagon into secretory
granule

Based on the sorting for entry model, nascent granule budding occurs in a specific site on
TGN, which contains sorting receptors and allows proteins with specific sorting signals
to be directed into secretory granules. The sorting by retention model suggests that all
protein components of the TGN are contained within the nascent secretory granule,
which then matures by budding off constitutively-secreted proteins. Currently, it is not
clear which of these models operate in α-cells, but it is generally believed that granule
biogenesis is governed by the natural entity of the prohormone and its synthesis
rate(136). Storage and concentration of proteins within secretory granule take place
within the dense core portion of secretory granules (137).
Advocators of the TGN-based sorting model have been striving to find a governor sorting
receptor in the TGN, and sorting signals within prohormones that interact with sorting
receptors. It has been proposed that membrane-bound form of the processing enzyme
carboxypeptidase E (CPE) can be a prohormone sorting receptor (138–141). It was
shown that ablation of CPE disturbed regulated secretion of proopiomelanocortin
(POMC), proenkephalin and proinsulin in related cell lines and the CPE fat mouse model,
in which CPE is degraded within the pituitary (140,141). Sorting signals can take the
form of amphipathic loops, such as for POMC (142) or proinsulin (140), or amphipathic
alpha helices, as is the case for the N-terminal region of prosomatostatin, and in the Cterminal regions of PC1/3, PC2, PC5/6a, and CPE (143). These signals may also interact
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directly with membrane lipids, in particular with lipid raft regions, to be sorted into
secretory granules (143).
In pancreatic β-cells, there is evidence to support the “sorting-by-retention” theory of
secretory granule biogenesis,, as the protein composition of immature secretory granules
is altered during the process of granule maturation (144). In this context, proinsulin and
the enzymes involved in the post-translational processing to mature insulin are retained
within the secretory granule, while other proteins designated for constitutive secretion are
removed (144).
By considering all of these findings, it is more likely that both “sorting for entry” and
“sorting by retention” mechanisms operate in the sorting of prohormones into secretory
granules. In this scenario, prohormones could be sorted into secretory granules by means
of sorting signals, followed by retention within the granule as maturation of secretory
granules takes place. The maturation process involves alterations in the components and
composition of the secretory granule, by removal of constitutively-secreted proteins,
acidification of the granule milieu, and exclusion of water to condense the intragranular
environment.
The cellular events underlying the sorting of proglucagon to secretory granules have not
been fully elucidated, and studying this mechanism is complicated by the multi-step
processing of proglucagon. The processing of proglucagon in the α-cell is largely
governed by the prohormone convertase (PC) family of enzymes. Proglucagon
processing begins with cleavage of proglucagon at K70R71, which yields glicentin and
major proglucagon fragment (MPGF) (Figure 1- 4)(145). This site is accessible to a
number of processing enzymes and is likely cleaved by furin or PC1/3 in the absence of
PC2 (148). This event occurs early in the secretory pathway, either in the TGN or
immature secretory granule. Subsequent cleavage of glicentin by PC2 at K31R32 results
in the production of mature glucagon. This cleavage event likely occurs within the mature
secretory granule since the acidic pH and millimolar calcium level of secretory granules
is optimal for PC2 activity (9,10,146,147). Thus, the sorting of proglucagon into the
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secretory granule is vital for the generation of active glucagon, and storage within
granules assures a robust secretory response in case of physiological need.
Previous work from the Dhanvantari lab has investigated some mechanisms of
proglucagon sorting into the secretory granule by searching for sorting receptors and
sorting signals. Using the α-cell line −TC1-6, it was shown that siRNA-mediated
knockdown of CPE increased constitutive secretion of glucagon (141), thereby
suggesting that CPE may play a role in directing proglucagon to secretory granules(141).
However, the processing of proglucagon to glucagon remained unchanged, and therefore
these results are not clear. The search for sorting signals provided more clarity on the
mechanisms of proglucagon sorting. Using Fc-tagged proglucagon-derived peptides that
could be detected by immunoprecipitation and immunofluorescence microscopy, two
dipolar α-helices containing hydrophobic patches with three charged residues within the
sequences play roles as sorting signals. One amphipathic α-helix was located within the
amino acid sequence of glucagon (SDYSKYLDSRRAQDFVQWLMN), and one within
GLP-1(SDVSSYLEGQAAKEFLAWLVK) (145). Interestingly, Fc-glicentin could be
sorted to secretory granules, but Fc-MPGF was not, indicating that proglucagon
processing occurs after sorting to secretory granules.

Figure 1-4. Cleavage processing of proglucagon in α-cells. Arrows depict
sorting signals. The Figure was extracted from reference 145 under the
license of https://www.asbmb.org/journals-news/editorial-policies.
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ATP synthase F1 subunit alpha (ATP5F1A) , Malate dehydrogenase 1

induced expression of PC1/3 and GLP-1 in primary culture of rat islets and also α-cell
line models (149). In addition, it was shown that the diabetes-related pro-inflammatory
cytokine, IL-6, caused an increase in the production of both GLP-1 and glucagon as well
as expression of PC1/3 in primary culture of both human and mouse islets (150). Also,
db/db (151), and ob/ob (152) showed the same expression pattern for PC1/3 , GLP-1 and
glucagon. However, the NOD type 1 diabetic mouse did not show expression of GLP-1
and PC1/3 in α-cells(151). Thus, the presence of PC1/3 and GLP-1 and other processed
fragments of MPGF (GLP-2 and IP-2) within the secretory granules of diabetic α-cells is
a subject of ongoing research.

1.8.2

Secretory granule exocytosis

After proglucagon processing and granule maturation, glucagon is stored in the granule
until a stimulus triggers exocytosis. Releasing stored glucagon from the large dense-core
secretory granules in α-cells needs coupling of stimulus and secretion. The electrically
excitable membrane of the α-cell is active with action potentials below the range of 4-5
mM glucose (153). Glucagon secretion could be in a Ca2+ dependent or independent
manner.
A) Ca2+ dependent pathway of glucagon secretion: it was shown that a set of channels
were clustered within the membrane of α-cells, which generate action potentials in the
absence or low levels of glucose. Activation of KATP channels in low glucose condition
brings about a level of membrane voltage that opens T-type Ca2+ channels. Influx of Ca2+
depolarizes the membrane to a level that opens Na+ channels and then N-type Ca2+
channels (non L-type, presumably P/Q type), which bring about glucagon secretion. At
this step, L-type Ca2+ channels are also opened, but do not play a role in glucagon
secretion (maybe due to spatial isolation). On the other hand, in high glucose condition,
generation of ATP increases ATP/ADP ratio, which inhibits KATP channels and
depolarizes the cell membrane (through L-type Ca2+ channels) at a level that it inactivates
those mentioned channels in generation of action potentials, and consequently, suppresses
electrical activity, Ca2+ influx and glucagon secretion. As it was discussed in 1.3.1, there
is also a KATP -independent mechanism for inhibition of glucagon secretion from α-cells.
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Based on this mechanism, high glucose condition inhibits glucagon secretion through
suppression of SOC and preventing Ca2+ entry(153,154).
B) Ca2+-independent pathway of glucagon secretion: This alternative theory expresses
that in the context of high glucose concentration (e.g. 12 mM), KATP channels do not play
a role in suppression of glucagon secretion. Accordingly, high glucose condition
suppresses secretory granule trafficking or inhibits glucagon exocytosis in non-diabetic
α-cells, which results in suppression of glucagon secretion. (155,156).
Based on experimental evidence from isolated mouse islets, a kinetic model of the
exocytotic behaviour of secretory granules in α-cells under low glucose conditions has
been derived (140). This model predicts the relationship between intracellular Ca2+ levels
and granule dynamics and mobilization (Figure 1- 5). A reserve pool of secretory
granules within the cytoplasm resupplies the primed pool in a reversible equilibrium rate.
Priming occurs as a result of sequential Ca2+ binding events. Following binding with
three Ca2+, granules fuse with the plasma membrane in a non-reversible manner, which
forms the fused pool and results in glucagon exocytosis (157).
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Figure 1-5. Kinetic model for trafficking of secretory granules in α-cells.
R(reserve pool); P0(primed pool); F (fused pool); r1(forward resupply
rate); r-1(backward resupply rate); Kon(binding rate); Koff (unbinding
rate); γ (fusion rate); r0(granule formation); rF( granule release). The
Figure was extracted from reference 157 according to the Creative
Commons Attribution License
(http://creativecommons.org/Licenses/by/4.0/).

It was quantitatively shown that in the presence of 1mM glucose, the mouse α-cell
Figure 1-8. Cleavage processing of proglucagon in α-cells. Arrows depict
contains ~4400 secretory granules, of which ~140 are docked. This means that the
sorting signals. The Figure was extracted from reference 145 under the
reserve pool is large, and can resupply the primed pool to maintain euglycemia over
license of https://www.asbmb.org/journals-news/editorial-policies.Figure
extended periods of time. On the other hand, in the presence of 16.7 mM glucose
1-9. Kinetic model for trafficking of secretory granules in α-cells.
numbers of the docked secretory granules increase to ~310 (157). By increasing exposure
R(reserve pool); P0(primed pool); F (fused pool); r1(forward resupply
of α-cells to glucose from 1 to 16.7 mM, the levels of secreted glucagon will be reduced
rate); r-1(backward resupply rate); Kon(binding rate); Koff (unbinding
from ~40 to ~20 pg/islet/h (158).
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proteins (62,161). This complex contains two subsets of proteins; i) the t-SNAREs
syntaxin 1A and SNAP-25, located in the plasma membrane; and ii) the v-SNAREs
VAMP2 and synaptotagmin VII, which are located in the granule membrane. Under low
glucose conditions, SNAP-25 and syntaxin 1A are translocated to the plasma membrane.
SNAP-25 itself may play a role in the transportation of granules from the RP to the RRP,
and then mediates their fusion with plasma membrane via interaction with syntaxin
1A(157,159). Then, C2 domain of synaptotagmin VII binds to syntaxin 1A and forms the
SNARE complex to prime the secretory granules for exocytosis (159) in a mechanism
similar to that in β-cells (162,163). .
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1.8.3

Diabetes and alterations in dynamics of secretory granules

It was shown that α-cells of patients with T2D show normal action potentials and Ca2+
entry into the cell; nonetheless, secretory granules remained close to the plasma
membrane for a longer period of time compared to non-diabetic α-cells, and exocytosis is
impaired (62). As mentioned above in section 1.3.1, the secretory behavior of dispersed
α-cells from patients with T2D is similar to that of non-diabetic dispersed α-cells, which
implies that paracrine effectors are determinants for the normal dynamics of glucagon
secretory granules (108).
One very recent study has shown that α-cells in intact islets from patients with T2D were
resistant to the effects of somatostatin due to a reduction in the expression of SSTR2.
(62). SSTR2 is associated with L-type Ca2+ channels, and is linked with Gi2 proteins; the
binding of somatostatin activates the serine/threonine protein phosphatase calcineurin
and prevents exocytosis through depriming secretory granules (164). Accordingly, it was
mentioned that all paracrine effectors (insulin, somatostatin and GABA) suppress
glucagon secretion through reducing priming, but not docking of secretory granules (62).
These results suggest that reductions in paracrine regulation disrupt the depriming of
secretory granules in diabetic α-cells, thus increasing secretory granule exocytosis,
leading to glucagon hypersecretion.
Therefore, in this section I have outlined how properties of the α-cell secretory granule
may be determinants of glucagon secretion, and how their alterations are linked to
hyperglucagonemia of diabetes. While it is known that granule contents and composition
are modified during normal granule maturation, a more complete picture of granule
remodeling and heterogeneity in normal islet cell physiology and in diabetes is required,
and can be provided by islet proteomics and single cell transcriptomics.

1.9

Pancreatic islet protein reference map

Development of proteomic techniques coupled with bioinformatic analysis has provided a
means to discover a wide range of low expression proteins within the pancreatic islet that
may provide a greater understanding of the mechanisms of glucagon secretion.
Specifically, this strategy has enabled the discovery of protein networks in organelles that
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may regulate islet hormone secretion, such as the rough endoplasmic reticulum (RER),
Golgi, mitochondria and secretory granules. In particular, secretory granule proteomics
has revealed some novel protein networks involved in proinsulin processing, insulin
secretory granule maturation, secretory granule trafficking and exocytosis and
degradation of proteins in the β-cell. Such an approach may also reveal new networks
that govern glucagon secretion and their dysregulation in diabetes.

1.9.1

Islet proteomics and glucagon secretion

In a proteomics study on normal human islets, it was proposed that there is correlation
between changes in islet protein profile and functional performance of islets, in particular
insulin secretion (165,166). Importantly, islet proteomics shows dynamic alterations in
secretory protein networks in response to changes in microenvironmental conditions, in
particular those networks governing granule trafficking and exocytosis. After incubation
of mouse islets for 24h in medium containing 5.6 mM versus 16.7 mM glucose,
comparative analysis showed an increase in proteins related to glucose catabolism,
cellular stress and cytoskeletal proteins, and a concomitant reduction in proteins related
to vesicle trafficking (e.g. VAMP2, SERCA complex, synaptotagmin-like protein 4,
Rab3b) under high glucose conditions. Accordingly, these alterations were accompanied
by reduction in insulin secretion(167), thus identifying metabolic and structural changes
that impact the β-cell secretory pathway in response to changes in prevailing glucose
concentrations in a long-term cumulative incubation.
In rodent models of diabetes, islet proteome studies have revealed interactions between
metabolic, structural and secretory protein networks. Proteomic analysis of islets from the
MKR mouse (insulin resistance), Zucker diabetic fatty rat (leptin receptor mutation),
HFD diabetic mouse (diet-induced obesity and diabetes) and STZ-treated mice
(chemically-induced T1D) all showed differential regulation for expression of proteins
involved in the redox system, chaperone activity, cytoskeleton, and vesicle trafficking
(166,168). Furthermore, there is downregulation of proteins involved in insulin
exocytosis in insulin-resistant pre-diabetes (169), demonstrating substantial alterations in
islet secretory protein networks prior to the onset of diabetes.
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Importantly, islet proteomics of diabetic db/db mice revealed potentially new proteins in
β-cells that may have roles in ER-Golgi vesicle transport, granule trafficking, and
signaling through PI3K-AKT and ERK1/2 pathways, such as: CD63 antigen (CD63),
Neudesin (NENF), Glycerol-3-phosphate phosphatase (PGP), Minor histocompatibility
antigen H13(HM13), Polyadenylate-binding protein-interacting protein 2B (PAIP2B),
Pyruvate kinase PKM (PKM; isotopes M1 and M2), Prominin-1 (PROM1),
Mitochondrial import receptor subunit TOM22 homolog (TOMM22), Protein SET
(SET), Apoptosis-stimulating of p53 protein 1 (PPP1R13B), and Methionine
aminopeptidase 2 (METAP2). The METAP2 has been introduced as a therapeutic target
for the treatment of diabetes and obesity(170).
Islet proteomics can also show how diabetes-induced derangements in β-cell secretory
networks can be restored by normalizing glucose conditions. Adaptation of islets from
diabetic db/db mice to euglycemic conditions brought about a non-diabetic mouse islet
proteomics profile in terms of both expression and phosphorylation of proteins involved
in ER-Golgi vesicular transport (Transport and Golgi organization protein 1 homolog,
MIA3; Coatomer subunit alpha, α-COP; GTP-binding protein SAR1b ;SAR1B), postGolgi vesicular transport (Vesicle-associated membrane protein 4, VAMP4; ADPribosylation factor-related protein 1, ARFRP1; Vesicle transport through interaction with
t-SNAREs homolog 1B , VTI1B; Brefeldin A-inhibited guanine nucleotide-exchange
protein 2, ARFGEF2), secretory granule trafficking (Ras-related protein Rab-3B ,Rab3b;
Ras-related protein Rab-27A, Rab27a; Rabphilin-3A, RPH3a1; Microtubule-associated
protein 2, MAP2; Polycomb protein Pcl, PCL0; Myosin-9, MYH9; Vesicle-trafficking
protein SEC22b, Sec22b), and exocytosis (Synaptotagmin-like protein 5, SYTL5;
Synaptotagmin-7, SYT7; Synaptotagmin-10, SYT10; Exonuclease 1, EXO1; Syntaxin-4 ,
STX4a; Syntaxin-18, STX18; Regulating synaptic membrane exocytosis protein 2,
RIMS2) (171). In this context, post-translational alterations such as phosphorylation and
sialylation were particularly important (170) and revealed a role for the Golgi protein
kinase FAM20C, which targets secretory proteins (e.g. BIG3), in trafficking and
secretory granule biogenesis (171). Meanwhile, such alterations could be restored
following treatment (for example in rat diabetic islets) with EPS (a hypoglycemic fungal
extracellular polysaccharides) or Imidazoline (cationic surfactant with an insulinotropic
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effect) (166). These types of experiments have revealed some new proteins involved in
insulin secretion that could be novel targets for pharmaceutical treatment of diabetes.

1.9.2

The state-of-the-art secretory granule proteomics

Recent advances in the isolation and purification of secretory granules have enabled
accurate coverage in the proteomic analysis of the granule compartment. Secretory
granule proteomics complement islet proteomics through; 1) uncovering genuine protein
components of secretory granules (172), and 2) unveiling alterations in protein
components of secretory granules in diabetes. Diabetes alters the protein components of
the secretory granule responsible for secretory granule trafficking, docking and
exocytosis. For instance, in islets from patients with T2D, islet proteomics revealed
down-regulation in a network of proteins that function in granule docking, fusion and
exocytosis, such as the SNARE proteins SNAP25, Syntaxin-1A, Syntaxin-binding
protein 1(STXBP1), Synaptotagmin-1(SYT1), Synaptotagmin-7 (SYT7) and the Rab
family of GTPases, Rab-3A, Rab-3B and Rab-3C, and new proteins that may function in
this network, such as Regulating synaptic membrane exocytosis protein 1 (RIMS1) and
RIMS2 and the presynaptic scaffold proteins Piccolo (PCLO) and Bassoon (BSN) (173).
Uncovered proteins in proteomic analysis of secretory granules can be categorized into
three groups; 1) Proteins annotated as secretory granule proteins, 2) proteins annotated to
have multiple localizations, and 3) proteins annotated as immature secretory granules or
contaminants.
Annotated secretory granule proteins can be subcategorized as a) secretory granule
proteins (e.g. INS-1E cell proteins of CPE, PC2,VAPM2, VAMP3, chromogranins) , b)
islet cell protein, but not related to any organelle (e.g. INS-1E cell proteins of tubulin
beta-2A chain, Annexin A11 , Kinesin-1 heavy chain) and c) non-islet cell proteins (e.g.
INS-1E cell proteins of neuronal differentiation-related gene protein, and Proprotein
convertase subtilisin/kexin type 1 inhibitor, proSAAS ) (172). Importantly, this
subcategorization could have clinical application in terms of introducing novel targets for
the treatment of diabetes. Proteomics of INS-1E secretory granules revealed the presence
of some membrane proteins within the granules (such as ARFRP1, ADP-ribosylation
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factor-related protein 1;SCFD1, Sec1 family domain-containing protein 1; syntaxin12,
STX12, syntaxin5, STX5; VPS45, Vacuolar protein sorting-associated protein 45, and
ATP6V0C, V-type proton ATPase 16 kDa proteolipid subunit ) that could play a role in
the secretory granule biogenesis, maturation, trafficking and exocytosis (174). For
instance, ATP6V0C is a subunit of vacuolar ATPase and regulates the acidification of the
secretory granule over the maturation process. The presence of SNARE proteins within
the secretory granule proposes their roles in the fusion step of exocytosis. The presence
of related proteins to immature secretory granules (such as STX12, VTI1A, STX6 and
VAMP4) within the secretory granule proposes homotypic fusion of immature secretory
granule, which is an important step in the maturation process (174). In this context, the
presence of transmembrane protein (such as Transmembrane 9 superfamily member 3,
TM9SF3, a nine-transmembrane protein) implies a role for transmembrane proteins in
secretory granule biogenesis, and their potential involvement in maturation, trafficking,
and exocytosis.
Annotated proteins with multiple localizations imply that other intracellular
compartments may interact with secretory granules and therefore have inputs into the
secretory pathway. For instance, proteomic analysis of granules isolated from INS-1E
cells revealed the presence of the endosomal proteins syntaxin 7 and VAMP 8 (172). In
islets from diabetic mice, a lysosomal protein, Rab7 interacting lysosomal protein (RILP)
is overexpressed, and plays a role in the maturation of secretory granules through crosstalk with lysosomes (175). As well, the presence of endosomal and lysosomal proteins in
secretory granules indicates cross-talk between these two subcellular compartments, and
may reveal new mechanisms of regulation of islet hormone secretion, and ultimately
novel therapeutic candidates for treatment of diabetes (176,177).

1.10 Endolysosomal system of islet cells in diabetic
condition
There is relationship between diabetes and lysosomal functions, in a way that alterations
in lysosomal activities take part in physiopathology of diabetes.
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1.10.1

Alterations in endolysosmal enzyme activities in islet cells

Alterations in the lysosomal enzyme activities have been reported in the liver, kidney,
heart, saliva, brain and plasma of people with diabetes. While there is no published
document to show activities of lysosomal system in α-cells, relationship between normal
activities of lysosomes and insulin secretion from β-cells has been documented (178). In
the β-cell, lysosomal enzyme of glucan-1,4-α-glucosidase has a direct relationship with
glucose-stimulated insulin secretion from β-cells. Importantly, significant levels of
abnormalities were shown in activities of lysosomal enzymes in islets of diabetic GK rats.
While glucan-1,4-α-glucosidase and acid α –glucosidase showed higher activities, acid
phosphatase, N-acetyl-β-D-glucosaminidase, cathepsin D, and β-glucuronidase showed
diminished activities (178). Further to aberrant enzyme activities of lysosomal system in
diabetes, there is uncontrolled lysosomal degradation of proinsulin/insulin in diabetic
condition (179).While uncontrolled degradation of insulin in endolysosomal system
participates in pathogenesis of type 2 diabetes, there is a question about implication of
this aberrant system for diabetic α-cells and its potential role in glucagon hypersecretion
and the hyperglucagonemia of diabetes.

1.10.2

Degradation of glucagon in endolysosomal system

In terms of glucagon degradation in α-cells, it has been shown that glucagon is taken up
by α-cells after secretion and then directed into the lysosome. Within the lysosome,
glucagon is dissociated from its receptor and then undergoes degradation (180).
illustrating the capability of the α-cell to degrade glucagon through the endolysosomal
system. Degradation of the endocytosed glucagon is governed by the rate of fusion
between endocytic vesicles and lysosomes. This fusion event is a rate limiting step for the
degradation of endocytic vesicle contents in the lysosome and could be altered in
response to changes in microenvironmental conditions. For instance, α-cells
simultaneously internalize several receptor-bound islet hormones, which may saturate the
endolysosomal system and consequently inhibit glucagon degradation (180).
In a parallel finding on β-cells, it was proposed that insulin also will be taken up after
secretion by β-cells and then undergo degradation in the lysosomal system (181). In
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diabetes, aberrant insulin degradation in β-cells has been proposed as underlying
mechanism for β-cell failure in type 2 diabetes (179). Importantly, in the context of
diabetes, there is no published document to show status of glucagon degradation within
endosomal/lysosomal system of α-cells.

1.11

Aims and rationale of the study

Based on the glucagoncentric hypothesis of diabetes, hyperglycemia of diabetes would be
due to hyperglucagonemia instead of hypoinsulinemia. Several theories have been
proposed to address underlying mechanisms of glucagon hypersecretion from α-cells.
While some researchers have focused on glucose-regulated glucagon secretion from αcells and alterations in its signaling processes in diabetes, some other researchers targeted
paracrine effectors as major determinants in glucagon secretion and their disturbances in
diabetes. Additionally, protein components of the regulated secretory pathway also
regulate glucagon secretion from α-cells. In this context, our laboratory has already
shown that alterations in ambient glucose levels alters levels of proteins in the regulated
secretory pathway in α-cells. The prevailing hypothesis is that dissecting the cellular
mechanisms of glucagon trafficking in the α-cell may reveal novel proteins, or networks
of proteins, that function in glucagon secretion, and provide explanations for the
hyperglucagonemia of diabetes.
Mapping of the α-cell secretory granule proteome under different microenvironmental
inputs, such as glucose or insulin, would likely provide answers to our questions
regarding the regulation of glucagon secretion in normal physiology, and in the
pathobiology of diabetes. It may also reveal novel inputs to secretory granules, new
cellular pathways by which glucagon secretion is regulated, and new insights into the
development of hyperglucagonemia.

The specific aims of my thesis are:
1) To determine the glucagon interactome in the secretory granules of α-cells and its
potential plasticity in response to microenvironmental conditions.
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2) To identify and characterize a protein within the interactome that modulates glucagon
secretion in normal α-cells by regulating its intracellular trafficking.
3) To determine how the interactome protein-mediated trafficking of glucagon is altered
in the hyperglucagonemia of diabetes.

1.12
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2.1

Abstract

Glucagon is stored within the secretory granules of pancreatic α-cells until stimuli trigger
its release. The α-cell secretory responses to the stimuli vary widely, possibly due to
differences in experimental models or microenvironmental conditions. We hypothesized
that the response of the α-cell to various stimuli could be due to plasticity in the network
of proteins that interact with glucagon within α-cell secretory granules. We used tagged
glucagon with Fc to pull out glucagon from the enriched preparation of secretory
granules in α-TC1-6 cells. Isolation of secretory granules was validated by
immunoisolation with Fc-glucagon and immunoblotting for organelle-specific proteins.
Then, enriched secretory granules were used for affinity purification with Fc-glucagon
followed by liquid chromatography/tandem mass spectrometry to identify secretory
granule proteins that interact with glucagon. Proteomic analyses revealed a network of
proteins containing glucose regulated protein 78 KDa, GRP78, and histone H4. The
interaction between glucagon and the ER stress protein GRP78 and histone H4 was
confirmed through co-immunoprecipitation of secretory granule lysates, and
colocalization immunofluorescence confocal microscopy. Composition of the protein
networks was altered at different glucose levels (25 mM vs 5.5 mM) and in response to
the paracrine inhibitors of glucagon secretion, GABA and insulin. siRNA-mediated
silencing of a subset of these proteins revealed their involvement in glucagon secretion in
α-TC1-6 cells. Therefore, results indicate a novel and dynamic glucagon interactome
within α-TC1-6 cell secretory granules. We suggest that variations in the α-cell secretory
response to stimuli may be governed by plasticity in the glucagon “interactome”.

Keywords: glucagon, α-cell, proteomics, co-immunoprecipitation, confocal microscopy,
glucagon interactome, glucagon secretion
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2.2

Introduction

Glucagon is the major glucose counter-regulatory hormone, and maintains euglycemia by
enhancing hepatic gluconeogenesis and glycogenolysis (1). However, both type 1 and
type 2 diabetes are characterized by varying levels of hyperglucagonemia (2), which
paradoxically exacerbates the hyperglycemia of diabetes (3, 4). More recently, it has been
shown that glucagon may be an amino acid regulatory hormone, suggesting a link
between hepatic amino acid metabolism and hyperglucagonemia (5). In pancreatic αcells, glucagon secretion is tightly regulated by nutritional, hormonal, and neural
effectors to maintain normal glucose homeostasis. However, in diabetes, this tight
coupling is disrupted (6), resulting in dysfunctional glucagon secretion, which may be a
factor in the development of type 2 diabetes (7). This abnormal glucagon secretion has
led to strategies (8) to control glucagon action to ameliorate the hyperglycemia of
diabetes, such as administering glucagon receptor antagonists or neutralizing antibodies
against the glucagon receptor (9, 10). Although effective in the short term, this strategy
tends to increase α-cell mass and worsen α-cell dysfunction over the long term (6).
Therefore, a preferable strategy may be to control the secretion, rather than the action, of
glucagon for improved glycemic control in diabetes.
In the context of the pancreatic islet, there is some debate as to whether glucagon
secretion is primarily regulated by the paracrine influence of the β-cell, or through
intrinsic factors (11, 12). Both insulin and GABA secreted from the β-cell strongly inhibit
glucagon secretion, as does somatostatin (13, 14). However, these actions are dependent
on prevailing glucose concentrations; at 5 mM glucose, both glucagon and insulin
secretion are maximally suppressed (11), suggesting that intrinsic factors may exert an
equally prominent influence on glucagon secretion. Some proposed mechanisms of
intrinsic regulation of glucagon secretion include glucose metabolic-induced changes in
Ca2+ and K+ membrane conductances or intracellular Ca2+ oscillations (15, 16). Intrinsic
factors can also include proteins involved in the intracellular trafficking of glucagon. We
have previously shown that prolonged culture of α-TC1-6 cells in medium containing 25
mM glucose resulted in the up-regulation of components of the regulated secretory
pathway (17), notably proteins associated with secretory granules, such as SNARE
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exocytotic proteins and granins. There may be direct interactions between granule
proteins, such as chromogranin A and carboxypeptidase E, to ensure proper trafficking of
glucagon into secretory granules (18), and distinct sorting signals within glucagon may
mediate these interactions (19). Therefore, proteins within the α-cell secretory granules
that directly interact with glucagon may provide additional clues for the regulation of
glucagon secretion.
In order to identify networks of secretory granule proteins that interact with glucagon, we
have continued to use the α-TC1-6 cell line, as this is a well-established cell line in which
to study the intrinsic regulation of glucagon secretion (20). This cell line has been
extensively used to study glucagon secretory pathway (17, 21) due to its resemblance to
the normal pancreatic α-cell in terms of proglucagon processing (22) and response to
insulin and somatostatin and nutritional effectors (12, 17). Our work has revealed a novel
glucagon “interactome” that exhibits plasticity in response to glucose, insulin and GABA,
and contains some novel glucagon-interacting proteins that may regulate glucagon
secretion in α-TC1-6 cells.

2.3

Materials and methods

Sources for all reagents, assays, and software packages are listed in Supplementary Table
2-1.

2.3.1

Gene construct and plasmid preparation

We designed a glucagon fusion construct [Fc-glucagon –pcDNA3.1(+)] as follows: the
amino acid sequence of glucagon derived from human proglucagon (GenScript, USA;
http://www.genscript.com) was fused to the 3′ end of cDNA encoding the CH2/CH3
domain of mouse IgG-2b (Fc), preceded by a 28 amino acid signal peptide as described
previously (19). As a negative control for all transfections, proteomics,
immunofluorescence microscopy, and co-immunoprecipitation experiments, we also
designed a Fc-pcDNA3.1(+) construct. DNA sequences were confirmed at the London
Regional Genomics Facility, Western University.
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2.3.2

Extraction and enrichment of secretory granules

Wild type α-TC1-6 cells (a kind gift from C. Bruce Verchere, Vancouver, BC) were
cultured in DMEM containing 25 mM glucose, L-glutamine, 15% horse serum, and 2.5%
fetal bovine serum, as described previously (17, 23). Based on the ATCC product sheet,
the base cell culture medium for α-TC1-6 cells is low glucose (5.5 mM) Dulbecco's
Modified Eagle's Medium (DMEM); however, for glucagon secretion (glucagon
hypersecretion) studies, high glucose DMEM (16.7 or 25 mM) has been traditionally
used to prepare α-TC-6 cells for downstream experiments (17, 24). Cells were grown to
90% confluency and transfected with Fc alone or Fc-glucagon using Lipofectamine 2000.
To determine changes in granule size, mass, and proteome, cells were transiently
transfected with Fc-glucagon or Fc-alone and then incubated with or without GABA (25
μM), insulin (100 pM), or GABA (25 μM) plus insulin (100 pM) in either 25 or 5.5 mM
glucose prior to the granule enrichment procedure. To account for all potential
modulators of glucagon secretion, including the possibility of autocrine regulation of
glucagon secretion (25, 26) we chose long-term cumulative incubation that has
previously been used by our team (17) and other investigators (23) for secretion studies in
α-TC1-6 cells.
At the end of the incubation period, granules were extracted as previously published (27)
with some modifications. Briefly, cells were detached using 5 mM EDTA in PBS (pH
7.4) containing cOmplete Mini Protease Inhibitor Cocktail (Supplementary Table 1) on
ice, centrifuged and resuspended in ice-cold homogenization buffer (20 mM Tris-HCl
pH7.4, 0.5 mM EDTA, 0.5 mM EGTA, 250 mM sucrose, 1 mM DTT, cOmplete Mini
Protease Inhibitor Cocktail, and 5 μg/mL Aprotinin). The cells were passed 10 times
through a 21G needle and again 10 times through a 25G needle. The resulting lysates
were centrifuged to obtain a post-nuclear supernatant (PNS). The nuclear fraction was
washed seven times in ice-cold homogenization buffer and stored at −80°C. The PNS
was centrifuged at 5,400 × g for 15 min at 4°C to obtain a post-mitochondrial
supernatant, which then was spun at 25,000 × g for 20 min, and the resultant pellet was
washed five times at 4°C. Enrichment was confirmed through immunoblotting for
organelle-specific markers as described below.
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2.3.3

Immunoblotting for organelle-specific markers

The enriched preparations of secretory granules from α-TC1-6 cells were lysed using
non-ionic lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100 plus
cOmplete Mini Protease Inhibitor Cocktail, and 5 μg/mL Aprotinin). Proteins were
resolved by 4–12% NuPAGE, transferred to a PVDF membrane and probed with the
following antibodies (Supplementary Table 1): vesicle-associated membrane protein 2
(VAMP2) for mature secretory granules; calreticulin for the endoplasmic reticulum;
TGN46 for the trans-Golgi network; and Lamin B1 for the nuclear envelope.
Immunoreactive bands were visualized using HRP-conjugated goat anti-rabbit secondary
antibody and Clarity Western ECL substrate. Images were acquired on a BioRad
ChemiDoc Imaging System. Total cell extracts were used as positive controls.

2.3.4

Nanoscale flow cytometry

Secretory granule preparation
We used nano-scale flow cytometry (A50-Micro nanoscale flow cytometer; Apogee
FlowSystems Inc.) to confirm enrichment of the secretory granules and to determine the
size distribution of the granules. α-TC1-6 cells were transfected with Fc-glucagon or Fc
alone, and secretory granules were extracted as described above. Granules were fixed in
freshly prepared 2% PFA (pH 7.4), permeabilized with 0.5% saponin at room
temperature, centrifuged at 25,000 × g for 20 min at 4°C and washed three times in 0.1%
saponin in PBS. Fc-containing granules were labeled with FITC-IgG (1:250 dilution in
0.1% saponin in 1% BSA/PBS) in the dark for 1 h, and diluted 200X in 0.1% saponin.
Size calibration
Secretory granules of non-transfected cells were used for size calibration. ApogeeMix
beads were used to establish sizing gates along the Y axis—large angle light scattering
(LALS) vs. X-axis- small angle light scattering (SALS) plot. The microparticle mixture
contained plastic spheres with diameters of 180, 240, 300, 590, 880, and 1,300 nm with
refractive indexes of 1.43 and 110 nm, and 500 nm green fluorescent beads with
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refractive index of 1.59. Based on the manufacturer's default settings, the calibrated gates
of the size distribution were 110, 179, 235, 304, 585, and 880 nm, which were used to
categorize subpopulations of the enriched secretory granules.
Nano-flow analysis
To count the numbers of Fc-glucagon+ granules, fluorescence of FITC excitation (L488)
was gated and the numbers of Fc-glucagon+ granules were counted at 110, 179, 235, 304,
585, and 880 nm within the LALS vs. L488 plot. To get the LALS vs. L488 plot, its gate
was normalized for the following isotypes: secretory granules of non-transfected cells,
secretory granules of Fc-transfected cells, FITC-IgG and diluent. This method resulted in
size distributions of the granules that were positive for Fc-glucagon, specifically. All
experiments were done in three biological samples and values were expressed as percent
distribution of gated granules.

2.3.5

Proteomic analysis of secretory granule proteins associated
with glucagon

Granule lysate preparation
α-TC1-6 cells were transfected by Fc-glucagon and treated with effectors (GABA, insulin
and GABA plus insulin) in media containing 25 or 5.5 mM glucose as described above.
To identify non-specific interactors, we used the Fc construct in untreated conditions.
Secretory granules were extracted as described above, and lysed in a non-ionic lysis
buffer.
Affinity purification
Fc or Fc-glucagon was purified from the granule lysate by immunoprecipitation as we
have done previously (19). Briefly, a slurry of Protein A-Sepharose beads
(Supplementary Table 1) was mixed 1:1 with the granule lysate and rotated overnight at
4°C. The mixture was then centrifuged at 500 × g for 2 min at 4°C and the pellet was
washed twice with 50 mM Tris (pH 7.5) and once with pre-urea wash buffer (50 mM Tris
pH 8.5, 1 mM EGTA, 75 mM KCl). Fc or Fc-glucagon was eluted with two volumes of
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urea elution buffer (7 M urea in 20 mM Tris buffer pH 7.5 plus 100 mM NaCl). This step
was repeated twice more and the supernatants were collected and pooled. The pooled
supernatant was mixed with acetone in a 1:4 ratio and kept at −20°C overnight, then
centrifuged at 16,000 × g for 15 min at 4°C. The pellet was air-dried for proteomic
analysis.
Proteomic analysis
Protein identification was conducted using LC-MS/MS according to the protocols of the
Western University Mass Spectrometry Laboratory
(https://www.schulich.uwo.ca/lrpc/bmsl/protocols/index.html). Briefly, the air-dried
pellet was reconstituted in 50 mM NH4CO3, and proteins were reduced in 200 mM
dithiothreitol (DTT), alkylated in freshly prepared 1M iodoacetamide and digested with
trypsin for 18 h at 37°C with occasional shaking. Tryptic peptides were acidified using
formic acid (0.25; v/v), loaded onto a Hypersep C18 column, washed, and eluted in 50%
acetonitrile. The eluent was dried down in a speed vacuum and reconstituted in
acetonitrile. Each experimental condition was done in three biological replicates. Peptide
sequences were identified using the mouse database and further analyzed for protein
categorization through PANTHER GO (http://www.Pantherdb.org), determination of
subcellular locations and activity using http://www.uniport.org, and functional proteinprotein interaction clustering through http://string-db.org. To predict protein-protein
interactions using string, clustering of proteins was done based on strength of data
support in the context of all active interaction sources. The minimum interaction score
was set at median of 0.4 and maximum at 5 for the first shell and no limitation for the
second shell.
Proteins that were pulled down using Fc alone were subtracted from proteins pulled down
by Fc-glucagon to obtain the profile of proteins that specifically interact with glucagon.
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2.3.6

Immunoprecipitation-immunoblotting of proteins associated
with glucagon

To validate the interaction of glucagon with either GRP78 or histone H4 within secretory
granules we first purified Fc-glucagon or Fc (as control) from the secretory granule
preparation by incubating the secretory granule lysate with Protein A-Sepharose beads
overnight at 4°C with rotation. The Fc or Fc-glucagon complex was eluted from the
beads with 0.1 M glycine buffer (pH 2.8). The eluate was concentrated 50 times using a
speed vac, run on a 10% Bis-Tris NuPAGE gel (Supplementary Table 1) and proteins
were transferred onto a PVDF membrane. After an overnight incubation with primary
antibodies against GRP78 or histone H4, bands were visualized with HRP-conjugated
goat anti-rabbit secondary antibody and Clarity Western ECL substrate (Supplementary
Table 1). Images were acquired on a BioRad ChemiDoc Imaging System.

2.3.7

Histone H4 assay

Enriched secretory granule fractions were prepared, resuspended in 0.2 N HCl, passed 10
times through a 30G needle, and kept at 4°C overnight. The reaction was stopped by
addition of 0.2 volumes of 1N NaOH. The supernatant was collected after centrifugation
at 6,500 × g at 4°C for 10 min. Protein levels were determined by BCA assay, and 100 ng
of protein was used for measuring total histone H4 (Histone H4 Modification Multiplex
ELISA-like format Kit, Supplementary Table 1), as per the manufacturer's instructions.
The nuclear fraction was also assayed for histone H4 as a positive control.

2.3.8

Immunofluorescence microscopy

To validate the presence of GRP78 and histone H4 in glucagon-positive secretory
granules, α-TC1-6 cells were cultured on collagen1-coated coverslips (three per
experiment), and processed for immunofluorescence microscopy as described previously
(18). Briefly, cells were fixed in 4% paraformaldehyde and permeabilized in 0.1%
saponin in 0.5% BSA for 1 h. After blocking in 10% goat serum, cells were incubated
with primary antibodies (mouse anti-glucagon and rabbit anti-GRP78 or rabbit antihistone H4) overnight. Coverslips were washed in PBS and incubated with goat anti64

mouse Alexa Fluor IgG 488 and goat anti-rabbit Alexa Fluor 594 (Supplementary Table
1) for 3 h in the dark at room temperature, then mounted using ProLong Gold Antifade
Mountant. Images were acquired on a Nikon A1R Confocal microscope with a 60x Nikon
Plan-Apochromat oil differential interference contrast objective lens using NIS-Elements,
software. To show secretory granule co-localization, images were post-processed by 2D
deconvolution. To measure the degree of co-localization, regions of interest were
manually drawn around distinct single or multicell bodies, positive for Fc-glucagon and
either GRP78 or histone H4 and cropped for analysis. Co-localization of the pixels from
each pseudo-colored image were used to calculate Pearson's correlation coefficient
(PCC), as we described previously (19).

2.3.9

siRNA-mediated depletion of targeted proteins

After treatment of α-TC1-6 cells with GABA and/or insulin in media containing 25 mM
glucose as described above, the proteomes were tabulated, and Venn diagram analysis
revealed 27 metabolic/regulatory/secretory proteins and 36
histone/cytoskeletal/ribosomal proteins that were common between the groups treated
with GABA and insulin. We selected 11 of these proteins (based on availability of the
pre-designed siRNA) for siRNA-mediated depletion: Peroxiredoxin-2 (PRDX2), Malate
dehydrogenase 1 (MDH1), Aconitate hydratase, mitochondrial (ACO2), 14-3-3 protein
zeta/delta (KCIP-1), ELKS/Rab6-interacting/CAST family member 1 (ERC1), Alphatubulin 2 (AT2), ATP synthase F1 subunit alpha (ATP5F1A), Histone H4, GRP78,
FXYD domain-containing ion transport regulator 2 (FXYD2), and Protein disulfideisomerase (PDI), (Silencer siRNA, Thermo Fisher Scientific Inc. MA, USA).
Gene silencing was based on a published protocol (28). Briefly, α-TC1-6 cells were
cultured to 60% confluency and transfected with final concentrations of 50 nM of pooled
siRNAs (three siRNAs for each target) or control scrambled siRNA using
Lipofectamine2000. Cells were incubated for 48 h, after which media were removed and
replaced. After 24 h, expression levels of the targeted proteins were evaluated by
immunoblotting using primary antibodies against each protein (Supplementary Table 1).
Meanwhile, siRNA mediated knockdown of the proglucagon gene was shown as a
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positive control using real-time PCR (Quant Studio Design and Analysis Real-Time PCR
Detection System) (Supplementary Figure 2-1).

2.3.10

Glucagon measurement

To measure cellular and secreted glucagon levels after siRNA-mediated gene silencing,
cell lysates or media were acidified in HCl-ethanol (92:2 v/v) in a 1:3 ratio, kept at −20°C
overnight, then centrifuged at 13,000 × g for 15 min at 4°C. The supernatant was then
mixed 1:1 with 20 mM Tris, pH 7.5 26 and glucagon levels were measured by ELISA
(Thermo Fisher Scientific, Supplementary Table 1) according to the manufacturer's
instructions. To measure Fc-glucagon, samples were diluted to reach an OD at the linear
part of the standard curve.

2.3.11

Glucagon secretion and cell glucagon content in response to
nutritional and paracrine effectors

α-TC1-6 cells cultured and kept under chronic exposure to 25 mM glucose and at
confluency rate of ~70% were plated out into six-well plates. After 24 h, two sets of
experiments were designed. In one set, medium was replaced by fresh 25 mM glucosecontaining medium and in the other set medium was replaced by fresh medium
containing 5.5 mM glucose. In both sets, cells were treated by GABA (25 μM), insulin
(100 pM), or GABA (25 μM) + insulin (100 pM), and incubated for 24 h in serum free
medium containing 0.5% BSA. At the end of incubation, plates were placed on ice and
media were collected, centrifuged at 16,000 × g for 5 min, and supernatant was removed
for glucagon measurement. The cells were washed three times with ice-cold PBS and
scraped in Glycine-BSA buffer (100 mM glycine, 0.25% BSA, cOmplete Mini Protease
Inhibitor Cocktail, 5 μg/mL Aprotinin, pH 8.8). The scraped cells were lysed by
sonication (12 s at 30% amplitude on ice), and centrifuged at 16,000 × g for 45 min, from
which the supernatant was collected for analysis. The protein concentration of the cell
lysate was measured using BCA assay. To measure glucagon levels, the cell lysate or
medium was mixed in an ethanol-acid solution (96% ethanol containing 0.18 M HCl) in a
1:3 ratio, kept at −20°C overnight, then centrifuged at 16,000 × g for 15 min at 4°C. The
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supernatant was then mixed with 20 mM Tris buffer, pH 7.5, and glucagon measurements
were conducted by ELISA.

2.3.12

Statistical analysis

Experiments were done in three biological replicates (three batches of newly thawed αcells), each of which had two technical replicates (on passaged cells following three
weeks adaptation to high glucose condition). Values were compared among treatment
groups by one-way ANOVA (Bonferroni post-hoc test) using Sigma Stat 3.5 software (α
= 0.05). For image analysis, co-localization of channels in the merged images was
calculated by PCC using NIS-Elements software (Nikon, Canada).

2.4

Results

Our method for purification of proteins that associate with glucagon within the α cell
secretory granules consisted of two sequential steps. First, we modified and used a
previously published method (27) for enrichment of the secretory granule fraction.
Second, we used Fc-glucagon for affinity purification to pull down proteins associated
with glucagon within the secretory granules.

2.4.1

Secretory granule enrichment

Immunoblotting for organelle-specific markers confirmed enrichment of secretory
granules (Supplementary Figures 2- 2A–D). The final granule fraction was positive for
the secretory granule marker, VAMP2. In contrast, the granule fraction did not contain
the trans-Golgi marker TGN46, the nuclear envelope marker LaminB1, or the
endoplasmic reticulum marker Calreticulin. As a positive control, the general cell lysate
contained all four markers.

2.4.2

Confirmation of the enriched secretory granules

Secretory granules in α-cells have been previously studied using transmission electron
microscopy and their average sizes have been reported to be in the range of 180–240 nm
(29–31). Accordingly, we confirmed the presence of secretory granules using nano-scale
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flow cytometry with Fc-glucagon as an exclusive marker for α-cell secretory granules
(32, 33). We used beads in the range of 110–880 nm for calibration in the range of the
reported sizes for secretory granules (Supplementary Figure 2- 3A). Fc-glucagon+
secretory granules distributed mostly to the gated regions of 179 and 235 nm
(Supplementary Figures 2- 3B, C), confirming enrichment of secretory granules from αTC1-6 cells.

2.4.3

Proteomic analysis of proteins that are associated with
glucagon within α-cell secretory granules

Fc or Fc-glucagon was purified from the granule lysate by affinity purification, and
proteins that interact with either Fc alone or Fc-glucagon were identified with LCMS/MS. Proteins that were pulled down by Fc alone in both 25 mM glucose
(Supplementary Table 2) and 5.5 mM glucose (Supplementary Table 3) conditions were
subtracted from the list of proteins identified using Fc-glucagon, thus identifying proteins
that specifically interact with glucagon, which we term the glucagon interactome.
Proteins were assigned the following categories: metabolic-secretory-regulatory,
histones, cytoskeletal, and ribosomal.
We identified 42 and 96 glucagon-interacting proteins within the category of metabolicregulatory-secretory proteins when the cells were cultured in media containing 25 mM
(Figure 2- 1A) and 5.5 mM glucose (Figure 2- 1B), respectively.
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Figure 2-1. The glucagon interactome in secretory granules of α-TC1-6 cells.
Cells were transfected with Fc-glucagon or Fc alone, and cultured in
DMEM containing 25 mM or 5.5 mM glucose for 24h. Fc-glucagon was
purified from enriched secretory granules and associated proteins were
identified by LC-MS/MS. (A) Proteomic map of the metabolic-regulatorysecretory proteins that are predicted to associate with glucagon in the
context of 25 mM glucose. Network clustering predicts direct interactions
between glucagon and glucose regulated protein 78 KDa (Hspa5, also
known as GRP78), and ATPase copper transporting alpha polypeptide
(Atp7). (B) Proteomic map of the metabolic-regulatory-secretory proteins
that are predicted to associate with glucagon in the context of 5.5 mM
glucose. Network clustering predicts direct interactions between glucagon
and GRP78, stathmin1 (Stmn1), and heat shock protein 90-alpha
(Hsp90aa1). The thickness of the lines indicates the strength of the predicted
protein-protein interaction.
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enriched secretory granules (Figure 2- 2A). Immunofluorescence microscopy showed colocalization of GRP78 and endogenous glucagon within the secretory granules in α-TC16 cells (Figure 2- 2B). There was a strong positive correlation between glucagon and
GRP78 immunoreactivities (PCC = 0.85 ± 0.08), indicating significant co-localization of
GRP78 and glucagon.
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Figure 2-3. Glucagon and GRP78 directly interact and are localized within
secretory granules in α-TC1-6 cells. (A) Western blot showing GRP78
immunoreactivity in: total cell extracts from untransfected (lane 2) and
transfected (lane 3) cells; affinity-purified Fc-glucagon from isolated
secretory granules (lane 4); and affinity-purified Fc alone from isolated
secretory granules (lane 5). GRP78 binds to Fc-glucagon, but not Fc alone.
(B) Immunofluorescence microscopy of glucagon (green), GRP78 (red) and
both images merged. Cells were cultured on collagen-coated coverslips for
24h in DMEM containing 25 mM glucose. Images were acquired, 2D
deconvoluted and analyzed with NIS software (Nikon, Canada). Pearson
correlation coefficient (PCC) indicates strong correlation between GRP78
and glucagon (PCC = 0.85 ± 0.08). ROI shows areas of colocalization of
GRP78 and glucagon within secretory granules.

2.4.5

GABA induces histone H4 interaction and co-localization

Figure 2-4. The glucagon interactome in secretory granules of α-TC1-6 cells.

with glucagon

Cells were transfected with Fc-glucagon or Fc alone, and cultured in DMEM
containing 25 mM or 5.5 mM glucose for 24h. Fc-glucagon was purified from
Interestingly, proteomic analysis also revealed the presence of histone proteins, along
enriched secretory granules and associated proteins were identified by LCwith structural proteins and ribosomal proteins, within the secretory granules in α-TC1-6
MS/MS. (A) Proteomic map of the metabolic-regulatory-secretory proteins
cells (Supplementary Table 4). Histone H4 was predicted to interact with glucagon in
that are predicted to associate with glucagon in the context of 25 mM glucose.
cells incubated in medium containing 5.5 mM glucose. Therefore, we reasoned that this
Network clustering predicts direct interactions between glucagon and glucose
interaction was responsive to external effectors. We treated α-TC1-6 cells with GABA, a
regulated protein 78 KDa (Hspa5, also known as GRP78), and ATPase
well-known modulator of glucagon secretion (21) and examined the interaction between
copper transporting alpha polypeptide (Atp7). (B) Proteomic map of the
histone and glucagon. Co-immunoprecipitation of granule lysates, histone H4 ELISA of
metabolic-regulatory-secretory proteins that are predicted to associate with
granule lysates, and immunofluorescence microscopy all validated the interaction of
glucagon in the context of 5.5 mM glucose. Network clustering predicts direct
histone H4 with glucagon and presence of histone H4 in secretory granules of α-TC1-6
interactions between glucagon and GRP78, stathmin1 (Stmn1), and heat
cells after treatment with GABA (Figure 2- 3). Affinity purification of Fc-glucagon or Fc
shock protein 90-alpha (Hsp90aa1). The thickness of the lines indicates the
alone from the secretory granule lysate was followed by immunoblotting for histone H4
strength of the predicted protein-protein interaction.Figure 2-5. Glucagon
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and GRP78 directly interact and are localized
within secretory granules in α-

TC1-6 cells. (A) Western blot showing GRP78 immunoreactivity in: total cell
extracts from untransfected (lane 2) and transfected (lane 3) cells; affinity-

(Figure 2- 3A). The presence of histone H4 immunoreactivity with Fc-glucagon, and not
Fc alone, demonstrates a direct interaction with glucagon in the enriched secretory
granules (Figure 2- 3A). We then confirmed the presence of histone H4 in the enriched
secretory granules of α-TC1-6 cells by ELISA (Figure 2- 3B). In cells treated with
GABA in 25 mM glucose, there was a detectable amount of histone H4 in the granules.
That this result was not due to contamination from the nuclear fraction was shown by the
finding that histone H4 levels were undetectable in the secretory granules of cells not
treated with GABA. As a positive control, the nuclear fraction showed high levels of
histone H4. Finally, immunofluorescence microscopy showed the presence of histone H4
in glucagon-containing secretory granules (Figure 2- 3C), and there was significant colocalization with glucagon as assessed by Pearson's correlation coefficient (PCC = 0.78 ±
0.08).

72

Figure 2-6. GABA induces direct interaction between glucagon and histone
H4 within secretory granules in α-TC1-6 cells. (A) Western blot shows
histone H4 immunoreactivity in: total cell extracts from untransfected (lane
2) and transfected (lane 3) cells; affinity-purified Fc-glucagon from isolated
secretory granules (lane 4); and affinity-purified Fc alone from isolated
secretory granules (lane 5). Histone H4 binds to Fc-glucagon, but not Fc
alone. (B) Quantitative ELISA measurement of histone H4 (left Y axis) and
glucagon (right Y axis) within the secretory granules (control GABA,
insulin) and the nuclear fraction of α-TC1-6 cells. Values are expressed as
mean ± SD and compared with 1-way ANOVA (α=0.05).*p<0.05; **p<0.001.
(C) Immunofluorescence microscopy of glucagon (green), histone H4 (red)
and both images merged. Cells were cultured on collagen-coated coverslips
for 24h in DMEM containing 25 mM glucose. Images were acquired, 2D
deconvoluted and analyzed with NIS software (Nikon, Canada). Pearson
correlation coefficient (PCC) indicates strong correlation between histone
H4 and glucagon (PCC = 0.78 ± 0.08). ROI shows areas of colocalization of
histone H4 and glucagon within secretory granules.

2.4.6

The glucagon interactome changes in response to glucose,
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correlation coefficient (PCC) indicates strong correlation between GRP78
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and glucagon (PCC = 0.85 ± 0.08). ROI shows areas of colocalization of
GRP78 and glucagon within secretory granules.Figure 2-8. GABA induces

were cultured in medium containing 25 mM glucose (Figure 2- 4) and in 5.5 mM glucose
(Figure 2- 5).

Figure 2-9. The glucagon interactome is altered in response to paracrine
effectors in 25 mM glucose. α-TC1-6 cells were transfected with Fc-glucagon
or Fc alone, and treated with GABA (25 µM), insulin (100 pM) or GABA
(25 µM) plus insulin (100 pM) for 24h in DMEM containing 25 mM glucose.
Fc-glucagon was purified from isolated secretory granules and associated
proteins were identified by LC-MS/MS. (A) Proteomic map of metabolicregulatory-secretory proteins that are associated with glucagon after
treatment of α-TC1-6 cells with GABA shows direct interactions with 4
proteins: GRP78, Heat shock 70 kDa protein 1B (Hspa1b) Heat shock
protein 90- alpha (Hsp90aa1), and Vimentin (Vim). (B) After treatment with
insulin or (C) GABA+Insulin, glucagon is predicted to interact only with
GRP78. Line thickness indicates the strength of data support.
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Figure 2-10. GABA induces direct interaction between glucagon and histone
H4 within secretory granules in α-TC1-6 cells. (A) Western blot shows

75

Figure 2-12. The glucagon interactome is altered in response to paracrine
effectors in 5.5 mM glucose. α-TC1-6 cells were transfected with Fcglucagon or Fc alone, and treated with GABA (25 µM), insulin (100 pM) or
GABA (25 µM) plus insulin (100 pM) for 24h in DMEM containing 5.5 mM
glucose. Fc-glucagon was purified from isolated secretory granules and
associated proteins were identified by LC-MS/MS. (A) Proteomic map of
metabolic-regulatory-secretory proteins that are associated with glucagon
after treatment of α-TC1-6 cells with GABA shows direct interactions with 6
proteins: GRP78, Heat shock protein 90- alpha (Hsp90aa1), Protein
convertase subtilisin/kexin type2 (PCSK2), Heat shock 70 kDa protein 1B
(Hspa1b), Calmodulin 1 (Calm1), Guanine nucleotide-binding protein
G(I)/G(S)/G(O) subunit gamma-7 (Gng7). (B) After treatment with insulin,
glucagon is predicted to directly interact with 7 proteins: GRP78, Heat shock
protein 90-alpha, Annexin A5 (Anxa5), Stathmin1 (Stmn1), PCSK2, Fatty
acid synthase (Fasn), and Chromogranin A (ChgA). (C) After treatment with
GABA+Insulin, glucagon is predicted to directly interact with GRP78 and
PCSK2. Line thickness indicates the strength of data support.
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The glucagon interactome is altered in response to paracrine effectors in 5.5
mM glucose. α-TC1-6 cells were transfected with Fc-glucagon or Fc alone,
and treated with GABA (25 µM), insulin (100 pM) or GABA (25 µM) plus

vimentin (Figure 2- 4A); however, in cells treated with insulin and GABA + insulin,
glucagon interacts directly with only GRP78 (Figures 2- 4B,C). The clusters of
metabolic-secretory-regulatory proteins that make up the rest of the glucagon
interactomes change in composition in response to the different treatments. The numbers
of proteins categorized as “structural molecule activities” decreased in response to
GABA (~45%) or insulin (~38%) and increased in the GABA + insulin group (~16%)
compared to the control (Supplementary Table 7). The numbers of cytoskeletal proteins
increased in the GABA (29%), insulin (12%), and GABA + insulin (35%) groups, while
the numbers of ribosomal proteins decreased in those groups by 51, 14, and 66%,
respectively (Table 2-1. A).
Table 2-1. A- Sub-groups of proteins categorized as “structural molecules” in the
glucagon interactome under conditions of 25 mM glucose. Panther GO-Slim
Molecular Function analysis resulted in 3 sub-categories. The values represent
protein hits as a percentage of the total number of hits within each sub-category
when α-TC1-6 cells were cultured in media containing 25 mM glucose.
Structural constituent

Structural

Extracellular

of cytoskeleton

constituent of

matrix structural

ribosome

constituent

Control

66.7

29.2

4.2

GABA

85.7

14.3

-

Insulin

75

25

-

GABA+Insulin

90

10

-

Compared to cells incubated in medium containing 25 mM glucose, there were dramatic
increases in the numbers of metabolic-regulatory-secretory proteins associated with
glucagon after treatment with GABA, insulin or GABA + insulin in cells incubated in
media containing 5.5 mM glucose (Figure 2- 5). In cells treated with GABA, glucagon is
predicted to directly interact with the following proteins: GRP78 (Hspa5), HSP 90alpha
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(Hsp90aa1), proprotein convertase subtilisin/kexin type 2 (PCSK2), heat shock 70 kDa
protein 1B (Hsp1b), calmodulin 1(Calm1), and guanine nucleotide-binding protein
G(I)/G(S)/G(O) subunit gamma-7 (Gng7) (Figure 2- 5A). Under insulin treatment, the
following proteins were predicted to directly interact with glucagon: GRP78, HSP 90alpha, annexin A5 (Anxa5), stathmin1 (Stmn1), fatty acid synthase (Fasn), and
chromogranin A (ChgA) (Figure 2- 5B); and only two proteins, GRP78 and PCSK2, were
predicted to directly interact with glucagon after treatment with GABA + insulin (Figure
2- 5C).
In the context of 5.5 mM glucose, the number of cytoskeletal proteins decreased, and the
number of ribosomal proteins increased compared to cells treated with GABA, insulin
and GABA + insulin in 25 mM glucose (Table 2-1. B). Interestingly, the total numbers of
proteins classified as “structural molecule activities” did not change appreciably across
treatments (Supplementary Table 8). However, differences became apparent when
cytoskeletal and ribosomal proteins were compared separately. When compared to 5.5
mM glucose alone, there were decreases of ~24 and ~35%, respectively, in the numbers
of cytoskeletal proteins when cells were treated with GABA or insulin alone, but a ~71%
increase in response to GABA + Insulin. Conversely, the numbers of ribosomal proteins
increased by ~26 and ~43% in response to GABA and insulin, respectively, and
decreased by ~69% in response to GABA + Insulin (Table 2-1. B).

78

Table 2-1. B - Sub-groups of proteins categorized as “structural molecules” in the
glucagon interactome under conditions of 5.5 mM glucose. Panther GO-Slim
Molecular Function analysis resulted in 3 sub-categories. The values represent
protein hits as a percentage of the total number of hits within each sub-category
when α-TC1-6 cells were cultured in media containing 5.5 mM glucose.
Structural constituent

Structural

Extracellular

of cytoskeleton

constituent of

matrix structural

ribosome

constituent

Control

50

45.5

4.5

GABA

38.1

57.1

4.8

Insulin

32.4

64.9

2.7

GABA+Insulin

85.7

14.3

-

2.4.7

The dynamic glucagon interactome reveals novel proteins
that regulate glucagon secretion

From our glucagon interactomes, we identified 11 proteins that interact with glucagon
after treatment of α-TC1-6 cells with either GABA or insulin in media containing 25 mM
glucose. To determine their effects on glucagon secretion, these proteins were depleted
with siRNAs (Supplementary Figure 2-4) and glucagon secretion and cell content were
measured.
Of these 11 proteins, knockdown of ELKS/Rab6-interacting/CAST family member 1
(ERC1) increased glucagon secretion (p < 0.001), while gene silencing of 14-3-3
zeta/delta (KCIP-1), cytosolic malate dehydrogenase (MDH1), FXYD domain-containing
ion transport regulator 2 (FXYD2) and protein disulfide-isomerase (PDI) reduced
glucagon secretion to the same statistically significant level (p < 0.001). As well,
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knockdown of peroxiredoxin-2 (PRDX2), ATP synthase F1 subunit alpha (ATP5F1A),
histone H4, and aconitate hydratase mitochondrial (ACO2) reduced glucagon secretion (p
< 0.01), as did knockdown of alpha-tubulin 2 (AT2) (p < 0.05) (Figure 2- 6A). Gene
silencing of MDH1, PRDX2, ATP5F1A, and FXYD2 reduced cellular glucagon content
to a significance level of p < 0.001. Gene silencing of KCIP-1, ACO2, Histone H4 and
PDI all reduced the levels of cellular glucagon content to a significance level of p < 0.01
and that for ERC1 at p < 0.05 (Figure 2- 6B). Gene silencing of GRP78 had no effect on
glucagon secretion, and reduced cellular glucagon content (p < 0.05).
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Figure 2-15. Glucagon secretion and cell content are regulated by a subset of
interactome proteins. (A) Glucagon secretion and (B) cell content in the
context of 25 mM glucose, and (C) glucagon secretion and (D) cell content in
the context of 5.5 mM glucose were assessed after siRNA-mediated gene
silencing of the following proteins: Alpha-tubulin 2 (AT2), ATP synthase F1
subunit alpha (ATP5F1A) , Malate dehydrogenase 1 (MDH1), Protein
disulfide-isomerase (PDI), ELKS/Rab6-interacting/CAST family member 1
(ERC1), Aconitate hydratase mitochondrial (ACO2), Peroxiredoxin-2
(PRDX2), 14-3-3 protein zeta/delta (KCIP-1), FXYD domain-containing ion
transport regulator 2 (FXYD2), histone H4, and GRP78 using pre-designed
siRNAs for the mouse genome. After siRNA transfection, α-TC1-6 cells were
cultured in DMEM containing 25 mM or 5.5 mM glucose for 24h and glucagon
levels were measured using ELISA. Values are expressed as mean ± SD
(α=0.05; n=3-4). *p<0.05; **p<0.01; ***p<0.001.
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that in 5.5 mM glucose. While neither GABA nor insulin affected glucagon secretion in
5.5 mM glucose, they suppressed glucagon secretion in 25 mM glucose (Supplementary
Figure 2- 5A). In the context of 25 mM glucose, GABA reduced cellular glucagon
content, while insulin increased cellular glucagon content (Supplementary Figure 2- 5B);
in contrast, neither GABA nor insulin alone affected cellular glucagon content, but in
combination, they decreased cellular glucagon content.

2.5

Discussion

We have identified a dynamic “glucagon interactome” within secretory granules of αcells that is altered in response to glucose levels and the paracrine effectors GABA and
insulin. We used a tagged glucagon construct, Fc-glucagon, to bring down proteins
within secretory granules. We validated enrichment of the secretory granules by nanoscale flow cytometry and immunoblotting with compartment-specific markers. We
identified a network of 392 proteins within the secretory granules that interact with
glucagon and showed a direct interaction with GRP78 and Histone H4. Components of
the interactome played a role in glucagon secretion, thus revealing a role for the
interactome in the regulation of glucagon secretion in α-TC1-6 cells.
We have previously shown that α-TC1-6 cells have elevated levels of both proglucagon
mRNA and glucagon secretion in response to 25 mM glucose (17), and other groups have
shown the same effect in isolated mouse islets (3), clonal hamster InR1G9 glucagonreleasing cells (3, 34), and perfused rat pancreas (35). We also showed that this
paradoxical glucagon release is accompanied by an up-regulation of components of the
regulated secretory pathway, particularly in the active forms of PC1/3 and PC2 that posttranslationally process proglucagon to glucagon, and in SNARE proteins that mediate
vesicle exocytosis (17). Under conditions of 5.5 mM glucose, the up-regulation in RNAbinding proteins that modulate biosynthesis of islet secretory granule proteins, along with
chaperonins, may indicate an increase in protein synthesis (36, 37). Chaperonins, as key
components of the cellular chaperone machinery, are involved in maturation of newlysynthesized proteins in an ATP dependent manner (36). As ATP-generating proteins,
such as ATP5F1A, MDH1, and glucose metabolic proteins, were also increased, we
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speculate that 5.5 mM glucose induced a stress response that resulted in increased protein
translation. This hypothesis is strengthened by the identification of cold shock protein,
peroxiredoxin, thiol-disulfide isomerase and thioredoxin within the glucagon interactome
at 5.5 mM glucose, all of which are up-regulated in pancreatic islets in response to stress
(37).
One protein that was consistently predicted as interacting directly with glucagon was the
ER stress protein and molecular chaperone GRP78. Previous proteomic studies have
identified GRP78 in islets and β-cells (38, 39). Its presence in α-cell secretory granules
may not be surprising, as it has previously been found in non-ER compartments such as
the nucleus and lysosomes. Our data suggest that GRP78 may be a novel sorting receptor
for glucagon in the regulated secretory pathway of α-cells. We have previously shown a
potential role of chromogranin A as a sorting receptor for glucagon in both α-TC1-6 cells
and PC12 cells (19), but unlike GRP78, we did not demonstrate any direct interactions
with glucagon. While knockdown of GRP78 did not reduce glucagon secretion, it did
reduce cell content, indicating a potential role in intracellular trafficking, but not
exocytosis, of glucagon.
Interestingly, we identified histone proteins as a functional part of the glucagon
interactome. The discovery of histone proteins within α-cell secretory granules is novel,
and supported by the findings that the cytosolic fraction of pooled islets from multiple
human donors had abundant amounts of the histone H2A (40). As well, quantitative
proteomics of both α-TC1 and ßTC3 cells revealed the presence of histones H4, H3,
H2A, H2B, and H1 (41). Our data indicate that one of these histones, H4, may directly
bind to glucagon and regulate its basal level of secretion, perhaps under conditions of
stress. Oxidative stress contributes to the pathogenesis of diabetes by disrupting the
balance between reactive oxygen species and antioxidant proteins (42). Such an
imbalance could target chromatin and globally alter profiles of gene expression,
especially those encoding histone and DNA-binding proteins (42, 43). Thus, we speculate
that the presence of histone H4 in the secretory granules could reflect a response to
microenvironmental stress. Furthermore, it has been suggested that histones contained
within secretory granules in neutrophils could function as a defense mechanism,
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interacting with the plasma membrane to generate extracellular traps in response to
bacterial infections (44). Thus, it is possible that histone proteins in the glucagon
interactome take a role in the fusion step of granule exocytosis. Additionally, secretion of
histones and other nuclear proteins has been associated with an inflammatory or
senescent secretory phenotype (45, 46).
The α-cell paracrine effectors, GABA and insulin, remodeled the glucagon interactome in
α-TC1-6 cells in a manner that was dependent on glucose levels. Compared to the
respective control groups, GABA altered >70 and >80% of the metabolic-regulatorysecretory proteins within the glucagon interactome in the context of 25 and 5.5 mM
glucose, respectively. One potentially novel GABA-regulated protein that may function
in glucagon secretion in 25 mM glucose is ERC1, which has a role in the formation of the
cytomatrix active zone and insulin exocytosis from β-cells (47), and we show for the first
time a potential inhibitory effect of ERC1 on glucagon secretion that may be dependent
on GABA. Ohara-Imaizumi et al. showed that ERC1 depletion in MIN6 cells and rat
pancreatic β-cells suppressed glucose stimulated insulin secretion (47). When pancreatic
β-cells were exposed to high glucose conditions, ERC1 takes a role in the process of
granule docking and fusion toward insulin exocytosis. Here, by showing that depletion of
ERC1 increased glucagon secretion at 25 mM glucose and reduced it at 5.5 mM glucose,
it is tempting to speculate that ERC1 is a part of the granule exocytosis machinery in αcells and plays a potential role in controlling glucagon exocytosis under diabetic
conditions. Another potentially novel player in GABA-regulated glucagon secretion is
KCIP-1, associated with β-cell survival (48). Furthermore, our proteomics findings
suggest that GABA may enhance glucose uptake and glucose tolerance through leucinerich repeat proteins. These proteins bind to the insulin receptor to promote glucose uptake
in β-cells (49), and thus may be a new paracrine, or even autocrine, regulator of α-cell
function. Interestingly, in the context of 5.5 mM glucose, GABA recruited PCSK2 and
secretogranin 2, known α- cell granule proteins that function in proglucagon processing
(19). Although our previous work showed no changes in PCSK2 in response to 5.5 mM
glucose (17), we now show that plasticity in PCSK2 expression may be due to GABA
under these glucose concentrations.
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In the context of 25 mM glucose, insulin treatment increased the number of biosynthetic
proteins, consistent with its role in cellular growth. Kinesin-like proteins also increased,
suggesting a potential role in α-cell secretory granule synthesis and glucose homeostasis,
as has been documented in β-cells (50). In the context of 5.5 mM glucose, insulin upregulated nucleoside diphosphate kinases A and B, proposed regulators of insulin
secretion (51). We also identified the small G proteins SAR1, Rab2A, and RhoA, present
in INS-1E cell secretory granules (52); however, their functions are not known.
Interestingly, treatment of the α-TC1-6 cells with GABA + insulin in 25 mM glucose
caused a dramatic decrease in the overall numbers of proteins within the glucagon
interactome. Interaction with GRP78 remained preserved, while a new protein,
microtubule-associated protein 2, appeared in the glucagon interactome. This protein may
have a potential role in glucose homeostasis, as it is down-regulated in isolated diabetic
rat islets exposed to low glucose conditions (53). In the context of 5.5 mM glucose, the
combination of GABA and insulin again predicted the presence of PCSK2 in the
glucagon interactome, as seen with GABA treatment alone and invites revisiting the
question of PCSK2 acting as a sorting receptor for glucagon (19).
The design of our experiments was to mimic blood glucose volatility in diabetes in
particular, and not in normal physiology, to investigate potential dynamic alterations in
the glucagon interactome (54). Here, we have identified the glucagon interactome in αTC1-6 cells after chronic exposure to extremely high glucose (25 mM), which, in
diabetes, paradoxically increases glucagon secretion from pancreatic α-cells (3, 5). We
further showed remodeling of this interactome by replacing that extremely high glucose
condition (25 mM) with a relatively low glucose (5.5 mM) medium, which mimic
conditions that represent glucose volatility in diabetes. However, we did not examine
changes in the glucagon interactome throughout a range of high and low glucose
conditions, which could be a limitation for the current study. Also, we used our negative
control, Fc alone, only in the two glucose conditions and not in treatments with GABA
and insulin, which may affect the interpretation of the interactome under these conditions.
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It is well-established that, under normal physiological conditions, glucagon secretion is
suppressed by high glucose (21). However, chronic hyperglycemia disrupts this fine
regulation and results in elevated glucagon secretion (34, 55). It has been documented
that chronic exposure to 25 mM glucose stimulates glucagon secretion in α-TC1-6 cells
(17), thus mimicking the α-cell response to glucose in the diabetic, and not normal,
condition.
While we presented a novel glucagon interactome within enriched secretory granules of
α-TC1-6 cells and its alterations due to nutritional or paracrine effectors, direct
comparisons to primary α-cells may be limited. When we compared our described
glucagon interactome with the transcriptomic profile of mouse α-cells (56), and human αcells (57), there were some differences in the protein profiles. Additionally, Lawlor et al.
(58) compared gene expression profiles of α-TC1 cells with their primary mouse and
human counterparts and showed a high level of discrepancy between them. One
possibility for this discrepancy may be changes in gene expression in primary cells while
cultured in vitro (17, 59). However, we feel that the findings we are reporting generally
show that: (1) networks of proteins can interact with glucagon within the secretory
granule compartment of the pancreatic α-cell; (2) this interactome is remodeled according
to the micro-environmental milieu; and (3) some proteins within the interactome can
regulate glucagon secretion. The next step will be to use our data to guide the
identification of glucagon-interacting proteins that may regulate glucagon secretion
within primary α-cells.
Under normal physiological conditions, GABA and insulin suppress glucagon secretion
in pancreatic α-cells (21, 60). This response to GABA and insulin may differ depending
on the cell line and experimental conditions used. Piro et al. (61) showed that with shortterm treatment, insulin significantly suppressed glucagon secretion in α-TC1-6 cells
without affecting cellular glucagon content. In INR1G cells, Kawamori et al. (62) showed
that silencing of the insulin receptor significantly increased glucagon secretion, indicating
that insulin receptor signaling is required for suppression of glucagon secretion. Here, we
show that treatment with insulin suppresses the long-term cumulative secretion of
glucagon when α-TC1-6 cells were cultured and chronically kept in 25 mM glucose.
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Interestingly, under these conditions, cellular glucagon content increased, perhaps due to
excess glucagon in the medium and its potential abolishing effect on insulin action (63).
In addition, this increase could be due to an autocrine effect of glucagon on proglucagon
gene expression, a notion that has been argued by Leibiger et al. for short-term effect of
glucagon on proglucagon gene expression in non-cumulative culturing (26). As well, it is
known that GABA inhibits glucagon secretion under high glucose conditions (64).
Importantly, our findings show reductions in both glucagon secretion and content.
Surprisingly, the combination of GABA and insulin did not suppress glucagon secretion,
leading to questions on the mechanism of the interactions between these two signaling
pathways.
In conclusion, we have described a novel and dynamic glucagon interactome in α-TC1-6
cells that is remodeled in response to glucose and the α-cell paracrine effectors, GABA
and insulin. Our proteomics approach has revealed a number of novel secretory granule
proteins that function in the regulation of glucagon secretion and illustrates the plasticity
in the protein components of the α-cell secretory granules. These findings provide an
important proteomics resource for further data mining of the α-cell secretory granules and
targeting diabetes treatment.
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Supplementary Figures

Supplementary Figure 2-1. Proglucagon gene knock down in α-TC1-6 cells.
cDNA synthesis was performed using total extracted RNA. Quantitative PCR
was achieved using Quant Studio Design and Analysis Real-Time PCR
Detection System in conjunction with the Maxima SYBR Green qPCR
Master Mix. The glucagon gene (Gcg) expression was determined in the
transfected cells with scrambled siRNA (control) or Gcg-KD. Glucagon gene
expression level was normalized to that of the internal control β-Actin. The
normalized level of transcripts in protein depleted cells was shown relative to
that of the negative control. Gene expression levels show >70% reduction in
the glucagon depleted group compare to the control.

Supplementary Figure 2-2. Proglucagon gene knock down in α-TC1-6 cells.
cDNA synthesis was performed using total extracted RNA. Quantitative PCR
was achieved using Quant Studio Design and Analysis Real-Time PCR
Detection System in conjunction with the Maxima SYBR Green qPCR
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Master Mix. The glucagon gene (Gcg) expression was determined in the
transfected cells with scrambled siRNA (control) or Gcg-KD. Glucagon gene
expression level was normalized to that of the internal control β-Actin. The

Supplementary Figure 2-3. Immunoblotting assessment of enrichment in
the extracted secretory granules. Western blot analyses of the cell extract
(CE), extract of the secretory granules in media containing 25 mM glucose
(E-25) and 5.5 mM glucose (E-5.5). Proteins were resolved on 4-12% SDSPAGE gel (NuPAGE), transferred to PVDF membrane and probed with
antibodies to identify (A) vesicle-associated membrane protein 2
(VAMP2) for mature secretory granules; (B) TGN46 for the trans-Golgi
network; (C) Lamin B1 for the nuclear envelope; and (D) Calreticulin for
the endoplasmic reticulum. The immunoreactive bands were visualized
using HRP-conjugated goat anti-rabbit secondary antibody and Clarity
Western ECL substrate.
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Supplementary Figure 2-4. Nano-scale flow cytometry of the enriched
secretory granules. (A) Calibrating nano flow cytometer for size distribution
of the enriched secretory granules using ApogeeMix beads. Circles indicate
bead sizes of 110, 179, 235, 304, 585 and 880 nm. (B) Gating the glucagon+
secretory granules (L488) using FITC secondary antibody against the Fc
segment of Fc-glucagon. (C) Size distribution of the secretory granules within
the gate containing glucagon+ secretory granules.

Supplementary Figure 2-5. Nano-scale flow cytometry of the enriched
secretory granules. (A) Calibrating nano flow cytometer for size distribution
of the enriched secretory granules using ApogeeMix beads. Circles indicate
bead sizes of 110, 179, 235, 304, 585 and 880 nm. (B) Gating the glucagon+
secretory granules (L488) using FITC secondary antibody against the Fc
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segment of Fc-glucagon. (C) Size distribution of the secretory granules within
the gate containing glucagon+ secretory granules.

Supplementary Figure 2-6. siRNA mediated gene silencing of target proteins in
the secretory granules. α-TC1-6 cells were transfected with 50 nM pooled of 3
predesigned siRNAs. Cell extract subjected to Western blot to follow expression
of the following target proteins. For each protein, band intensity of the expressed
protein was determined using ImageJ software. Values of ≥ 70% reduction in
protein expression levels were considered as successful protein depletion. Alphatubulin 2 (AT2), ATP synthase F1 subunit alpha (ATP5F1A), cytosolic malate
dehydrogenase (MDH1), Protein disulfide-isomerase (PDI), ELKS/Rab6interacting/CAST family member 1 (ERC1), Aconitate hydratase mitochondrial
(ACO2), peroxiredoxin-2 (PRDX2), FXYD domain-containing ion transport
regulator 2 (FXYD2), 14-3-3 zeta/delta (KCIP-1), Histone H4 and Glucose
regulated protein 78 KDa (GRP78).
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Supplementary Figure 2-7. siRNA mediated gene silencing of target proteins in
the secretory granules. α-TC1-6 cells were transfected with 50 nM pooled of 3
predesigned siRNAs. Cell extract subjected to Western blot to follow expression

25 mM

5.5 mM

25 mM

5.5 mM

Supplementary Figure 2-8. Alterations in glucagon secretion and cell glucagon
content of α-TC1-6 cells in response to nutritional and paracrine effectors. αTC1-6 cells were cultured and kept under high glucose (25 mM) condition for a
long-term. These chronically exposed cells to high glucose condition were
treated with GABA (25 µM), insulin (100 pM) or GABA (25 µM) + insulin (100
pM) for 24h in 25 mM or 5.5 mM glucose containing media. At the end if
incubation, glucagon levels were measured in the media and cell extract. Values
were expressed as mean ± SD (n=4-5) and compared among groups using oneWay ANOVA (α=0.05).*p<0.05, **p<0.01. ***p<0.001.

Figure 2-18. Overexpression of Stathmin-2 increases the presence of glucagon in
late endosomes. After transfection with either empty vector (A), vector encoding
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 cells were immunostained
using primary antibodies against glucagon and the late endosome-lysosome
marker LAMP2A. Images were acquired and analysed for co-localization as
described in Figure 1. (A) In wt cells, glucagon and LAMP2 show some colocalization at the plasma membrane100
(arrowheads). (B) In cells overexpressing
Stmn2, there is colocalization of glucagon and LAMP2A in the cell body
(arrowheads) and at the plasma membrane (arrows). (C) In cells in which
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Supplementary Tables

Supplementary Table 2-1. Reagents and resources.
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research
Resource
Identification
number

GABA

Sigma

Cat # A2129

Insulin

Sigma

Cat # 105-16

ApogeeMix beads

Apogee

Cat # 1493

FlowSystems Inc.
Lipofectamine 2000 Invitrogen

Cat # 11668-027

Acetonitrile

BDH

Cat # 83639.100E

Formic acid

Optima

Cat # A117-50

Dithiotreitol

Fisher Scientific

Cat # BP172-5

Iodoacetamide

Alfa Aesar

Cat # A14715

Protein A

GE Healthcare Life

Cat # 71-7090-00

Sepharose CL-4B

Science

AF

HYPERSEP C18

ThermoFisher

Cat # 60108-303

column

Scientific

Mini Protease

Sigma-Aldrich

Cat # 11836153001

Inhibitor Cocktail
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Trypsin

Promega

Cat # V5111

Supplementary Table 2-1 (Continued)
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research Resource
Identification
number

Collagen type 1

Sigma

Cat # C3867

NuPAGE

Invitrogen

Cat # NP0335Box

iBlot Gel Transfer

Invitrogen

Cat # IB401001

Abcam

Cat # Ab21685

Abcam

Cat # ab181869

stacks, PVDF
Anti-GRP78 Bip
(HSPA5) antibody
Anti-VAMP2
antibody
Anti-TGN46

AB_ 2721005
Abcam

Cat # 1605

antibody
Anti-LaminB1

AB_443307
Abcam

Cat # ab16048

antibody
Anti-Histone H4

AB_ 443298
Abcam

Cat # ab10158

antibody (ChIP
grade)
Anti-Glucagon

AB_ 296888
Abcam

Cat # Ab10988

antibody

AB_ 297642
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ProLong Gold

Molecular Probes

Cat # P36935

antifade reagent
with DAPI

Supplementary Table 2-1 (Continued)
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research Resource
Identification
number

AlexaFluor 488

Molecular Probes

Cat # A-11001

goat anti-mouse IgG
AlexaFluor 488

AB_ 2534069
Molecular Probes

Cat # A-11012

goat anti-rabbit IgG
Fc-specific FITC

AB_ 2534079
Sigma

Cat # F4143

antibody
Anti-ERC1

AB_ 259587
Abcam

Cat # ab 180507

Abcam

Cat # ab 180152

Abcam

Cat # ab 176569

Abcam

Cat # ab 129105

Anti-peroxiredoxin2 Abcam

Cat # ab 109367

antibody
Anti- MDH1
antibody
Anti-ATP5A
antibody
Anti-Aconitase 2
antibody

antibody
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Anti-TUBA1B

Abcam

Cat # ab 108629

Abcam

Cat # ab 51129

antibody
Anti-14-3-3zeta
antibody

Supplementary Table 2-1 (Continued)
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research
Resource
Identification
number

Anti Na/K ATPase

Thermo Fisher

Cat# PA5-75640

antibody

Scientific

Anti-PDI antibody

Abcam

Cat # ab 3672

Anti-Calreticulin

Abcam

Cat # ab 2907

Abcam

Cat # ab 10158

antibody
Anti-Histone H4
antibody
Software and Algorithms
Panther

http://Pantherdb.org

Classification
System
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SCR_015893

ExPASY

http://string-db.org

SCR_015894

UniportKB

http://uniport.org

SCR_004426

STRING

https://string-db.org

SCR_005223

Bioinformatics
Resource Portal

Experimental model: cell line
α-TC1-6 cell

mouse pancreatic αcell line

Supplementary Table 2-1 (Continued)
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research
Resource
Identification
number

Recombinant DNA
FC_pcDNA3.1(+)

http://www.genscript.com

FC-

http://www.genscript.com

glucagon_pcDNA3.1(+)
Commercial assays
Glucagon assay kit

ThermoFisher

Cat # EHGCG

Scientific
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BCA protein assay kit

Biovision

Cat # K813-2500

Incorporated
Histone H4

Abcam

Cat # Ab185914

RNeasy extraction kit

Qiagen

Cat # 74104

SuperScript III First

Thermo Fisher Cat # 11752050

Strand Synthesis

Scientific

Modification Multiplex
Assay Kit

Supermix
Maxima SYBR Green

Thermo Fisher Cat # K0221

qPCR Master Mix

Scientific

Maxima SYBR Green

Thermo Fisher Cat # K0221

qPCR Master Mix

Scientific

siRNA
14-3-3 zeta/delta

Thermo Fisher Cat # S76190
Scientific

Cat # S76191
Cat # S76189

Aconitase

Thermo Fisher Cat # S61847
Scientific

Cat # S61845
Cat # S61846
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Supplementary Table 2-1 (Continued)
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research
Resource
Identification
number

Sodium-Potassium

Thermo Fisher

Cat # S62726

transporting subunit

Scientific

Cat # S201066

gamma
Cat # S62725
Protein disulfide-

Thermo Fisher

Cat # S71205

isomerase

Scientific

Cat # S71206

Peroxiredoxin-2

Thermo Fisher

Cat # S204749

Scientific

Cat # S232273
Cat # S232272

Malate

Thermo Fisher

Cat # S69980

dehydrogenase

Scientific

Cat # S69981

cytoplasmic
Cat # S69979
Aconitate hydratase

Thermo Fisher

Cat # S61847

mitochondrial

Scientific

Cat # S61845
Cat # S61846

ELKS/Rab6-

Thermo Fisher

Cat # S200972

interacting/CAST

Scientific

Cat # S99972

family member 1
Cat # S99973
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Supplementary Table 2-1 (Continued)
REAGENT or

SOURCE

IDENTIFIER

RESOURCE

Research Resource
Identification
number

Tubulin alpha-1B

Thermo Fisher

Cat # S202331

chain

Scientific

Cat # S202330
Cat # S75582

ATP synthase

Thermo Fisher

Cat # S62742

subunit alpha

Scientific

Cat # S62744

mitochondrial
Cat # S62743
Histone H4

Thermo Fisher

Cat # S234377

Scientific

Cat # S234480
Cat # S234061

GCG (PPG)

Thermo Fisher

Cat# s66523

Scientific

Cat# s66522
Cat# s66524

β-Actin

Thermo Fisher

Cat# s61899

Scientific

Cat# s200989
Cat# s200988

Mission siRNA

Sigma

SIC001

Universal Negative
Control #1
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Supplementary Table 2-2. List of proteins that interact the with Fc segment alone
under conditions of 25 mM glucose.
Associated proteins with Fc segment in 25 mM glucose containing medium
Endoplasmin, Protein disulfide-isomerase A6, Leucine zipper protein 1, Eukaryotic
initiation factor 4A-II, DnaJ homolog subfamily C member 12, UPF0565 protein
C2orf69 homolog, Obg-like ATPase 1, Catenin beta-1, Nascent polypeptide-associated
complex subunit alpha, muscle-specific form, Protein scribble homolog, AP2associated protein kinase 1, Drebrin-like protein, Sorting nexin-2, Nucleoporin NUP53,
Transient receptor potential cation channel subfamily M member 6, Transcription
elongation factor A protein-like 3, Tyrosine-protein phosphatase non-receptor type 23,
Protein phosphatase 1G, T-complex protein 1 subunit zeta, Malate dehydrogenase,
mitochondrial, Protein CutA, Transaldolase, Dihydropyrimidinase-related protein 2,
60S ribosomal protein L10-like, Probable cation-transporting ATPase 13A1, 40S
ribosomal protein S30, Phosphatidylethanolamine-binding protein 1, RNA-binding
protein 14, Synaptosomal-associated protein 25, 60S ribosomal protein L8,
Phosphatidylinositol-binding clathrin assembly protein, Importin subunit beta-1, Tcomplex protein 1 subunit delta, Proliferating cell nuclear antigen, Zyxin, Non-histone
chromosomal protein HMG-17, Aldose reductase, T-complex protein 1 subunit eta,
Sulfated glycoprotein 1, Stress-induced-phosphoprotein 1, Peroxiredoxin-1, 40S
ribosomal protein S6, Ataxin-2-like protein, C-1-tetrahydrofolate synthase,
cytoplasmic, Endophilin-B1, ProSAAS, Histidine triad nucleotide-binding protein 1,
Transitional endoplasmic reticulum ATPase, Desmoplakin, Myosin-10, Clathrin light
chain A, 26S protease regulatory subunit 6A, Rab GDP dissociation inhibitor alpha,
Eukaryotic translation initiation factor 4 gamma 1, N-acetylglucosamine-6-sulfatase,
Histone H3.3C, Eukaryotic initiation factor 4A-I, Transketolase, 60S ribosomal protein
L22, Glucosidase 2 subunit beta, Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase 48 kDa subunit, Nuclear transport factor 2, Golgin subfamily A
member 4, Tryptophan--tRNA ligase, cytoplasmic, Eukaryotic translation initiation
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factor 4B, Tripeptidyl-peptidase 2, Ubinuclein-2, V-type proton ATPase subunit G 1,
Peroxiredoxin-4, Aminoacyl tRNA synthase complex-interacting multifunctional
protein 1, Potassium voltage-gated channel subfamily C member 3, Afadin, Nuclear
autoantigenic sperm protein, 60S ribosomal protein L19, Histone H3.1, Vacuolar
protein sorting-associated protein VTA1 homolog, Coatomer subunit alpha, COP9
signalosome complex subunit 3, Thioredoxin domain-containing protein 17,
Serine/threonine-protein kinase PAK 2, Rho-associated protein kinase 2, G proteinregulated inducer of neurite outgrowth 1, Pleckstrin homology domain-containing
family G member 5, F-actin-capping protein subunit beta, Histone H1.3, Microtubuleassociated protein 4, Septin-9, Stromal membrane-associated protein 2, Trifunctional
purine biosynthetic protein adenosine-3, Eukaryotic initiation factor 4A-III, Creatine
kinase B-type, Chromatin target of PRMT1 protein,
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Supplementary Table 2-3. List of proteins that interact the with Fc segment alone
under conditions of 5.5 mM glucose.
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial, Histone-lysine Nmethyltransferase SETD1B, Importin subunit beta-1, Aldose reductase, Tumorassociated calcium signal transducer 2, Heterogeneous nuclear ribonucleoprotein A3,
Elongation factor 1-gamma, 60S ribosomal protein L22, Calmodulin, Ubiquitinconjugating enzyme E2 N, Actin, alpha skeletal muscle, Peptidyl-prolyl cis-trans
isomerase FKBP2, V-type proton ATPase catalytic subunit A, Ubiquitin-like modifieractivating enzyme 1, Nascent polypeptide-associated complex subunit alpha, L-lactate
dehydrogenase B chain, Farnesyl pyrophosphate synthase, Protein FAM171A2, Msx2interacting protein, T-complex protein 1 subunit gamma, Calreticulin, Electron transfer
flavoprotein subunit alpha, mitochondrial, ER membrane protein complex subunit 2,
40S ribosomal protein S2, L-lactate dehydrogenase A chain, Acyl-CoA-binding
protein, Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha
isoform, L-lactate dehydrogenase C chain, Alpha-actinin-4, Nuclease-sensitive
element-binding protein 1, Chromogranin-A, Prefoldin subunit 2, Protein FAM117B,
Stromal interaction molecule 2, ATP-dependent RNA helicase DDX3X, Nucleosome
assembly protein 1-like 4, 60S ribosomal protein L5, Protein SET, Neurofilament light
polypeptide, Transgelin-2
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Supplementary Table 2-4. Profile of the histone, cytoskeletal and ribosomal proteins
contained within the glucagon interactome when α-TC1-6 cells were incubated for
24h in media containing 25 mM or 5.5 mM glucose.
25 mM glucose containing medium

5.5 mM glucose containing medium

Histone H2A type 1, Histone H2A type 1-

Histone H2A type 3, Histone H2A type 1-

F, Histone H2A type 1-F, Histone H2A

F, Histone H2B type 1-B, Histone H1.3,

type 1-H, Histone H2A type 1-K, Histone

Histone H2A type 2-A, Histone H2B type

H2A type 2-A, Histone H2A type 2-B,

1-H, Histone H2B type 3-A, Histone H4,

Histone H2A type 2-C, Histone H2A type Histone H3.3, Histone H3.3C, Histone
3, Histone H2A.J, Histone H2AX,

H2A.J, Histone H2A type 1-K, Histone

Histone H2B type 1-B, Histone H2B type

H3.1, Histone H2A type 2-C, Histone

1-C/E/G, Histone H2B type 1-F/J/L,

H2A type 1, Histone H2B type 1-K,

Histone H2B type 1-H, Histone H2B type

Histone H3.2, Histone H2B type 1-M,

1-K, Histone H2B type 1-M, Histone H2B Histone H1.2, Histone H2B type 3-B,
type 1-P, Histone H2B type 2-B, Histone

Histone H2B type 2-B, Histone H2B type

H2B type 2-E, Histone H2B type 3-A,

2-E, Histone H2B type 1-C/E/G, Histone

Histone H2B type 3-B

H2A type 1-H, Histone H1.5, Histone
H2B type 1-P, Histone H1.1, Histone
H2A type 2-B, Histone H2A type 1-F,
Histone H2B type 1-B, Histone H2AX,
Histone H2B type 1-F/J/L

Actin cytoplasmic 2, Actin cytoplasmic 1,
Actin alpha skeletal muscle, Actin aortic
smooth muscle, Actin alpha cardiac
muscle 1, Actin gamma-enteric smooth
muscle, Beta-actin-like protein 2, Tubulin
beta-4B chain, Tubulin alpha-1C chain,
Tubulin alpha-1A chain, Tubulin alpha1B chain, Tubulin beta-5 chain, Tubulin

Actin, cytoplasmic 1, Actin, cytoplasmic
2, Tubulin beta-4B chain, Tubulin beta4A chain, Tubulin beta-5 chain, Tubulin
alpha-1C chain, Tubulin beta-3 chain,
Tubulin alpha-1A chain, Tubulin alpha1B chain

beta-2B chain, Tubulin beta-4A chain,
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Tubulin beta-3 chain, Tubulin beta-2A
chain
40S ribosomal protein S15a, 60S
ribosomal protein L23a, 40S ribosomal
60S ribosomal protein L13, 40S ribosomal protein S7, 40S ribosomal protein S25,
protein S14, 60S ribosomal protein L23a,

60S ribosomal protein L13, 40S ribosomal

60S ribosomal protein L11, 60S acidic

protein S14, 40S ribosomal protein S12,

ribosomal protein P1, Elongation factor 1-

Elongation factor 1-alpha 2, 60S acidic

delta, Elongation factor 1-alpha 2,

ribosomal protein P1, 60S ribosomal

Eukaryotic translation initiation factor

protein L11, 60S ribosomal protein L18,

5A-1, Elongation factor 1-alpha 1

60S acidic ribosomal protein P2,
Elongation factor 2, Ubiquitin-60S
ribosomal protein L40, Eukaryotic
translation initiation factor 4B
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Supplementary Table 2-5. Profile of the histone, cytoskeletal and ribosomal proteins
within the glucagon interactome. α-TC1-6 cells were cultured in media containing
25 mM glucose and treated with GABA (Table S5-A), insulin (Table S5-B) and
GABA+ insulin (Table S5-C). Proteins were identified using LC-MS/MS.
Table-S5-A
GABA + 25 mM glucose
Histone H2A type 1, Histone H2A type 1-F, Histone H2A type 1-F, Histone H2A type
1-H, Histone H2A type 1-K, Histone H2A type 2-A, Histone H2A type 2-B, Histone
H2A type 2-C, Histone H2A type 3, Histone H2A.J, Histone H2AX, Histone H2B type
1-B, Histone H2B type 1-C/E/G, Histone H2B type 1-F/J/L, Histone H2B type 1-H,
Histone H2B type 1-K, Histone H2B type 1-M, Histone H2B type 1-P, Histone H2B
type 2-B, Histone H2B type 2-E, Histone H2B type 3-A, Histone H2B type 3-B,
Histone H4

Actin cytoplasmic 1, Actin cytoplasmic 2, Anionic trypsin-2, Tubulin alpha-1A chain,
Tubulin alpha-1B chain, Tubulin alpha-1C chain, Tubulin beta-2A chain, Tubulin beta2B chain, Tubulin beta-3 chain, Tubulin beta-4A chain, Tubulin beta-4B chain,
Tubulin beta-5 chain

60S acidic ribosomal protein P1, 60S ribosomal protein L11, Elongation factor 1-alpha
1, Eukaryotic translation initiation factor 4E
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S5-B
Insulin + 25 mM glucose
Histone H1.5, Histone H1t, Histone H2A type 1, Histone H2A type 1-F, Histone H2A
type 1-F, Histone H2A type 1-H, Histone H2A type 1-K, Histone H2A type 2-A,
Histone H2A type 2-B, Histone H2A type 2-C, Histone H2A type 3, Histone H2A.J,
Histone H2AX, Histone H2B type 1-B, Histone H2B type 1-C/E/G, Histone H2B type
1-F/J/L, Histone H2B type 1-H, Histone H2B type 1-K, Histone H2B type 1-M,
Histone H2B type 1-P, Histone H2B type 2-B, Histone H2B type 2-E, Histone H2B
type 3-A, Histone H2B type 3-B, Histone H4

Actin alpha cardiac muscle 1, Actin alpha skeletal muscle, Actin aortic smooth
muscle, Actin cytoplasmic 1, Actin cytoplasmic 2, Actin gamma-enteric smooth
muscle, Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin alpha-1C chain,
Tubulin beta-2A chain, Tubulin beta-2B chain, Tubulin beta-3 chain, Tubulin beta-4A
chain, Tubulin beta-4B chain, Tubulin beta-5 chain

40S ribosomal protein S14, 60 kDa heat shock protein mitochondrial, 60S acidic
ribosomal protein P1, 60S ribosomal protein L11, Elongation factor 1-alpha 1,
Elongation factor 1-alpha 2, Eukaryotic translation initiation factor 5A-1
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S5-C
GABA+ insulin + 25 mM glucose
Histone H2B type 1-B, Histone H2B type 1-B, Histone H2B type 1-C/E/G, Histone
H2B type 1-F/J/L, Histone H2B type 1-H, Histone H2B type 1-K, Histone H2B type 1M, Histone H2B type 1-P, Histone H2B type 2-B, Histone H2B type 2-B, Histone H2B
type 2-E, Histone H2B type 3-A, Histone H2B type 3-B

Actin alpha cardiac muscle 1, Actin alpha skeletal muscle, Actin aortic smooth muscle,
Actin cytoplasmic 1, Actin cytoplasmic 1, Actin gamma-enteric smooth muscle,
Tubulin alpha-1A chain, Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin
alpha-1C chain, Tubulin alpha-1C chain

60S ribosomal protein L23a
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Supplementary Table 2-6. Profile of the histone, cytoskeletal and ribosomal proteins
within the glucagon interactome. α-TC1-6 cells were cultured in media containing
5.5 mM glucose and treated with GABA (Table S6-A), insulin (Table S6-B) and
GABA+insulin (Table S6-C). Proteins were identified using LC-MS/MS.
Table S6-A
GABA + 5.5 mM glucose
Histone H1.3, Histone H1.5, Histone H2A type 1, Histone H2A type 1-F, Histone H2A
type 1-H, Histone H2A type 1-K, Histone H2A type 2-A, Histone H2A type 2-C,
Histone H2A type 3, Histone H2A.J, Histone H2B type 1-B, Histone H2B type 1C/E/G, Histone H2B type 1-F/J/L, Histone H2B type 1-H, Histone H2B type 1-K,
Histone H2B type 1-P, Histone H2B type 2-B, Histone H2B type 2-E, Histone H2B
type 3-A, Histone H2B type 3-B, Histone H3.1, Histone H3.3, Histone H3.3C, Histone
H4, Histone H1.2, Histone H2B type 1-B, Histone H2B type 1-M, Histone H3.2
Actin cytoplasmic 1, Actin cytoplasmic 2, Tubulin alpha-1A chain, Tubulin alpha-1B
chain, Tubulin alpha-1C chain, Tubulin beta-3 chain, Tubulin beta-5 chain
40S ribosomal protein S14, 40S ribosomal protein S15, 40S ribosomal protein S25,
40S ribosomal protein S5, 40S ribosomal protein SA, 60S acidic ribosomal protein P1,
60S acidic ribosomal protein P2, 60S ribosomal protein L11, 60S ribosomal protein
L15, 60S ribosomal protein L18, 60S ribosomal protein L7a, 60S ribosomal protein
L7a, Ubiquitin-60S ribosomal protein L40, Eukaryotic initiation factor 4A-I,
Eukaryotic initiation factor 4A-II, Eukaryotic initiation factor 4A-III, Elongation factor
1-alpha 1, Elongation factor 2
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Table S6-B
Insulin + 5.5 mM glucose
Histone H1.1, Histone H1.2, Histone H1.3, Histone H1.4, Histone H1.5, Histone H1t,
Histone H2A type 1, Histone H2A type 1-F, Histone H2A type 1-H, Histone H2A type
1-K, Histone H2A type 2-A, Histone H2A type 2-C, Histone H2A type 3, Histone
H2A.J, Histone H2B type 1-B, Histone H2B type 1-C/E/G, Histone H2B type 1-F/J/L,
Histone H2B type 1-H, Histone H2B type 1-K, Histone H2B type 1-M, Histone H2B
type 1-P, Histone H2B type 2-B, Histone H2B type 3-A, Histone H2B type 3-B,
Histone H3.1, Histone H3.2, Histone H3.3, Histone H3.3C, Histone H4
Actin alpha cardiac muscle 1, Actin alpha skeletal muscle, Actin aortic smooth muscle,
Actin cytoplasmic 1, Actin cytoplasmic 2, Actin gamma-enteric smooth muscle,
Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin alpha-3 chain, Tubulin
alpha-4A chain, Tubulin beta-5 chain, Tubulin-specific chaperone A
40S ribosomal protein S12, 40S ribosomal protein S14, 40S ribosomal protein S15a,
40S ribosomal protein S18, 40S ribosomal protein S19, 40S ribosomal protein S20,
40S ribosomal protein S25, 40S ribosomal protein S3, 40S ribosomal protein S3, 40S
ribosomal protein S3a, 40S ribosomal protein S8, 40S ribosomal protein SA, 60 kDa
heat shock protein mitochondrial, 60S acidic ribosomal protein P1, 60S acidic
ribosomal protein P2, 60S ribosomal protein L11, 60S ribosomal protein L12, 60S
ribosomal protein L13, 60S ribosomal protein L15, 60S ribosomal protein L18, 60S
ribosomal protein L23a, 60S ribosomal protein L26, 60S ribosomal protein L27, 60S
ribosomal protein L7, 60S ribosomal protein L7, 60S ribosomal protein L9, Elongation
factor 1-alpha 1, Elongation factor 1-alpha 2, Elongation factor 1-beta, Elongation
factor 1-delta, Elongation factor 2, Eukaryotic initiation factor 4A-I, Eukaryotic
initiation factor 4A-II, Eukaryotic initiation factor 4A-III, Transcription elongation
factor A protein-like 3, Transcription elongation factor A protein-like 3, Transcription
elongation factor A protein-like 5, Transcription factor SOX-1,
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Table S6-C
GABA+ insulin + 5.5 mM glucose
Histone H1.5, Histone H2A type 1, Histone H2A type 1-F, Histone H2A type 1-H,
Histone H2A type 1-K, Histone H2A type 2-A, Histone H2A type 2-C, Histone H2A
type 3, Histone H2A.J, Histone H2AX, Histone H2B type 1-B, Histone H2B type 1C/E/G, Histone H2B type 1-H, Histone H2B type 1-M, Histone H2B type 1-P, Histone
H2B type 2-B, Histone H2B type 3-A, Histone H2B type 3-B, Histone H4, Histone
H2A type 2-B, Histone H2B type 1-F/J/L
Actin cytoplasmic 1, Tubulin alpha-1A chain, Tubulin alpha-1B chain, Tubulin alpha1C chain, Tubulin beta-2A chain, Tubulin beta-2B chain, Tubulin beta-3 chain,
Tubulin beta-4A chain, Tubulin beta-4B chain, Tubulin beta-5 chain
60S ribosomal protein L11, Elongation factor 1-alpha 1, Elongation factor 2
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Supplementary Table 2-7. Functional categories of the proteins within the glucagon
interactome in the context of 25 mM glucose. Proteins were functionally categorized
using Panther GO-Slim Molecular Function analysis. Values show protein hits as
percentage of the total number of hits within each category when α-TC1-6 cells were
cultured in media containing 25 mM glucose.
Control

GABA

Insulin

GABA+
insulin

Binding

47.4

46.1

48.5

51.4

Structural

24.7

13.7

15.4

28.6

19.6

22.5

26.2

17.1

1

5.9

2.3

-

4.1

1

2.3

-

3.1

6.9

4.6

2.9

-

2.9

-

-

-

1

0.8

-

molecule
activity
Catalytic
activity
Receptor
activity
Translation
regulator
activity
Transporter
activity
Signal
transducer
activity
Antioxidant
activity
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Supplementary Table 2-8. Functional categories of proteins within the glucagon
interactome in the context of 5.5 mM glucose. Proteins were functionally categorized
using Panther GO-Slim Molecular Function analysis. Each value shows protein hit
as percentage of the total number of hits within each category when α-TC1-6 cells
were cultured in media containing 5.5 mM glucose.

Control

GABA

Insulin

GABA+
insulin

Binding
Structural

48.4

43.8

43.5

50.6

15

11.4

14.9

17.6

25.5

28.6

31

22.4

2

1.6

1.2

1.2

2.6

1.1

2

2.4

3.9

4.9

4.3

4.7

2

1.6

1.6

1.2

molecule
activity
Catalytic
activity
Receptor
activity
Translation
regulator
activity
Transporter
activity
Antioxidant
activity
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Channel

-

0.5

-

-

-

6.5

1.6

-

regulator
activity
Signal
transducer
activity
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3. Stathmin-2 Mediates Glucagon Secretion from Pancreatic
α-cells
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3.1 Abstract
Inhibition of glucagon hypersecretion from pancreatic α-cells is an appealing strategy for
the treatment of diabetes. Our hypothesis is that proteins that associate with glucagon
within α-cell secretory granules will regulate glucagon secretion, and may provide
druggable targets for controlling abnormal glucagon secretion in diabetes. Recently, we
identified a dynamic glucagon interactome within the secretory granules of the α cell line,
α-TC1-6, and showed that select proteins within the interactome could modulate
glucagon secretion. In the present study, we show that one of these interactome proteins,
the neuronal protein stathmin-2, is expressed in α-TC1-6 cells and in mouse pancreatic αcells, and is a novel regulator of glucagon secretion. The secretion of both glucagon and
Stmn2 was significantly enhanced in response to 55 mM K+, and immunofluorescence
confocal microscopy showed co-localization of stathmin-2 with glucagon and the
secretory granule markers chromogranin A and VAMP-2 in α-TC1-6 cells. In mouse
pancreatic islets, Stathmin-2 co-localized with glucagon, but not with insulin, and colocalized with secretory pathway markers. To show a function for stathmin-2 in
regulating glucagon secretion, we showed that siRNA—mediated depletion of stathmin-2
in α-TC1-6 cells caused glucagon secretion to become constitutive without any effect on
proglucagon mRNA levels, while overexpression of stathmin-2 completely abolished
both basal and K+-stimulated glucagon secretion. Overexpression of stathmin-2 increased
the localization of glucagon into the endosomal-lysosomal compartment, while depletion
of stathmin-2 reduced the endosomal localization of glucagon. Therefore, we describe
stathmin-2 as having a novel role as an α-cell secretory granule protein that modulates
glucagon secretion via trafficking through the endosomal-lysosomal system. These
findings describe a potential new pathway for the regulation of glucagon secretion, and
may have implications for controlling glucagon hypersecretion in diabetes.

Keywords: glucagon, α-cell, glucagon hypersecretion, glucagon interactome, stathmin-2
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3.2

Introduction

Hyperglucagonemia is a characteristic sign of diabetes, causing fasting hyperglycemia
and glycemic volatility. Clinically, glycemic variability contributes to the development of
diabetes complications (1). Persistent hyperglucagonemia may exacerbate abnormal
glucose metabolism in patients with type 2 diabetes and lead to metabolic disturbances in
obese and prediabetic individuals (2). Further complicating glucose homeostasis in
diabetes is the direct effect of glucose on the α-cells; while glucagon secretion is
maximally suppressed at plasma glucose concentrations of 5–10 mM, it increases at
glucose levels above 10 mM, thus exacerbating hyperglycemia (3–6). Therefore,
controlling excess glucagon secretion may be a potential therapeutic strategy for diabetes
(7) so that glycemia and glucose metabolism may be better regulated. Such an approach
has been suggested as a priority for the treatment of diabetes (1).
Combating hyperglucagonemia could be theoretically achieved by (i) inhibition of
glucagon action at target organs by blocking the glucagon receptor, or (ii) inhibition of
glucagon secretion from the pancreatic α cells. While in the short-term the former could
be an effective therapeutic strategy, it can lead to α cell hyperplasia and
hyperglucagonemia over a long-term period (8), along with a risk of hypoglycemia (9)
and disturbances in lipid metabolism (10). Therefore, inhibiting glucagon secretion,
rather than blocking the glucagon receptor, may be a more appropriate therapeutic
approach for the treatment of hyperglucagonemia of diabetes (11).
It has been documented that suppression of glucagon secretion can be mediated at the
systemic, paracrine or intrinsic level (12). As a systemic modulator, GLP-1 inhibits
glucagon secretion; however, there are controversies as to whether GLP-1 directly
inhibits glucagon secretion from α cells by signaling through the α-cell GLP-1R (13–15),
or indirectly by increasing inter-islet somatostatin or insulin secretion (13, 16). Glucagon
secretion is also suppressed by paracrine signaling through the insulin, somatostatin and
GABAA receptors on the α cell (16–18) At an intrinsic level, glucose directly or
indirectly inhibits glucagon secretion from the α cell (19–22) by altering downstream
activities of Ca2+ channels, KATP channels (23), and trafficking of secretory granules (24).
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We are pursuing the hypothesis that glucagon secretion can also be controlled by proteins
within the secretory granule that associate with glucagon. By conducting secretory
granule proteomics in α-TC1-6 cells, we have recently described a dynamic glucagon
interactome, and shown that components of this interactome can play a role in
modulating glucagon secretion (25). Of these components, a protein of particular interest
is Stathmin-2 (Stmn2 or SCG10), a member of the stathmin family of Golgi proteins (26)
that may play a role in the regulation of neuroendocrine secretion (27). In the human
islet, Stmn2 expression may be unique to α-cells, as shown by genome-wide RNA-Seq
analysis (28) and single cell transcriptomics (23), and α-cell Stmn2 mRNA expression is
differentially regulated in type 2 diabetes (29). These studies, together with our
proteomics findings, led us to hypothesize that Stmn2 may function in α cells to modulate
glucagon secretion. In the present study, we show that Stmn2 is co-localized with
glucagon in secretory granules of α-TC1-6 cells and controls glucagon secretion by
trafficking through the endosomal/lysosomal system.

3.3
3.3.1

Materials and methods
Cell culture

α-TC1-6 cells (a kind gift from C. Bruce Verchere, University of British Columbia,
Vancouver, BC, Canada) were cultured in regular DMEM medium containing 5.6 mM
glucose (Cat# 12320032, Thermo Fisher Scientific) supplemented with 15% horse serum
(Cat# 26050088, Thermo Fisher Scientific), 2.5% FBS (Cat# 16000044, Thermo Fisher
Scientific), L-glutamine and sodium pyruvate. For secretion experiments, cells were
plated in 6 –well plates and for all experiments, a low passage number (up to P6) was
used. Twenty-four hours prior to secretion experiments, media were removed and
replaced with DMEM without supplements. To evaluate (25) the regulated secretion of
glucagon, cells were washed twice with HBSS, pre-incubated for 2 h in DMEM without
supplements, then incubated for 15 min with or without KCl (55 mM). These media were
collected into tubes containing protease inhibitor (PMSF, 45 mM) and phosphatase
inhibitors (sodium orthovanadate, 1 mM; and sodium fluoride 5 mM) while tubes were
kept on ice. After collection, media were centrifuged at 13,000× g for 5 min at 4°C, and
the supernatant was collected into new microfuge tubes and immediately kept at −80°C
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until analysis. After media were removed, cells were washed using ice-cold PBS (pH 7.4)
and lysed in RIPA buffer (Cat# 89900, Thermo Fisher Scientific) containing
abovementioned protease and phosphatase inhibitors. The lysed cells were centrifuged at
13,000× g for 5 min at 4°C and the supernatant was kept at −80°C for protein assays.

3.3.2

Gene construct and plasmid preparation

To generate the expression plasmid for Stmn2, the Kozak sequence (GCCACC), signal
peptide sequence and coding sequence of mouse Stmn2
(https://www.uniprot.org/uniprot/P55821) were ligated into the NheI and ApaI restriction
sites of pcDNA3.1(+) MAr. The construct was synthesized by GENEART GmbH, Life
Technologies (GeneArt project 2018AAEGRC, Thermo Fisher Scientific). Then, Max
Efficiency DH5α competent cells (Thermo Fisher Scientific, Cat# 18258012) were
transformed according to the manufacturer's protocol. Plasmids were then extracted and
purified using the PureLink HiPure Plasmid Maxiprep Kit (Thermo Fisher Scientific,
Cat# K210006) for downstream experiments. Correct assembly of the final construct was
verified by gene sequencing at the London Regional Genomics Facility, Western
University. For Stmn2 overexpression studies, α-TC1-6 cells were transiently transfected
by pcDNA3.1 (+) MAr-stmn2 construct or empty vector (negative control). All
transfections were done using Lipofectamine 2000 (Cat#11668-027, Invitrogen). To
monitor normal cell growth and morphology, cells were checked daily by the EVOS cell
imaging system (Thermo Fisher Scientific). The efficiency of transfection was
determined in a preliminary study at >70% through co-transfection with pEGFP.

3.3.3

Gene silencing experiments

siRNA-mediated depletion of stathmin-2
Functional analysis of Stmn2 was done by gene silencing experiments. siRNAs targeting
three regions within the Stmn2 mRNA (Cat# s73356, s73354, s73355) were chosen from
pre-designed mouse siRNAs (Silencer siRNA, Thermo Fisher Scientific). The control
group was treated with Mission siRNA Universal Negative Control # 1 (Cat# SIC001,
Sigma-Aldrich). Gene silencing was done based on a previously published protocol (30)
and as we have done previously with some modifications (25). Briefly, α-TC1-6 cells
127

were cultured in regular DMEM to 60% confluency. Media were removed and replaced
with 2 mL Opti-MEM (Cat# 31985-070, Gibco) containing 50 nM pooled siRNAs with
Lipofectamine 2000. After 8 h, media were changed to regular DMEM without sera (FBS
and horse serum) and cultured for 72 h. Then, media were refreshed and cells were
cultured for 15 min in the absence or presence of 55 mM KCl as described above. Gene
silencing was confirmed by analyzing mRNA expression levels of Stmn2. After
removing media, cells were washed by cold PBS (pH 7.4) and total RNA was extracted
(RNeasy extraction kit; Cat # 74104, Qiagen). cDNA synthesis was performed using the
SuperScript III First Strand Synthesis Supermix for qRT-PCR (Cat # 11752050, Thermo
Fisher Scientific), according to the supplier's protocol. Real-time PCR was performed
using Quant Studio Design and Analysis Real-Time PCR Detection System in
conjunction with the Maxima SYBR Green qPCR Master Mix (Cat # K0221, Thermo
Fisher Scientific) using specific primers for Stmn2: forward, 5′GCAATGGCCTACAAGGAAAA-3′; reverse, 5′-GGTGGCTTCAAGATCAGCTC-3′;
and β-Actin; forward, 5′-AGCCATGTACGTAGCCATCC-3′; reverse, 5′CTCTCAGCTGTGGTGGTGAA-3′. Gene expression levels for stathmin-2 were
normalized to that of β-Actin. The normalized level of transcripts in the depleted cells
was shown relative to that of the non-targeting negative control. Relative expression
levels were determined as percent of alterations compared to the control. Statistical
analysis was performed using t-test at α = 0.05.
Proglucagon gene expression levels following Stmn2 depletion
After siRNA treatments, proglucagon gene expression levels were measured by real-time
PCR as described above using proglucagon-specific primers (forward: 5′CAGAGGAGAACCCCAGATCA-3′, reverse: 5′-TGACGTTTGGCAATGTTGTT-3′).

3.3.4

Immunoblotting

To test for effects of siRNA transfection on levels of Stmn2, α-TC1-6 cells were lysed
using non-ionic lysis buffer (50 mM Tris pH 7.4, 150mM NaCl, 1% Triton X-100 plus
cOmplete Mini Protease Inhibitor Cocktail and 5 μg/mL Aprotinin). Proteins were
resolved by 4-12% NuPAGE gel (Cat # NP0335Box, Invitrogen), transferred to a PVDF
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membrane (Cat # IB401001, Invitrogen) and probed with primary antibodies (Stmn2,
Cat# 720178, Thermo Fisher Scientific; 1:1000; beta actin, Cat# ab8227, Abcam, 1:1000)
overnight. Immunoreactive bands were visualized using HRP-conjugated goat anti-rabbit
secondary antibody (Cat# 31460, Invitrogen; 1:1000) and Clarity Western ECL substrate
(Cat# 170-5061, Bio-Rad). Images were acquired on a BioRad ChemiDoc Imaging
System. Total cell extracts from control cells were used as positive control.

3.3.5

Immunofluorescence confocal microscopy

α-TC1-6 cells
To determine if Stmn2 and glucagon could be co-localized to the same intracellular
compartments, we used immunofluorescence confocal microscopy. Wild type α-TC1-6
cells were seeded on collagen (type I)-coated coverslips and grown in regular DMEM,
then incubated in non-supplemented DMEM for 24 h. At the end of incubation, cells
were washed once with PBS, fixed in 2% paraformaldehyde (in PBS) for 30 min,
permeabilized with 0.25% Triton X-100 (in PBS) for 5 min and washed with PBS. After
1 h incubation with blocking buffer (10% goat serum in 1% BSA/PBS), coverslips were
incubated with primary antibodies against glucagon (mouse anti- glucagon antibody, Cat
# ab10988, Abcam; 1:1000), Stathmin-2 (goat anti-SCG10 antibody, Cat # ab115513,
Abcam; 1:1000), secretory granule marker, chromogranin A (mouse anti-ChgA antibody,
Cat# MAB319, Sigma; 1:1000), secretory granule marker, VAMP2 (rabbit anti-VAMP2,
Cat# ab215721, Abcam; 1:1000), early endosome marker, EEA1 (rabbit antiEEA1, Cat #
ab 2900, Abcam; 1:500) or the lysosomal marker, Lamp2A (rabbit anti-Lamp2A, Cat#
ab18528, Abcam; 1:500) overnight. After washing with PBS, coverslips were incubated
with the following secondary antibodies as appropriate: goat anti-mouse IgG Alexa Fluor
488 (Cat# A-11001, Molecular Probes; 1:500), goat anti-rabbit IgG Alexa Fluor 594
(Cat# A11037, Invitrogen; 1:500) or donkey anti-goat IgG Alexa Fluor 555 (Cat#
ab150130, Abcam; 1:500) Invitrogen) for 2 h in the dark at room temperature. Then,
coverslips were washed with PBS and mounted on glass slides using DAPI containing
ProLong antifade mountant (Cat # P36935, Molecular Probes) for image analysis by
confocal immunofluorescence microscopy (Nikon A1R, Mississauga, Canada). Coverslip
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preparation was done at least four different times with freshly thawed cells. Each thawed
batch of the cell was cultured and passaged three times.
Mouse pancreatic islets
All mice were treated in accordance with the guidelines set out by the Animal Use
Subcommittee of the Canadian Council on Animal Care at Western University based on
the approved Animal Use Protocol AUP 2012-020. Six to eight-week old male C57BL/6
mice (n = 7) were sacrificed by cervical dislocation under anesthesia with inhalant
isoflurane. Pancreata were collected and fixed in 10% buffered formalin for 3 days and
treated with 70% ethanol for 1 day before paraffin embedding at the Molecular Pathology
Core Facility, Robarts Research Institute, Western University. The paraffin-embedded
blocks were longitudinally sectioned in 5 μm slices and fixed onto glass microscope
slides. The samples were de-paraffinized by graded washes using xylene, ethanol and
PBS. Background Sniper (Cat# BS966H, Biocare Medical) was used to reduce nonspecific background staining. Samples were incubated with primary antibodies against
glucagon (1:500), Stmn2 (1:250), insulin (Cat# ab7842, Abcam; 1:250) and TGN46
(Cat# ab16059, Abcam; 1:200) and followed by secondary antibodies of goat anti-mouse
IgG Alexa Fluor 488 (1:500), donkey anti-goat IgG Alexa Fluor 555 (1:500), and goat
anti-guinea pig IgG Alexa Fluor 647 (Cat# A21450, Invitrogen; 1:500). Nuclei were
stained with DAPI (1:1000), and tissues were mounted in Prolong Antifade mountant
(Cat# P36982, Thermo Fisher Scientific). As a background control for Stmn2, islet
staining for Stmn2 was done using only the secondary antibody.
Image acquisition
High-resolution images were acquired through a Nikon A1R Confocal microscope with a
×60 NA plan-Apochromat oil differential interference contrast objective and NISElements software (Nikon, Mississauga, Canada) using a pinhole of 1 Airy unit. Images
were sampled according to Nyquist criteria, and images of the Nyquist-cropped areas
were captured at 1,024 × 1,024 pixel resolution, and deconvoluted by the 2Ddeconvolution algorithm of the NIS-Elements software, thereby optimizing images for
accurate co-localization of fluorescent signals.
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Image Analysis
For cell image analysis, we prepared three coverslips for each group. Image analysis was
performed by NIS-Elements software (Nikon, Mississauga, Canada), using the colocalization option and Pearson's correlation coefficient (PCC). Regions of interest (ROI)
were manually drawn around distinct single or multicellular bodies, and merged values of
glucagon and Stmn2 were taken for analysis. Colocalization of the pixels from each
pseudo-colored image was used to calculate Pearson's correlation coefficient, as we
described previously (25, 31).
For mouse pancreatic islets, images were captured using four channels of green
(glucagon), red (Stmn2), purple (insulin) and blue (nucleus; DAPI). To calculate the
extent of co-localization between glucagon and stathmin-2 (glucagon+, Stmn2+), images
of 15 islets per pancreas were captured and analyzed by Pearson's correlation coefficient
(PCC). To this end, we manually drew ROIs around each islet and then defined PCC
values for colocalization between Stmn2 and glucagon or insulin using the colocalization
option of the NIS-Elements software. To predict expression levels of Stmn2 in α or βcells of the pancreatic islets we have performed binary analysis using M-Thresholding
algorithm of NIS-Elements software, followed by regression analysis of Stmn2 vs.
glucagon or insulin using GraphPad Prism 7.

3.3.6

Immunoelectron microscopy

Double immunogold transmission electron microscopy was done based on the protocol
by Aida et al. (32) with some modifications. Briefly, pieces of mouse pancreata were cut
and immediately placed into McDowell Trump's fixative (Cat# 18030-10; Electron
Microscopy Sciences) for 1h. Then, after washing with PBS, samples were dehydrated in
increasing concentrations of ethanol (10, 20, 30, 50, 70, 90, 100, and 100%) at 30 min per
concentration. We followed the following protocol for LR White embedding and
incubation: Incubation in ethanol-LR White mixture (3:1, v/v; 2 h), ethanol-LR White
(1:1, v/v; 8 h), ethanol-LR White mixture (1:3, v/v; 12 h), pure LR White mixture (12 h),
pure LR White (12 h) and pure LR White (12 h). The sample was then placed into a beem
capsule, filled with pure LR White and incubated at 50°C for 24 h. Semi-thin sections
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(500 nm) were cut from the embedded sample for Toluidin blue staining (1% Toluidin
blue for 2 min). By defining the position of the islets, ultra-thin sections (70 nm) were
prepared using a diamond microtome. The sections were mounted on formvar-carbon
coated nickel grid (300 meshes) (Cat# FCF300-NI, Electron Microscopy Sciences). Then,
slices were washed with Tris-buffered saline (Tris 1M, NaCl 5M pH 8) containing 0.05%
Tween 20 (TBS-T) and incubated in blocking buffer (2% BSA in PBS plus 0.05% Tween
20) for 30 min at room temperature. Slices were incubated with primary antibodies (1:10
in blocking buffer) against glucagon (Cat# ab92517; Abcam) and Stmn2 (Cat# ab115513;
Abcam) at 4°C overnight. After washing with TBS-T, slices were incubated with gold
conjugated secondary antibodies (1:50 in blocking buffer) of donkey anti-goat IgG (18
nm; cat# ab105270, Abcam) and goat anti-rabbit IgG (10 nm; Cat# ab27244; Abcam) for
2 h at room temperature. After washing with TBS-T and staining with Uranyless (Cat#
22409, Electron Microscopy Sciences), transmission electron microscopy was conducted
at the Biotron Experimental Research Center, Western University, London, ON, Canada.

3.3.7

Primary islet culture

Islet preparation and culture
Islet preparation and culture was done according to the Li et al. (33) protocol with some
modifications. Male C57BL/6 mice (n = 5–6) were euthanized by CO2. The abdominal
cavity was opened and 3 mL of 1.87 mg/mL collagenase V (Cat# C9263, Sigma;) in
Hanks' Balanced Salt Solution was injected into the common bile duct. The pancreas was
then removed, placed into a Falcon tube containing 2 mL of the ice-cold collagenase V
solution and incubated for 12 min at 37°C with occasional shaking. Digestion was
stopped by adding 1mM CaCl2 and the cell suspension was washed twice in the CaCl2
solution. Islets were collected into a sterile petri dish using a 70 μm cell strainer with
RPMI1640 containing 11 mM glucose plus 20 mM glutamine, 10% FBS and penicillin
(110 U/mL) and streptomycin (100 μg/mL). 180 islets were handpicked into the medium
under a stereomicroscope and incubated for 2 h in the cell culture incubator. The medium
was then changed to RPMI1640 containing 11 mM glucose plus 10% FBS and penicillin
(110 U/mL) and streptomycin (100 μg/mL) and cultured overnight at 37°C.
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Islet glucagon secretion experiments
Glucagon secretion from islets was measured based on the protocol by Suckow et al.
(34). Briefly, islets were washed three times using Krebs-Ringer bicarbonate (KRB)
buffer (135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2,
1.5 mM CaCl2, 10 mM HEPES; pH 7.4) containing 11 mM glucose, and then preincubated in this buffer for 1 h. Glucagon secretion was tested by incubating islets in
KRB containing 1 mM glucose in the presence or absence of arginine (25 mM) for 20
min. Media were collected into microcentrifuge tubes containing enzyme inhibitors
(PMSF, 45 mM; Aprotinin, 5 μg/mL and sodium orthovanadate, 1 mM). Samples were
centrifuged at 14,000 × g for 5 min at 4°C and the supernatant was collected and kept at
−80°C until analysis.
Measurement of glucagon and stathmin-2
Glucagon levels in the media were determined by ELISA (Cat # EHGCG, Thermo Fisher
Scientific) according to the manufacturer's instructions. Stmn2 levels in the media were
measured using mouse stathmin-2 ELISA kit (Cat# MBS7223765, MyBioSource)
according to the manufacturer's instruction. For each measurement, the values were
compared between groups by t-test and among groups by 1-Way ANOVA and
Bonferroni post-hoc test (α = 0.05). Cell protein levels were determined using BCA assay
and used for normalization of the glucagon or Stmn2 levels.

3.3.8

Statistical analysis

Values were compared among treatment groups by one-way ANOVA or between groups
by unpaired t-test using Sigma Stat 3.5 software (α = 0.05). For image analysis, colocalization of channels in the merged images was calculated by Pearson's correlation
coefficient (PCC) using NIS-Elements software (Nikon, Canada).

3.4

Results

Immunostaining of glucagon and Stmn2 in α-TC1-6 cells revealed significant colocalization, as shown in Figure 3-1A and by a positive Pearson's correlation coefficient
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(0.74 ± 0.05) between endogenously expressed glucagon and Stmn2. Linear regression of
binary intensities showed a sensitive and significant relationship between colocalization
of glucagon and Stmn2 (Figure 3- 1B). The secretion of both glucagon and Stmn2 was
significantly enhanced in response to 55 mM K+ (Figure 3- 1C), with corresponding
decreases in cell contents (Figure 3- 1D). To further confirm the presence of stathmin-2
in secretory granules, α-TC1-6 cells were immunostained for stathmin-2 and the
secretory granule markers chromogranin A (Figure 3- 1E) and VAMP2 (Figure 3-1F).
There was moderate colocalization (35) between Stmn2 and chromogranin A (PCC 0.58
± 0.07) or VAMP2 (PCC 0.56 ± 0.09) (Figure 3-1G), indicating that Stmn2 is partially
localized to the secretory granule compartment in α-TC1-6 cells.
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Figure 3-1. Stathmin-2 localizes to secretory granules in α-TC1-6 cells. α-TC1-6
cells were immunostained using primary antibodies against glucagon (GCG,
green) and stathmin-2 (Stmn2, red). DAPI (blue) indicates the nucleus in the
merged image. Resolution of the images was extended by applying Nyquist XY
scan and then 2D- Deconvolution in NIS Elements image analysis software.
Images are representative of four biological replicates with 3 technical replicates
each. (A) Areas of yellow in the merged image show colocalization of glucagon
and Stmn2. (B) Linear regression analysis of binary intensities of glucagon and
Stmn2 predicts a significant (p<0.001) correlation. Each value represents mean
intensities of 5-7 cells. The secretion of both glucagon and Stmn2 (C) was
significantly increased after KCl stimulation (KCl Stim)for 15 min. Cell Stmn2
and glucagon levels show reduction following KCl stimulation (KCl Stim) (D).
Values are expressed as mean ± SEM (n=5). *p<0.05. Stmn2 colocalizes with the
secretory granule proteins ChgA (E) and VAMP2 (F), as indicated by yellow
punctate staining. (G) The extent of colocalization was analyzed by Pearson
correlation coefficient for Stmn2 with ChgA or with VAMP2. Dots represent all
biological and technical replicates.
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Figuremouse
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3.4.1

secretion from α-TC1-6 cells. The model denotes status of glucagon secretion
Immunostaining of mouse pancreatic islets showed a pattern of Stmn2
from α-TC1-6 cells in normal physiology or in the event of Stmn2- depletion or
immunofluorescence similar to that of glucagon, and not insulin (Figure 3- 2A). Analysis
overexpression. Blue arrows indicate the normal trafficking of glucagon, together
by Pearson correlation showed a strong colocalization between glucagon and Stmn2 in
with Stmn2, to secretory granules, where they are stored until their release is
the islets (PCC = 0.77 ± 0.02), but not between insulin and Stmn2 (Figure 3-2B). Linear
triggered by a stimulus. Stmn2 overexpression (red arrows) reduces the amount
regression analysis of the binary intensities revealed a very strong and significant
of glucagon available for secretion by diverting secretory granules to lysosomes.
relationship between Stmn2 and glucagon immunofluorescence (Figure 3- 2C), while
Stmn2 depletion (black arrows) reduces the trafficking of glucagon into secretory
there was no significant relationship between Stmn2 and insulin (Figure 3- 2D). There
granules and promotes the constitutive release of glucagon.Figure 3-3. Stathmin-2
was also a strong relationship between Stmn2 and the trans Golgi marker, TGN46 (PCC
localizes to secretory granules in α-TC1-6 cells. α-TC1-6 cells were
= 0.72 ± 0.09) in both islet clusters (Figure 3- 2E) and mature islets (Figure 3- 2F).
immunostained using primary antibodies against glucagon (GCG, green) and
stathmin-2 (Stmn2, red). DAPI (blue) indicates the nucleus in the merged image.
Resolution of the images was extended
136by applying Nyquist XY scan and then 2DDeconvolution in NIS Elements image analysis software. Images are
representative of four biological replicates with 3 technical replicates each. (A)
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Figure 3-4. Stathmin-2 is present in α-cells, but not β-cells, in murine pancreatic
islets. Pancreata of C57BL/6 mice (n=7; 5µm sections) were immunostained for
against glucagon (GCG), stathmin-2 (Stmn2) and insulin (INS). Images were
acquired and analysed for co-localization as described in Figure 1. (A) Both
glucagon and Stmn2 localize to the mantle of the islets, and areas of yellow in the
merged image demonstrate dual positive α-cells (glucagon+ and Stmn2+). (B)
Pearson’s correlation coefficient for colocalization of Stmn2 and glucagon or
insulin. (C) Linear regression analysis predicts a strong positive correlation
between the binary intensities of glucagon and Stmn2 (p<0.001). (D) There is no
correlation between the binary intensities of insulin and Stmn2. (E, F)
Colocalization of Stmn2 and the trans-Golgi marker TGN46 in murine pancreatic
islets. Areas of white (arrows in the magnified panel) indicate co-localization of
glucagon, Stmn2 and TGN46 in islet clusters (E) and a single islet (F).
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Figure 3-7. Glucagon and Stmn2 are present within secretory granules of
pancreatic α-cells. (A) Immunogold labels for both glucagon (10 nm; white
arrows) and Stmn2 (18 nm; black arrows) are localized within secretory
granules. The low magnification image (25000×, scale bar = 1 μm) shows the
ultrastructure of one α-cell. N (nucleus); M (mitochondria); ER (endoplasmic
reticulum); SG (secretory granule). The magnified image (41000×, scale bar
= 0.6 μm) highlights the presence of immunogold labels within a single
secretory granule. (B) Isolated mouse islets were incubated in the presence or
absence of 25 mM Arg for 20 min. Both glucagon and Stmn2 secretion from
murine islets is stimulated by arginine. Values were normalized to the nonstimulated condition and expressed as mean ± SEM (n=5-6). *p<0.01.

3.4.2
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magnification image (25000×, scale bar = 1 μm) shows the ultrastructure of
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Figure 3-10. Silencing Stathmin-2 increased glucagon secretion and
overexpression of stathmin-2 suppressed glucagon secretion in α-TC1-6 cells.
Wild type (wt; control) and stathmin-2 depleted (Stmn2-KD) α-TC1-6 cells
were preincubated 2h in serum- free medium and then incubated with or
without KCl (55 mM) for 15 min. (A) Glucagon secretion is significantly
stimulated by KCl in wt cells, while in Stmn2-KD cells, basal glucagon
secretion is increased and does not respond to KCl. * p<0.01 compared to basal
secretion in wt cells. (B) Stmn2 mRNA levels are decreased by about 70% after
siRNA-mediated depletion in α-TC1-6 cells. Values are means ± SEM (n=5), *
p<0.01. (C) siRNA-mediated silencing of Stmn2, shutdown expression of
Stmn2.Western blot (WB) shows a faint band for Stmn2 after siRNA-mediated
depletion of Stmn2 in α-TC1-6 cells. (D) Proglucagon mRNA levels are not
affected by siRNA- mediated depletion of stathmin-2. (E) Glucagon secretion is
inhibited by overexpression of Stmn2. α-TC1-6 cells were transfected with
pcDNA3.1 (+) MAr-stmn2 construct or empty vector (control). Both basal
(p<0.001) and K+-stimulated (p<0.001) (KCl stimulation; KCl Stim) glucagon
secretion were inhibited by overexpression of Stmn2. Values are means ± SEM
(n=4).

3.4.3

Stmn2 directs glucagon into early endosomes

Figure 3-11. Glucagon and Stmn2 are present within secretory granules of
In wild type α-TC1-6 cells, there was weak co-localization between glucagon and the
pancreatic α-cells. (A) Immunogold labels for both glucagon (10 nm; white
early endosome marker EEA1 (Figure 3- 5A) (PCC = 0.15 ± 0.02). When Stmn2 was
arrows) and Stmn2 (18 nm; black arrows) are localized within secretory
overexpressed (Figure 3- 5B), the extent of colocalization between glucagon and EEA1
granules. The low magnification image (25000×, scale bar = 1 μm) shows the
increased markedly (PCC = 0.53±0.08). Depletion of Stmn2 (Figure 3- 5C) drastically
ultrastructure of one α-cell. N (nucleus); M (mitochondria); ER (endoplasmic
reduced the extent of colocalization (PCC = 0.05) between glucagon and EEA1.
reticulum); SG (secretory granule). The magnified image (41000×, scale bar =
Pearson's correlation coefficient of co-localization between glucagon and Stmn2 showed
0.6 μm) highlights the presence of immunogold labels within a single secretory
a significant increase when Stmn2 was overexpressed (p < 0.001) and a significant
granule. (B) Isolated mouse islets were incubated in the presence or absence of
reduction when Stmn2 was knocked down (p < 0.05) compared to the control (Figure 325 mM Arg for 20 min. Both glucagon and Stmn2 secretion from murine islets
is stimulated by arginine. Values were normalized to the non-stimulated
condition and expressed as mean ± SEM
(n=5-6). *p<0.01.Figure 3-12.
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Silencing Stathmin-2 increased glucagon secretion and overexpression of
stathmin-2 suppressed glucagon secretion in α-TC1-6 cells. Wild type (wt;

5D). These findings suggest that Stmn2 plays a role in directing glucagon toward early
endosomes.

143

Figure 3-13. Stathmin-2 modulates glucagon trafficking through early
endosomes. After transfection with either empty vector (A), vector encoding
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 cells were immunostained
using primary antibodies against glucagon and the early endosome marker
EEA1. Images were acquired and analysed for co-localization as described in
Figure 1. Colocalization of glucagon and EEA1 (yellow puncta) are indicated
by arrows in wt cells (A) or arrowheads in cells overexpressing Stmn2 (B). (D)
Level of colocalization between glucagon and EEA1 was determined by
Pearson’s correlation coefficient in wt cells, cells in which Stmn2 was
overexpressed (OE) and in which Stmn2 was knocked down by siRNA (KD).
Values were expressed as mean ± SEM (n=5) and compared by 1-Way
ANOVA. *p<0.05; **<0.001 compared to wt.

3.4.4

Stmn2 overexpression increases glucagon presence in the

Figurelate
3-14.
Silencing Stathmin-2 increased
glucagon secretion and
endosome/lysosome
compartment
overexpression of stathmin-2 suppressed glucagon secretion in α-TC1-6 cells.
Similar to our findings in early endosomes, there was a weak correlation between
Wild type (wt; control) and stathmin-2 depleted (Stmn2-KD) α-TC1-6 cells
glucagon and the late endosome-lysosome marker, Lamp2A (PCC = 0.2 ± 0.02) in wild
were preincubated 2h in serum- free medium and then incubated with or
type α-TC1-6 cells (Figures 3- 6A,D). Following overexpression of Stmn2, the levels of
without KCl (55 mM) for 15 min. (A) Glucagon secretion is significantly
colocalization between glucagon and Lamp2A were significantly increased (PCC = 0.89
stimulated by KCl in wt cells, while in Stmn2-KD cells, basal glucagon
± 0.05, p < 0.001) (Figures 3- 6B,D). Depletion of Stmn2 significantly reduced the extent
secretion is increased and does not respond to KCl. * p<0.01 compared to basal
of colocalization between glucagon and Lamp2A compared to wild type cells (PCC =
secretion in wt cells. (B) Stmn2 mRNA levels are decreased by about 70% after
0.001, p < 0.01) (Figures 3- 6C,D). Interestingly, the signal intensity of the endosiRNA-mediated depletion in α-TC1-6 cells. Values are means ± SEM (n=5), *
lysosomal marker, Lamp2A, was significantly increased (p < 0.01) upon overexpression
p<0.01. (C) siRNA-mediated silencing of Stmn2, shutdown expression of
of Stmn2, but did not change upon depletion of Stmn2 (Figure 3- 6E).
Stmn2.Western blot (WB) shows a faint band for Stmn2 after siRNA-mediated
depletion of Stmn2 in α-TC1-6 cells. (D) Proglucagon mRNA levels are not
affected by siRNA- mediated depletion of stathmin-2. (E) Glucagon secretion is
inhibited by overexpression of Stmn2. α-TC1-6 cells were transfected with
pcDNA3.1 (+) MAr-stmn2 construct or empty vector (control). Both basal
(p<0.001) and K+-stimulated (p<0.001) (KCl stimulation; KCl Stim) glucagon
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secretion were inhibited by overexpression of Stmn2. Values are means ± SEM
(n=4). Figure 3-15. Stathmin-2 modulates glucagon trafficking through early
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Figure 3-16. Overexpression of Stathmin-2 increases the presence of glucagon in
late endosomes. After transfection with either empty vector (A), vector encoding
Stmn2 (B) or siRNAs against Stmn2 (C), α-TC1-6 cells were immunostained
using primary antibodies against glucagon and the late endosome-lysosome
marker LAMP2A. Images were acquired and analysed for co-localization as
described in Figure 1. (A) In wt cells, glucagon and LAMP2 show some colocalization at the plasma membrane (arrowheads). (B) In cells overexpressing
Stmn2, there is colocalization of glucagon and LAMP2A in the cell body
(arrowheads) and at the plasma membrane (arrows). (C) In cells in which
Stmn2 levels are depleted, there is almost no detectable co-localization of
glucagon and LAMP2A. (D) Level of colocalization between glucagon and
LAMP2A was determined by Pearson’s correlation coefficient in wt cells, cells
in which Stmn2 was overexpressed (OE) and in which Stmn2 was knocked down
by siRNA (KD). (E) Fluorescence intensity of Lamp2A in wt cells, and following
overexpression (Stmn2-OE) or knockdown (Stmn2-KD) of Stmn2. Values are
expressed as mean ± SD and compared by 1-Way ANOVA. *p<0.01; **<0.001
3.5
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6 cells and mouse pancreatic α-cells, respectively. Stathmin-2 is part of a family of
*p<0.05; **<0.001 compared to wt.Figure 3-18. Overexpression of Stathmin-2
increases the presence of glucagon in 146
late endosomes. After transfection with
either empty vector (A), vector encoding Stmn2 (B) or siRNAs against Stmn2
(C), α-TC1-6 cells were immunostained using primary antibodies against

neuronal phosphoproteins that associates with intracellular membranes, notably the Golgi
and vesicle transporters, in neurons (36). Although Stmn2 has been identified as a
neuron-specific protein that functions in differentiation and development, its presence in
pancreatic α-cells is not surprising, as several types of neuronal proteins, such as SNARE
proteins, neurotransmitters and granins, are also expressed in endocrine cells (37–39).
The expression of neuronal proteins such as Stmn2 in α-cells may be due to the absence
of the transcriptional repressor RE-1 silencing transcription factor (REST) in mature
endocrine cells (40, 41). The absence of Stmn2 in mouse pancreatic β-cells suggests that
transcriptional silencing programs may operate in a cell-specific manner.
Our results indicate that Stmn2 is localized largely to punctate structures within α-TC1-6
cells, notably at the plasma membrane. Its colocalization with glucagon, ChgA and
VAMP2 at the plasma membrane suggests that it is efficiently sorted from the Golgi to
plasma membrane-associated secretory granules. Double immunogold labeling TEM
confirmed the presence of glucagon and Stmn2 within secretory granules of α-cells in
mouse pancreatic islets. The presence of Stmn2 within the dense core of the granule
suggests that it is part of the soluble granule cargo along with glucagon. These results are
consistent with our secretory granule proteomics, which predicted the presence of both
glucagon and Stmn2 in secretory granules of α-TC1-6 cells (25). Our model also
predicted that the complement of proteins within α-cell secretory granules differs in
response to microenvironmental inputs, so it possible that Stmn2 is present only in a
subpopulation of secretory granules. The trafficking of Stmn2 to secretory granules in αTC1-6 cells may occur through specific molecular domains within its sequence. The
subcellular trafficking pattern of Stmn2 in neurons and neuroendocrine cells is
determined by its N-terminal extension, which contains a Golgi localization domain and a
membrane anchoring domain that contains two conserved Cys residues as sites for
palmitoylation (36). This lipid modification occurs in the Golgi (42) and is sufficient and
necessary for the association of Stmn2 with Golgi membranes, and its sorting to postGolgi vesicles (42, 43). While we have not directly shown that palmitoylation of these
Cys residues is required for localization in secretory granules in α-TC1-6 cells, it is likely
that this is a conserved sorting mechanism in neuroendocrine cells.
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Consistent with its localization within secretory granules, the secretion of both glucagon
and Stmn2 was significantly enhanced in response to 55 mM K+. Although there was a
statistically significant response to KCl, α-TC1-6 cells as a rule do not show robust
secretory responses to KCl, glucose or other secretagogues. In general, α-TC1-6 cells
differ in their complement of transcriptional and epigenetic factors from mouse primary
α-cells, which may explain the relatively blunted secretory response seen in this cell line
(44). The reduced response to glucose in particular could be due to a low efficiency in
coupling between the glycolytic and TCA pathways, as has been shown in pancreatic
islets (45). We have not shown alterations in glucagon secretion in response to
physiological secretagogues such as glucose, which could be a limitation for our current
study. Nonetheless, we were able to show similar secretory behavior of glucagon and
Stmn2 in isolated mouse islets, thus confirming their localization within the releasable
pool of secretory granules in pancreatic α-cells. While Stmn2 is a membrane–bound
protein, it is also present in normal human blood as determined by serum ELISA (46) and
plasma proteomics (47) and therefore can be also secreted. There is some evidence of a
lower molecular weight form of Stmn2 that may correspond to a cleaved, soluble form
(43, 48). In our model, it may be that a portion of Stmn2 becomes cleaved within the
secretory granule, thus becoming part of the soluble cargo that is released.
By manipulating the expression of Stmn2, we were able to demonstrate a role in the
control of glucagon secretion. There is precedence for a role for Stmn2 in the regulation
of neuroendocrine secretion that has some interesting parallels with our results. While we
showed that silencing of Stmn2 increased the constitutive secretion of glucagon, one
study showed that silencing Stmn2 in PC12 cells decreased both basal and stimulated
secretion of chromogranin A (27). In that study, it was shown that Stmn2 interacted
directly with ChgA and its depletion reduced the buoyant density of chromaffin granules,
suggesting that Stmn2 may participate in secretory granule formation, perhaps in
partnership with ChgA (42) and thus promote regulated secretion. Although we could not
demonstrate a direct interaction between Stmn2 and glucagon (data not shown), our
results align with the idea that Stmn2 may be a sorting partner for glucagon, perhaps
indirectly by interacting with other granule proteins such as ChgA or carboxypeptidase E
(31), in the regulated secretory pathway of α-cells.
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Overexpression of Stmn2 resulted in an almost complete shutdown of glucagon secretion
and an increase in the localization of glucagon in early endosomes and lysosomes. These
results may suggest induction of ER stress. However, overexpression of Stmn2 in
Neuro2A cells, another cell line commonly used to examine regulated secretion, had the
opposite effect and enhanced trafficking of post-Golgi carriers to the plasma membrane
(49). There are only a few reports on how ER stress in α-cells is manifest; in one report,
palmitate-induced ER stress in isolated rat α-cells resulted in an increase in glucagon
secretion, not inhibition, even though the traditional markers of ER stress [DNA damageinducible transcript 3 protein (Ddit3; Chop), X-box-binding protein (1Xbp1s),
Endoplasmic reticulum chaperone BiP (Hspa5; BiP)] were elevated (50). Another study
showed that in vivo depletion of Xbp1, which plays a crucial role in the unfolded protein
response, induced dysfunctional glucagon secretion that was not fully suppressed by
insulin (51). Therefore, the suppression of glucagon secretion by Stmn2 overexpression is
not consistent with the phenotype of ER stress in the α-cell. Instead, these results,
together with the increased the presence of glucagon in the lysosomal compartment,
suggest that Stmn2 overexpression causes alterations in glucagon trafficking independent
of ER stress.
We believe that the overexpression experiments suggest a mechanism whereby an
increase in Stmn2 in the α-cell inhibits glucagon secretion by targeting glucagon
secretory granules for degradation in the endosome-lysosome pathway, perhaps in a
manner similar to that of insulin secretory granules in Type 2 diabetes (52). Very
recently, it has been shown that insulin secretion can be inhibited by the targeting of
proinsulin for lysosomal degradation by Rab7-interacting lysosomal protein (RILP) (53).
The proposed mechanism of action was through interactions between RILP and an insulin
secretory granule membrane protein, Rab26. It is tempting to speculate that Stmn2 could
have a similar mechanism of action in α-cells. The increase in LAMP2A fluorescence
intensity upon Stmn2 overexpression further suggests a role for Stmn2 in modulating
glucagon secretion through increased lysosome function or biogenesis. We are currently
investigating this mechanism of control of glucagon secretion in mouse islets.
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In conclusion, we propose that Stmn2, a protein that is associated with glucagon in
secretory granules, modulates glucagon secretion in α-cells by playing a role in its
intracellular trafficking. Under conditions that decrease Stmn2 levels, constitutive
secretion of glucagon is increased; and under conditions that increase levels of Stmn2,
glucagon is targeted to the endolysosomal system, presumably for degradation (Figure 37). Our findings, which are mainly based on the clonal α-cell line α-TC1-6, represent a
potentially novel intracellular pathway for the control of glucagon secretion, and may
lead to new mechanistic insights in the dysregulation of glucagon secretion in diabetes.
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Figure 3-19. Proposed pathways by which stathmin-2 modulates glucagon
secretion from α-TC1-6 cells. The model denotes status of glucagon secretion
from α-TC1-6 cells in normal physiology or in the event of Stmn2- depletion
or overexpression. Blue arrows indicate the normal trafficking of glucagon,
together with Stmn2, to secretory granules, where they are stored until their
release is triggered by a stimulus. Stmn2 overexpression (red arrows) reduces
the amount of glucagon available for secretion by diverting secretory granules
to lysosomes. Stmn2 depletion (black arrows) reduces the trafficking of
glucagon into secretory granules and promotes the constitutive release of
glucagon.
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4.1

Abstract

Glucagon hypersecretion from the pancreatic α-cell is a characteristic sign of diabetes,
which exacerbates fasting hyperglycemia. Thus, targeting glucagon secretion from α-cells
may be a promising approach for combating hyperglucagonemia. We have recently
shown that stathmin-2 (Stmn2), a protein that associates with glucagon in secretory
granules, can regulate glucagon secretion by directing glucagon towards the
endolysosomal system in α-cells. Here, we examined how Stmn2-mediated glucagon
trafficking is affected in diabetes, and if such a mechanism could explain the
hyperglucagonemia of diabetes. To this end, C57BL/6 mice were rendered diabetic by
streptozotocin (STZ; 30 mg/kg i.p. for 5 days). Using confocal immunofluorescence
microscopy, we showed strong colocalization between Stmn2 and glucagon in intact
islets of both non-diabetic (PCC 0.77±0.02) and diabetic mice (PCC 0.83±0.06).
Immunogold labeling transmission electron microscopy showed the presence of both
glucagon and Stmn2 in the dense core portion of secretory granules in both control and
diabetic mice. The secretion of both glucagon and Stmn2 from either normal or diabetic
islets was significantly enhanced by arginine. In contrast, cell glucagon content was
significantly increased in diabetic islets, (p<0.001), but Stmn2 levels were reduced
(p<0.01). In islets from diabetic mice, there was an increase (p<0.001) in glucagon
immunofluorescence that was concomitant with a decrease (p<0.01) in Stmn2
immunofluorescence, and expression of Gcg mRNA increased ~4.5 times, while Stmn2
mRNA levels did not change. We then followed changes in glucagon and Stmn2
trafficking in diabetes. In islets from control mice, both glucagon and Stmn2 showed a
moderate level of colocalization with the lysosomal marker, Lamp2A; however, this
colocalization was dramatically reduced (p<0.001) in islets from diabetic mice.
Interestingly, the co-localization of Stmn2 with the late endosome marker, Rab7,
significantly (p<0.01) increased in islets from diabetic mice, while the co-localization
between glucagon and Rab7 did not change. As well, there was a significant increase in
the intensity of Rab7 in diabetic α-cells compared to control. Retrograde shuttling of
glucagon towards early endosome or recycling endosome was not prominent in α-cells.
Thus, we propose that the hyperglucagonemia of diabetes may be partially explained by a
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decrease in the lysosomal trafficking of glucagon and Stmn2 associated with a relative
decrease in cellular Stmn2 and re-routing of Stmn2 to late endosomes.

Keywords: diabetes, hyperglucagonemia, glucagon secretion, stathmin-2, lysosome,
endosome
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4.2 Introduction
In diabetes, glucagon secretion from the pancreatic α-cell becomes abnormally upregulated, resulting in hyperglucagonemia. This paradoxical glucagon hypersecretion
from α-cells then causes exacerbation of hyperglycemia (1–3). It has been suggested that,
in order to fully control hyperglycemia in diabetes, glucagon secretion should be
suppressed. Therefore, the mechanisms and pathways that underlie the abnormal
secretion of glucagon must be elucidated, so that potential targets for suppressive therapy
can be identified.
Studies have shown that glucagon secretion can be controlled by targeting mediators of
intracellular signaling and exocytosis within the α-cell. Agonists of the glucagon-like
peptide receptor (GLP-1R) inhibit glucagon secretion by directly acting on α-cells, or
indirectly through releasing insulin, Zn2+, and GABA from β-cells, or by releasing
somatostatin from δ-cells (4). GABA receptor agonists also directly inhibit glucagon
secretion through binding with GABAA receptor on α-cells, increasing Cl- influx, and
hyperpolarization of plasma membrane (5,6). Antagonists of the glucose-dependent
insulinotropic peptide receptor (GIP-R) directly suppress the glucagonotropic effect of
GIP on α-cells (7). Insulin itself suppresses glucagon secretion through binding its
receptor on α-cells (8,9) or indirectly by increasing secretion of somatostatin from δ-cells
(10). Amylin inhibits amino acid-dependent exaggerated glucagon secretion in patients
with diabetes (11,12). Blockers of KATP channels inactivate ion channels, and reduce αcell electrical activity, which result in suppression of glucagon secretion (13–15). n
addition to blocking the effects of glucagon on hepatic glucose mobilization, antiglucagon receptor antibodies may also block the autocrine effect of glucagon on
glucagon secretion from α-cells (16,17).
All of the above mechanisms eventually converge on the α-cell secretory pathway by
which glucagon is stored in and secreted from secretory granules. We hypothesize that
elucidating the intracellular mechanisms of glucagon trafficking through the α-cell
secretory pathway could also yield clues on possible mechanisms of the regulation of
glucagon secretion. Using α-TC1-6 cells, we have shown that components of the
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regulated secretory pathway are up-regulated after chronic exposure to high levels of
glucose (18) and proposed that proteins that associated with glucagon within secretory
granules (glucagon interactome) play a role in the regulation of glucagon secretion (19).
We showed that the interactome was responsive to glucose, GABA and insulin, known
modulators of glucagon secretion. In particular, treatment with insulin, which is a potent
inhibitor of glucagon secretion at euglycemic and hypoglycemic conditions (8), appeared
to recruit stathmin-2 (Stmn2 or SCG10) to the interactome, thus potentially identifying
another inhibitor of glucagon secretion. In a subsequent study, we showed that Stmn2 is
co-secreted in a regulated manner with glucagon, and when over-expressed, suppressed
glucagon secretion by increasing its trafficking through the endolysosomal pathway in αTC1-6-cells(20).
There is one report on the reuptake of glucagon by α-cells after secretion and trafficking
to the endolysosomal system for degradation (21). Our previous study was the first to
show that the endolysosomal system may figure prominently in the intracellular
trafficking of glucagon as it is directed through the regulated secretory pathway(20).
Interestingly, parallel findings in β-cells showed that there is a shuttling of insulin from
secretory pathway towards the endolysosomal system for degradation, which may be an
underlying mechanism for β-cell failure in type 2 diabetes (22). Therefore, the
endolysosomal trafficking pathway may be a novel pathway for the dysregulation of both
insulin and glucagon secretion in diabetes. We hypothesize that a disruption in the
Stmn2-mediated trafficking of glucagon through the endolysosomal pathway might be a
possible mechanism by which glucagon secretion becomes dysregulated in diabetes,
resulting in glucagon hypersecretion and hyperglucagonemia.
In the present study, we show that there is a discordance in the levels of glucagon and
Stmn2 in diabetic mouse islets. This discordance is associated with increased glucagon
secretion, cell content and mRNA levels, and an inhibition of the trafficking of both
glucagon and Stmn2 to the lysosome. There appears to be re-routing of Stmn2 to late
endosomes which accompanies the increased secretion of glucagon. Therefore, we
propose that the loss of the α-cell lysosomal trafficking pathway in diabetes could
contribute to glucagon hypersecretion and hyperglucagonemia.
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4.3
4.3.1

Materials and methods
Animals

C57BL/6 male mice (8 weeks old) were purchased from the Jackson Laboratory (Bar
Harbor, Maine, United States). Mice were kept at 12h light/12h dark cycle and had free
access to water and regular chow diet. All mice were treated and euthanized in
accordance with the guidelines set out by the Animal Use Subcommittee of the Canadian
Council on Animal Care at Western University based on the approved Animal Use
Protocol AUP 2012-020. Mice were fasted 5h before blood collection or euthanasia.
Induction of diabetes: Streptozotocin (STZ; Cat# S0130, Sigma) was dissolved in
freshly prepared 0.1 M sodium citrate buffer, pH 4.5, and immediately used. Mice (n=18)
were intraperitoneally injected with 30 mg/kg STZ for 5 consecutive days and used for
microscopic (total n=7; 7 out of 7 for immunofluorescent microscopy; 4 out of 7 for
transmission electron microscopy), islet secretion (n=7) and gene expression (n=4)
studies. Three days after the last STZ injection, blood was sampled by tail vein lancing
and glucose levels were determined with the OneTouch Ultra glucometer. Values above
14 mmol/L were considered an indicator of diabetes onset (https://www.jax.org). Control
mice (n=18) were injected with citrate buffer alone at the same regimen. Animals were
euthanized 14 days after the last STZ injection by cervical dislocation under deep
isoflurane anesthesia.
Blood collection: Prior to cervical dislocation and under isoflurane induced anesthesia,
blood (1 mL) was collected by cardiac puncture into microcentrifuge tubes containing 15
µL of anticoagulant (15% Na2-EDTA) and 15 µL of freshly prepared enzyme inhibitor
cocktail (Cat# 4693159001 Millipore Sigma). Samples were kept on ice and then
centrifuged at 1500 g for 15 min at 4°C. Plasma was collected and kept at -80°C until
analysis.
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4.3.2

Preparation of pancreas tissue sections for confocal
immunofluorescence

Microscopy: Immediately after euthanasia, pancreata of STZ-treated (n=7) and vehicletreated (n=7) mice were excised, fixed in 10% buffered formalin for 3 days and treated
with 70% ethanol for one day before paraffin embedding. Paraffin-embedded tissue
blocks were longitudinally sectioned in 5 µm slices and fixed on glass microscope slides.
The tissue samples were de-paraffinized by graded washes using xylene, ethanol and
PBS. Antigen retrieval was conducted in sodium citrate buffer (10 mM sodium citrate,
0.05% Tween 20, pH 6) with 20 min steam heating of slides in a steam cooker. After
permeabilization with 0.1% Triton X-100 in PBS, Background Sniper (Cat# BS966H,
Biocare Medical) was used to block non-specific background staining. Samples were
incubated with primary antibodies against glucagon (Cat # ab10988 or Cat# ab92517,
Abcam; 1:1000), Stmn2 (Cat # ab115513, Abcam; 1:250 or Cat# 720178, Thermo Fisher
Scientific; 1:500), insulin (Cat# ab7842, Abcam; 1:500 or Cat# I2018, Sigma; 1:1000),
late endosome marker, Rab7 (Cat# ab126712, Abcam; 1:500), lysosomal marker,
Lamp2A (Cat# ab18528, Abcam; 1:1000), or recycling endosome markers Rab11A (Cat#
ab180778, Abcam; 1:100) and Rab11B (Cat# ab 228954, Abcam;1:100). The
corresponding secondary antibodies used were goat anti-mouse IgG Alexa Fluor 488
(Cat# A-11001, Molecular Probes; 1:500), donkey anti-goat IgG Alexa Fluor 555 (Cat#
ab150130, Abcam; 1:500), goat anti-guinea pig IgG Alexa Fluor 647 (Cat# A21450,
Invitrogen; 1:500), donkey anti-rabbit 488 (Cat#ab150073, Abcam; 1:500), donkey antimouse 555 (Cat# A-31570, Molecular Probes; 1:500) and goat anti-rabbit IgG Alexa
Fluor 594 (Cat# A 11037, Invitrogen; 1:500). Nucleus counter-staining was done by
DAPI and coverslips were mounted using Prolong Antifade mountant (Cat# P36982,
Thermo Fisher Scientific). As a background control for Stmn2, islet staining for Stmn2
was done using only the secondary antibody.
Image acquisition: Images were acquired through Nikon A1R Confocal microscope with
a ×60 NA plan-Apochromat oil differential interference contrast objective and NISElements software (Nikon, Mississauga, Canada). Acquisition of high-resolution images
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was done by selecting Nyquist XY scan area, 1024×1024-pixel size scanning of the
selected area and 2D- Deconvolution of the captured images.
Image Analysis: Three adjacent longitudinal slices of pancreas were placed on each
glass slide. In total, 10 slides were prepared from each pancreas. Image analysis was
performed by NIS-Elements software (Nikon, Mississauga, Canada). To calculate
colocalization values of endosomal and lysosomal markers with glucagon or Stmn2
within the same islet, channels were pseudocolored for Lamp2A, Rab7, Rab11A or
Rab11B. Colocalization of pixels from each pseudocolored image was used to calculate
Pearson’s correlation coefficient (PCC), as we have done previously (23)(19). Regions of
interest (ROIs) were manually drawn around each islet and then defined PCC values for
colocalization between Stmn2 and target markers (glucagon, insulin, Lamp2A, Rab7,
Rab11A, Rab11B) were calculated using the colocalization algorithm of NIS-Elements
software. To show the relationships between expression levels of Stmn2 and the target
markers (glucagon, insulin, Lamp2A, Rab7, Rab11A, Rab11B) in α or β- cells of the
pancreatic islets, binary images were generated using M-Threshold algorithm of NISElements software. ROIs were manually drawn around each binary arranged image of the
islet and the fluorescence intensity of each marker was calculated. Levels of fluorescence
intensities were normalized by dividing by the intensity of DAPI within each ROI. These
values were used for linear regression analysis between Stmn2 and the target markers.

4.3.3

Double immunogold labeling transmission electron
microscopy

Double immunogold labeling TEM was done based on the protocol of Aida et al (2014)
with some modifications (24) as we have recently used (20). Briefly, in both non-diabetic
(n=4) and diabetic (n=4) mice, pancreas was dissected, and a piece of pancreas in its long
axis was cut, and immediately placed into McDowell Trump’s fixative (Cat# 18030-10,
Electron Microscopy Sciences) for 1h. Then, after washing with PBS, samples were cut
into smaller pieces, and dehydrated in the increasing concentrations of ethanol (10%,
20%, 30%, 50%, 70%, 90%, 100% and 100%) at 30 min per concentration. Samples were
sequentially embedded in LR White Resin (Cat# 14381, Electron Microscopy Sciences)
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as follows: ethanol-LR White mixture A (3:1, v/v; 2h), ethanol-LR White mixture B (1:1,
v/v; 8h), ethanol-LR White mixture C (1:3, v/v; 12h), and 3 × 12h in pure LR White.
Samples were then placed into a beem capsule, filled with pure LR White and incubated
at 50°C for 24h. Semi-thin sections (500 nm) were cut from embedded samples for
Toluidin blue staining (1% Toluidin blue for 2 min). After defining the position of the
islets within the pancreatic tissue, ultra-thin section slices (70 nm) were prepared using a
diamond microtome. The sections were mounted on formvar-carbon coated nickel grid
(300 meshes; Cat# FCF300-NI, Electron Microscopy Sciences). Afterwards, slices were
washed with Tris-buffered saline, 0.1% Tween 20 (TBS-T) and incubated in blocking
buffer (2% BSA in PBS plus 0.05% Tween 20) for 30 min at room temperature. Slices
were incubated with primary antibodies (1:10 in blocking buffer) against glucagon (Cat#
ab10988; Abcam) and Stmn2 (Cat# ab115513; Abcam) at 4°C overnight. After washing
with TBS-T, slices were incubated with gold-conjugated secondary antibodies of donkey
anti-goat (18 nm; cat# ab105270, Abcam; 1:50) and donkey anti-mouse (10nm; cat#
ab39593, Abcam; 1:50) for 2h at room temperature. After washing with TBS-T and
staining with Uranyless (Cat# 22409, Electron Microscopy Sciences), TEM was
conducted at the Biotron Experimental Research Center, Western University, London,
ON, Canada.

4.3.4

Proglucagon and stathmin-2 gene expression

Handpicked islets (~180) from control (n=4) and diabetic (n=4) mice were placed into 1
mL Trizol (Cat# 15596018, Ambion) and processed for RNA extraction, as described
previously (25,26) . Islets were homogenized by being passed 10 times through a 25gauge needle, and again through a 27-gauge needle. After centrifugation at 10000×g for 5
min at 4°C, the supernatant was mixed with chloroform, vortexed for 30 seconds and
placed on ice for 2 min. After centrifugation at 12000×g for 15 min at 4°C, the aqueous
layer was collected and mixed with 0.5 volumes of high salt solution (0.8 M Na-citrate
containing 1.2 M NaCl). Isopropanol (0.5 volumes) was added, and the samples were
mixed, incubated for 10 min at room temperature and centrifuged at 12000×g for 30 min
at 4°C. The pellet was dissolved in 70% ethanol and RNA was purified by RNeasy kit
(Cat # 74104, Qiagen) according to the supplier’s protocol. cDNA synthesis was
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performed using the SuperScript III First Strand Synthesis Supermix for qRT-PCR (Cat #
11752050, Thermo Fisher Scientific), according to the manufacturer’s protocol. Realtime PCR was performed using Quant Studio Design and Analysis Real-Time PCR
Detection System in conjunction with the Maxima SYBR Green qPCR Master Mix (Cat
# K0221, Thermo Fisher Scientific) using specific primers for Stmn2: forward, 5'GCAATGGCCTACAAGGAAAA-3'; reverse, 5'-GGTGGCTTCAAGATCAGCTC-3';
Gcg: forward, 5'-AACAACATTGCCAAACGTCA-3'; reverse, 5'TGGTGCTCATCTCGTCAGAG-3' and 18S rRNA: forward, 5'ACGATGCCGACTGGCGATGC-3'; reverse, 5'-CCCACTCCTGGTGGTGCCCT-3'.
Gene expression levels were normalized to that of 18S rRNA. Gene expression in the
diabetic condition was normalized to the corresponding control group and expressed as
percent of matched control. Statistical analysis was performed using t-test at α = 0.05.

4.3.5

Primary islet culture

Islets were isolated and cultured as we have done previously (20) using a modified
protocol from Li et al. (27). Non-diabetic (n=7) or diabetic mice (n=7) were euthanized.
The abdominal cavity was opened and 3 mL of 1.87 mg/mL collagenase V (Cat# C9263,
Sigma;) in Hanks' Balanced Salt Solution was injected into the common bile duct. The
pancreas was then removed, placed into a Falcon tube containing 2 mL of the ice-cold
collagenase V solution and incubated for 12 min at 37°C with occasional shaking.
Digestion was stopped by adding 1mM CaCl2 and the cell suspension was washed twice in
the CaCl2 solution. Islets were collected into a sterile petri dish using a 70 µm cell strainer
with RPMI1640 containing 11 mM glucose plus 20 mM glutamine, 10% FBS and
penicillin (110U/mL) and streptomycin (100 µg/mL). A total of 180 islets were handpicked
under a stereomicroscope and incubated for 2h at 37°C. The medium was then changed to
RPMI1640 containing 11 mM glucose plus 10% FBS and penicillin (110U/mL) and
streptomycin (100 µg/mL) and islets were cultured overnight at 37°C.
Glucagon secretion experiments: Glucagon secretion from islets was measured based on
the protocol by Suckow et al (2014). Briefly, islets were washed three times using KrebsRinger bicarbonate (KRB) buffer (135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 mM
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NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES; pH 7.4) containing 11 mM
glucose, and then pre-incubated in this KRB for 1h. Islets were then incubated in KRB
containing 1mM glucose in the presence or absence of arginine (25 mM) for 20 min. Media
were collected into microcentrifuge tubes containing enzyme inhibitors (PMSF, 45 mM;
Aprotinin, 5 µg/mL and sodium orthovanadate, 1mM). Samples were centrifuged at 14000
× g for 5 min at 4°C and the supernatant was collected and kept at -80°C until analysis.
Islets were lysed in lysis buffer (0.1 M citric acid, 1% Triton X-100 plus enzyme inhibitors)
and homogenized by passing 10 times through a 25-gauge needle, and again through a 27gauge needle. The extracts were centrifuged at 14000×g for 15 min at 4°C and the
supernatant was collected and kept at -80°C until analysis (28).
Measurement of glucagon and stathmin-2: Glucagon levels in the media and islet
extracts were determined by ELISA (Cat # EHGCG, Thermo Fisher Scientific) according
to the manufacturer’s instructions. Stmn2 levels in the media and islet extracts were
measured using stathmin-2 ELISA kit (Cat# MBS7223765, MyBioSource) according to
the supplier’s instruction. For each measurement, the values were compared between
groups by t-test and among groups by one-way ANOVA (α = 0.05). Total cellular protein
was determined using BCA assay and used to normalize cellular glucagon or Stmn2 per
mg of cell protein. Then, alterations in values were expressed as percent changes
compared to the baseline control. To this end, the Arg-stimulated secretion of glucagon
or Stmn2 was normalized to the baseline level of glucagon and Stmn2, respectively, and
expressed as relative fold changes.
Statistical analyses: Comparison of values among groups was done by one-way
ANOVA (Bonferroni post-hoc test), and between groups by t-test using Sigma Stat 3.5
software at α=0.05. For colocalization analysis of images, Pearson correlation coefficient
values were extracted using NIS-Elements software and then values were compared
between groups by t-test (α=0.05).
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4.4
4.4.1

Results
Induction of diabetes in C57BL/6 mice

Measuring blood glucose levels following STZ injection showed fasting hyperglycemia
(>14 mmol/L), indicating onset of diabetes (Figure 4- 1A). Plasma levels of glucagon
were significantly (p<0.001) higher and plasma levels of insulin were significantly
reduced (p<0.001) in STZ-treated mice compared to the control group (Figure 4- 1B, C),
and there was a significantly (p<0.001) higher glucagon: insulin ratio in STZ-treated
mice compared to the control (Figure 4- 1D). These findings indicate development of a
diabetic metabolic and hormonal profile following STZ administration.
A

B

C

D
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Figure 4-1. Streptozotocin (STZ) induced diabetes in C57BL/6 mice. (A)
Plasma glucose, (B) plasma insulin, (C) plasma glucagon, and (D)
glucagon: insulin ratio per µm2 of islet in STZ-induced diabetic mice.
Values (mean± SD) were compared between diabetic (n=7) and control
(n=7) mice by t-test. *p<0.001.

Figure 4-2. Predicted proteins in the first shell of interacting proteins
with glucagon within the glucagon interactome. α-TC1-6 cells were

4.4.2

Glucagon and Stmn2 co-localize in islets of diabetic and
non-diabetic mice

cultured (A) in 25 mM glucose containing medium (HGM); or

supplemented with GABA, insulin (INS) or GABA+INS. (B) α-TC1-6
Confocal immunofluorescence microscopy studies on islets of non-diabetic mice (Figure
cells were cultured (A) in 5.5 mM glucose containing medium (LGM); or
4- 2A) showed colocalization between glucagon and Stmn2 (Figure 4- 2B) but not
supplemented with GABA, insulin (INS) or GABA+INS.Figure 4-3.
between insulin and Stmn2 (Figure 4- 2C). This pattern of co-localization was conserved
Streptozotocin (STZ) induced diabetes in C57BL/6 mice. (A) Plasma
in islets from diabetic mice (Figures 4- 2D-F). Quantification and analysis (Figure 4- 2G)
glucose, (B) plasma insulin, (C) plasma glucagon, and (D) glucagon:
revealed strong colocalization between glucagon and Stmn2 in α-cells of both control
insulin ratio per µm2 of islet in STZ-induced diabetic mice. Values
(PCC 0.77± 0.02) and STZ-induced diabetic mice (PCC 0.83 ± 0.06). In contrast, there
(mean± SD) were compared between diabetic (n=7) and control (n=7)
was almost no colocalization between insulin and Stmn2 in both control (PCC 0.04±0.03)
mice by t-test. *p<0.001.
and STZ-induced diabetic mice (PCC 0.03±0.06).
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Figure 4-4. Stathmin-2 colocalizes with glucagon but not insulin in both nondiabetic and STZ-induced diabetic mice. (A) Islets of non-diabetic mice (n=7)
were immunostained for glucagon (GCG), insulin (INS) and stathmin-2
(Stmn2); (B) after removing INS channel, colocalization was determined
between GCG and Stmn2; (C) after removing GCG channel, and
pseudocoloring of INS channel to green, colocalization was determined
between Stmn2 and INS. (D) Islets of diabetic mice (n=7) were immunostained
for GCG, INS and Stmn2; (E) after removing INS channel, colocalization was
determined between GCG and Stmn2; (F) after removing GCG channel and
pseudocoloring of INS channel to green, colocalization was determined between
Stmn2 and INS. In each panel, marked area by square was magnified to show
a typical individual cell. (G) Correlation between GCG and Stmn2 or INS and
Stmn2 was determined by Pearson’s correlation coefficient (PCC) using NISElements software. Images were acquired by Nikon A1R confocal microscope.

Figure 4-5. Streptozotocin (STZ) induced diabetes in C57BL/6 mice. (A)

4.4.3

STZ-induced diabetes increases glucagon levels and

Plasma glucose, (B) plasma insulin, (C) plasma glucagon, and (D) glucagon:

reduces Stmn2 levels in α-cells

insulin ratio per µm2 of islet in STZ-induced diabetic mice. Values (mean± SD)
wereofcompared
between
diabetic
(n=7)increased
and control
(n=7)
miceofby
t-test.
Analysis
fluorescence
intensities
revealed
cellular
levels
glucagon
*p<0.001.Figure
Stathmin-2
colocalizes
with glucagon
but notdiabetic
insulinmice
in
(p<0.001)
and reduced4-6.
levels
of Stmn2 (p<0.01)
in islets
of STZ-induced
both
and STZ-induced
mice.Stmn2
(A) Islets
of non-diabetic
(Figure
4-non-diabetic
3A). As a consequence,
the ratio diabetic
of glucagon:
in α-cells
of STZmice
(n=7)
were
immunostained
for
glucagon
(GCG),
insulin
(INS)
and
induced diabetic mice significantly increased (p<0.01) compared to the non-diabetic
stathmin-2
(Stmn2);
(B) after
removing
INSofchannel,
colocalization
controls
(Figure 43B). Linear
regression
analysis
binary sum
intensities was
showed a
determined
between GCG
and
Stmn2; (C)
after removing
GCG
strong
positive correlation
between
expression
of Stmn2
and glucagon
in channel,
α-cells ofand
nonpseudocoloring
of INS
channel
green,
colocalization
was determined
diabetic
mice (R2 = 0.9,
p<0.001)
thatto
was
disrupted
in STZ-induced
diabetic mice (R2 =
INS. (D) Islets of diabetic mice (n=7) were immunostained
0.07,between
p >0.05)Stmn2
(Figureand
4- 3C).
for GCG, INS and Stmn2; (E) after removing INS channel, colocalization was
determined between GCG and Stmn2; (F) after removing GCG channel and
pseudocoloring of INS channel to green, colocalization was determined between
Stmn2 and INS. In each panel, marked area by square was magnified to show
174 between GCG and Stmn2 or INS and
a typical individual cell. (G) Correlation

Stmn2 was determined by Pearson’s correlation coefficient (PCC) using NISElements software. Images were acquired by Nikon A1R confocal microscope.
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Figure 4-7. Imbalanced ratios of stathmin-2 and glucagon in islets of STZinduced diabetic mice. Islets were immunostained for stathmin-2 (Stmn2) and
glucagon and images were acquired by A1R confocal microscope. (A)
Expression of glucagon and Stmn2 were determined in islets of non-diabetic
and diabetic mice by immunofluorescence intensity analysis . (B) Ratios of
glucagon: Stmn2 levels were calculated per µm2 of islets in non-diabetic and
diabetic mice. (C) Linear regression analysis on binary image intensities of the
Stmn2 and glucagon. Filled circles and open squares demonstrate values in
non-diabetic and diabetic islets, respectively.

This increase in cellular glucagon was paralleled by a ~ 4.5 times increase in the levels of
Figure 4-8. Stathmin-2 colocalizes with glucagon but not insulin in both nonGcg mRNA, while there was no effect on Stmn2 mRNA levels (Figure 4- 4).
diabetic and STZ-induced diabetic mice. (A) Islets of non-diabetic mice (n=7)
were immunostained for glucagon (GCG), insulin (INS) and stathmin-2
(Stmn2); (B) after removing INS channel, colocalization was determined
between GCG and Stmn2; (C) after removing GCG channel, and
pseudocoloring of INS channel to green, colocalization was determined
between Stmn2 and INS. (D) Islets of diabetic mice (n=7) were immunostained
for GCG, INS and Stmn2; (E) after removing INS channel, colocalization was
determined between GCG and Stmn2; (F) after removing GCG channel and
pseudocoloring of INS channel to green, colocalization was determined between
Stmn2 and INS. In each panel, marked area by square was magnified to show
a typical individual cell. (G) Correlation between GCG and Stmn2 or INS and
Stmn2 was determined by Pearson’s correlation coefficient (PCC) using NISElements software. Images were acquired by Nikon A1R confocal
microscope.Figure 4-9. Imbalanced ratios of stathmin-2 and glucagon in islets
of STZ-induced diabetic mice. Islets were immunostained for stathmin-2
(Stmn2) and glucagon and images were acquired by A1R confocal microscope.
(A) Expression of glucagon and Stmn2 were determined in islets of non-diabetic
and diabetic mice by immunofluorescence intensity analysis . (B) Ratios of
176per µm2 of islets in non-diabetic and
glucagon: Stmn2 levels were calculated

diabetic mice. (C) Linear regression analysis on binary image intensities of the
Stmn2 and glucagon. Filled circles and open squares demonstrate values in

Figure 4-10. Expression of Stmn2 and Gcg mRNA levels were determined in
islets of non-diabetic (n=4) and diabetic (n=4) mice by RT-qPCR. Gene
expression levels were normalized to that of 18S rRNA. For each gene
alterations in diabetic condition was normalized by the corresponding
control group and expressed as matched control percent. Comparison
between control and diabetic ones was done by t-test, α=0.05.
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Both glucagon and Stmn2 are localized within secretory
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was done by t-test, α=0.05.
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Figure 4-13. The presence of stathmin-2 and glucagon within secretory
granules of α-cells. (A) Double immunogold labelling transmission electron
microscopy of islets in non-diabetic and (B) STZ-induced diabetic mice was
done by antibody against glucagon (10 nm gold, white arrows in the magnified
section) and stathmin-2 (18 nm gold, black arrows in the magnified section).
The low magnification images (19000×, scale bar = 1 μm) show the
ultrastructure of one α-cell. N (nucleus); ER (endoplasmic reticulum); SG
(secretory granule); PM (plasma membrane). The magnified images (21000×,
scale bar = 0.6 μm) highlight the presence of immunogold labels within a single
secretory granule.

Figure 4-14. Expression of Stmn2 and Gcg mRNA levels were determined in
islets of non-diabetic (n=4) and diabetic (n=4) mice by RT-qPCR. Gene
expression levels were normalized to 178
that of 18S rRNA. For each gene
alterations in diabetic condition was normalized by the corresponding control
group and expressed as matched control percent. Comparison between control

4.4.5

Arginine stimulates parallel increases in glucagon and
Stmn2 secretion

In line with our recent findings (20), there was an increase in the secretion of both
glucagon (~2.9 times) and Stmn2 (~2.3 times) from isolated islets in response to 25 mM
Arg. In islets from diabetic mice, the glucagon secretory response was exaggerated, with
increased basal and Arg-stimulated secretion (Figure 4- 6A). There was also a small but
significant increase in basal Stmn2 secretion and a significant increase in response to Arg
in diabetic islets (Figure 4- 6B). There was a concomitant reduction in cell glucagon
content of non-diabetic islets in response to Arg (Figure 4- 6A). In contrast, cell glucagon
content of diabetic islets was elevated in the absence of Arg, and remained elevated after
Arg stimulation (Figure 4- 6A), consistent with the diabetic phenotype of glucagon
production. In parallel with the pattern of cell glucagon content in non-diabetic islets, cell
Stmn2 content also decreased in response to Arg (Figure 4- 6B). Interestingly, cell Stmn2
content was reduced in islets of diabetic mice, and further reduced after Arg stimulation
(Figure 4- 6B), thereby showing a different profile from that of glucagon in diabetes.

179

Figure 4-16. Parallel alterations in secretion of glucagon and Stmn2 from αcells in both non-diabetic and diabetic mice. (A) Secretion of glucagon and
islet glucagon content in isolated islets of non-diabetic (C; n=7) and diabetic
mice (STZ; n=7) at the presence or absence of Arginine (25 mM, 20 min).
Secretion values were normalized by baseline control secretion and expressed
as fold changes. Glucagon contents were normalized by baseline control and
expressed as percent changes. (B) Secretion of Stmn2 and islet Stmn2 content
in isolated islets of non-diabetic (C; n=7) and diabetic mice (STZ; n=7) at the
presence or absence of Arginine (25 mM, 20 min). Secretion values were
normalized by baseline secretion in control and expressed as fold changes.
Glucagon contents were normalized by baseline content in control and
expressed as percent changes. Values were expressed as mean ± SEM and
compared among groups by 1-Way ANOVA at α=0.05. *p<0.05; **p<0.01;
***p<0.001.

4.4.6

Trafficking of glucagon and Stmn2 to the lysosome is

Figure 4-17. The presence of stathmin-2 and glucagon within secretory
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(Figure 4- 7C) in normal mouse islets. In contrast, Lamp2A did not colocalize with either
glucagon or Stmn2 in individual α-cells in islets of STZ-induced diabetic mice (Figures
4- 7D-F). Quantification and analysis of colocalization showed a moderate level of
colocalization between Lamp2A and glucagon (PCC 0.48±0.08) and between Lamp2A
and Stmn2 (PCC 0.52±0.09) in the control group (Figure 4- 7G). In contrast, STZ induced diabetes significantly reduced levels of colocalization between glucagon and
Lamp2A (PCC 0.14±0.03; p<0.01) and also between Stmn2 and Lamp2A (PCC
0.15±0.03; p<0.01) (Figure 4- 7G).
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Figure 4-19. The localization of Stmn2 and glucagon in lysosomes of α-cells is
inhibited in diabetes. (A) Islets from non-diabetic mice (n=7) were
immunostained with antibodies against glucagon (GCG), stathmin-2 (Stmn2)
and the lysosomal marker, Lamp2A. Representative images are shown. (B)
Colocalization of glucagon and Lamp2A. The Lamp2A image was
pseudocoloured red for visualization of co-localization in the merged image and
inset. (C) Colocalization of Stmn2 and Lamp2A. The Lamp2A image was
pseudocoloured green for visualization of co-localization in the merged image
and inset. (D) Islets of diabetic mice (n=7) were immunostained for glucagon,
Stmn2 and Lamp2A. (E) Colocalization of glucagon and Lamp2A. The
Lamp2A image was pseudocoloured red for visualization of co-localization in
the merged image and inset. (F) Colocalization of Stmn2 and Lamp2A. The
Lamp2A image was pseudocoloured green for visualization of co-localization in
the merged image and inset. All images were acquired and post-processed as
described in Methods. In each merged panel, selected areas (white square)
were magnified to show individual cells within islets. (G) Analysis of
colocalization of glucagon and LAMP2A, and Stmm2 and LAMP2A in normal
and diabetic (STZ) islets. Pearson’s correlation coefficient (PCC) values are
shown as means ± SEM. Each dot represents a mean of 9-15 images per mouse.
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islets of non-diabetic (C; n=7) and diabetic mice (STZ; n=7) at the presence or
absence of Arginine (25 mM, 20 min). Secretion values were normalized by

colocalization with glucagon (Figure 4- 8E). Quantification and analysis showed a
moderate level of colocalization between glucagon and Rab7 in both control (PCC
0.42±0.1) and STZ-induced diabetic (PCC 0.48±0.1) mice (Figure 4- 8G). Colocalization
between Stmn2 and Rab7 in the control group was weak (PCC 0.29±0.12), but
significantly increased (PCC 0.48±0.09, p<0.01) in islets from STZ-induced diabetic
mice. In addition, the fluorescence intensity of Rab7 itself increased in α cells from islets
of diabetic mice (Figures 4- 8H, I), and quantification demonstrated that this increase was
significant (p<0.001) (Figure 4- 8J). Importantly, quantification and analysis
demonstrated (Figure 4- 8J) similar levels of Rab7 fluorescence intensity in α and β-cells
of control mice. However, following induction of diabetes, Rab7 intensity significantly
increased (p < 0.001) in α-cells, but not in β-cells.

184

G

G

185

J

186

Figure 4-22. Diabetes enhanced colocalization of Stmn2 with late endosome in
α-cells. (A) Islets from non-diabetic mice (n=7) were immunostained with
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the late
endosome marker, Rab7. Representative images are shown. (B) Colocalization
of glucagon and Rab7. The Rab7 image was pseudocoloured red for
visualization of colocalization in the merged image and inset. (C)
Colocalization of Stmn2 and Rab7. The Rab7 image was pseudocoloured
green for visualization of colocalization in the merged image and inset. (D)
Islets from diabetic mice (n=7) were immunostained for glucagon, Stmn2 and
Rab7; (E) Colocalization of glucagon and Rab7. The Rab7 image was
pseudocoloured red for visualization of colocalization in the merged image
and inset. (F) Colocalization of Stmn2 and Rab7. The Rab7 image was
pseudocoloured green for visualization of colocalization in the merged image
and inset. All images were acquired and post-processed as described in
Methods. In each merged panel, selected areas (white square) were magnified
to show individual cells within islets. (G) Analysis of colocalization of glucagon
and Rab7, and Stmm2 and Rab7 in normal and diabetic (STZ) islets.
Pearson’s correlation coefficient (PCC) values are shown as means ± SEM.
Each dot represents a mean of 15 images per mouse. (H) Fluorescent
intensities of glucagon, insulin (INS) and Rab7 were shown in islets from nondiabetic and (I) diabetic mice. (J) Analysis of fluorescent intensities of Rab7 in
α and β-cells. Intensities of DAPI- stained nuclei were used to normalize Rab7
intensities.

Figure 4-23. The localization of Stmn2 and glucagon in lysosomes of α-cells is
inhibited in diabetes. (A) Islets from non-diabetic mice (n=7) were
immunostained with antibodies against glucagon (GCG), stathmin-2 (Stmn2)
187

and the lysosomal marker, Lamp2A. Representative images are shown. (B)
Colocalization of glucagon and Lamp2A. The Lamp2A image was
pseudocoloured red for visualization of co-localization in the merged image

4.4.8

Glucagon and Stmn2 do not localize within the early
endosome

The early endosome marker, EEA1, appeared to be localized strongly to the core of the
islet (Figure 4- 9A). As shown by the magnified images, EEA1 did not colocalize with
either glucagon (Figure 4- 9B) or Stmn2 (Figure 4- 9C). These patterns of colocalization
remained unchanged in diabetes (Figures 4- 9D-F). Quantification and analysis showed a
very weak colocalization of EEA1 with glucagon (PCC 0.07±0.05) or Stmn2 (PCC
0.07±0.04) in the control group. Following induction of diabetes, colocalization of EEA1
with glucagon (PCC 0.03±0.07) or Stmn2 (PCC 0.04±0.07) still remained very weak.
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Figure 4-25. Glucagon and stathmin-2 are not localized in early endosomes in
α-cells. (A) Islets from non-diabetic mice (n=7) were immunostained with
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the early
endosome marker, EEA1. Representative images are shown. (B) Colocalization
of glucagon and EEA1. The EEA1 image was pseudocoloured red for
visualization of colocalization in the merged image and inset. (C) Colocalization
of Stmn2 and EEA1. The EEA1 image was pseudocoloured green for
visualization of colocalization in the merged image and inset. (D) Islets from
diabetic mice (n=7) were immunostained for glucagon, Stmn2 and EEA1. (E)
Colocalization of glucagon and EEA1. The EEA1 image was pseudocoloured
red for visualization of colocalization in the merged image and inset. (F)
Colocalization of Stmn2 and EEA1. The EEA1 image was pseudocoloured
green for visualization of colocalization in the merged image and inset. All
images were acquired and post-processed as described in Methods. In each
merged panel, selected areas (white square) were magnified to show individual
cells within islets. (G) Analysis of colocalization of glucagon and EEA1, and
Stmm2 and EEA1 in normal and diabetic (STZ) islets. Pearson’s correlation
coefficient (PCC) values are shown as means ± SEM. Each dot represents a
mean of 9-15 images per mouse.

4.4.9

Glucagon is not present in recycling endosome
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of colocalization in the merged image and inset. (F) Colocalization of Stmn2
and Rab7. The Rab7 image was pseudocoloured green for visualization of

4- 10M) confirmed the weak colocalization between glucagon and Rab11A (PCC
0.13±0.05) or Rab11B (PCC 0.13±0.04) in non-diabetic mice, and in diabetic mice
(colocalization of glucagon with Rab11A, PCC 0.13±0.04 or Rab11B, PCC 0.13±0.03).
In contrast, insulin showed a strong colocalization with Rab11A (PCC 0.63±0.09) or
Rab11B (PCC 0.61±0.06), which significantly decreased (p<0.001) following induction
of diabetes (colocalization of insulin with Rab11A, PCC 0.35±0.5) or Rab11B, PCC
0.38±0.07).
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Figure 4-28. Glucagon is not localized in recycling endosome of α-cells. (A) Islets
from non-diabetic mice (n=7) were immunostained with antibodies against
glucagon (GCG), insulin (INS) and the recycling endosome marker, Rab11A. (B)
Colocalization of glucagon and Rab11A. The Rab11A image was pseudocoloured
red for visualization of colocalization in the merged image and inset. (C)
Colocalization of insulin and Rab11A. The Rab11A image was pseudocoloured
green for visualization of colocalization in the merged image and inset. (D) Islets
from diabetic mice (n=7) were immunostained for glucagon, insulin and Rab11A.
(E) Colocalization of glucagon and Rab11A. The Rab11A image was
pseudocoloured red for visualization of colocalization in the merged image and
inset. (F) Colocalization of insulin and Rab11A. The Rab11A image was
pseudocoloured green for visualization of colocalization in the merged image and
inset. (G) Islets from non-diabetic mice were immunostained for glucagon,
insulin and Rab11B. (H) Colocalization of glucagon and Rab11B. The Rab11B
image was pseudocoloured red for visualization of colocalization in the merged
image and inset. (I) Colocalization of insulin and Rab11B. The Rab11B image
was pseudocoloured green for visualization of colocalization in the merged image
and inset. (J) Islets from diabetic mice were immunostained for glucagon, insulin
and Rab11B. (K) Colocalization of glucagon and Rab11B. The Rab11B image
was pseudocoloured red for visualization of colocalization in the merged image
and inset. (L) Colocalization of insulin and Rab11B. The Rab11B image was
pseudocoloured green for visualization of colocalization in the merged image and
inset. All images were acquired and post-processed as described in Methods. In
each merged panel, selected areas (white square) were magnified to show
individual cells within islets. (M) Analysis of colocalization of glucagon and
Rab11A or Rab11B, and Stmm2 and Rab11A or Rab11B in normal and diabetic
(STZ) islets. Pearson’s correlation coefficient (PCC) values are shown as means ±
SEM. Each dot represents a mean of 9-15 images per mouse.

Figure 4-29. Glucagon and stathmin-2 are not localized in early endosomes in α195

cells. (A) Islets from non-diabetic mice (n=7) were immunostained with
antibodies against glucagon (GCG), stathmin-2 (Stmn2) and the early endosome

4.5

Discussion

Diabetes is always accompanied by a degree of hyperglucagonemia, which reflects
dysregulated glucagon secretion from α-cells. We have recently proposed that protein
components of glucagon interactome within secretory granules of α-cells may regulate
glucagon secretion (19) and one of these proteins, Stmn2, may mediate glucagon
secretion through the endolysosomal system in α-TC1-6 cells and islets from non-diabetic
mice (20). In the present study, we show that in diabetes, there is a disruption in the ratio
of glucagon:Stmn2 together with hyperglucagonemia. These phenomena were
accompanied by a sharp reduction in the trafficking of both glucagon and Stmn2 into the
lysosome, and increased localization of Stmn2 within the late endosome, but not in the
early or recycling endosomal compartment. We propose that, in diabetic α-cells,
glucagon hypersecretion may result from a loss of Stmn2-mediated trafficking of
glucagon to the lysosomal pathway.
In non-diabetic α-cells, glucagon secretion is regulated by several factors (29) mainly
nutritional elements, such as glucose, amino acids and free fatty acids (2,12,30–33),
neuronal effectors, such as norepinephrine and acetylcholine (12,34), and hormonal
stimuli, particularly through paracrine regulation by insulin and somatostatin, and
autocrine regulation by glucagon itself) (12,35–39). Diabetes disrupts this fine regulation,
resulting in glucagon hypersecretion and aggravation of hyperglycemia. Most notably,
alterations in the paracrine control of glucagon secretion by insulin results in an abnormal
α-cell response to high glucose concentrations, either through insulin deficiency (40,41)
or α cell insulin resistance(41,42). Additionally, impairments in hepatic amino acid
turnover increases glucagon secretion from α-cells through the liver-α-cell axis (43,44).
As well, higher secreted glucagon and concomitantly co-secreted glutamate from diabetic
α-cells exacerbate glucagon hypersecretion in an autocrine manner (45).
The search for novel regulators of glucagon secretion has revealed that proteins
associated with the α-cell secretory pathway may also comprise mechanisms that underlie
hyperglucagonemia. Exposure of α-TC1-6 cells to chronically high glucose
concentrations resulted in an up-regulation of several secretory granule proteins,
196

including processing enzymes, chromogranins and exocytotic proteins (18), indicating
that many components of the α-cell secretory pathway play a role in glucagon
hypersecretion in diabetes. Secretory granule proteomics in α-TC1-6 cells revealed
several proteins predicted to associate with glucagon as possible mediators of glucagon
secretion (19), and our recent work has shown that Stmn2 may be one such novel
regulator (20). Knockdown of Stmn2 enhanced glucagon secretion from α-TC1-6 cells,
indicating that Stmn2 could be a negative regulator of glucagon secretion. Our present
results demonstrating a reduction in Stmn2 cell content in diabetes concomitantly with
glucagon hypersecretion are consistent with these results. A similar database search has
shown that another granule protein, brefeldin A-inhibited guanine nucleotide exchange
protein 3 or BIG3, also regulated glucagon secretion from mouse pancreatic islets, and
its depletion in vivo resulted in glucagon hypersecretion (46), possibly through promoting
secretory granule biogenesis or maturation. Therefore, proteins within the α-cell secretory
pathway are emerging as prominent regulators of glucagon secretion by mediating the
intracellular trafficking of glucagon, and may explain dysregulated glucagon
hypersecretion in diabetes.
In the present study, we observed that the relationship between glucagon and Stmn2 was
disrupted, indicated by increased glucagon and decreased Stmn2 cell content.
Proglucagon gene transcription, glucagon synthesis and secretion are all highly
responsive to prevailing glucose concentrations (18,47–49), reflecting the
hyperglucagonemic state of diabetes. However, it appears that Stmn2 mRNA and protein
levels show a different profile. A BLAST search of the promoter region of the Stmn2
gene (GeneBank: AH000817 ; mouse Stmn2 complete cds) against sequence of the
glucose response element in the mouse glucagon receptor gene (50) (GeneBank:
AF229079.1; mouse Gcgr complete cds), did not reveal any sequence homology. Thus,
the enhanced secretion of Stmn2 in diabetes may reflect its localization in secretory
granules, which may be elevated in number and exocytotic activity in hyperglucagonemia
(48), or an increase in α-cell mass(5,51).
The altered balance between glucagon and Stmn2 has also been found in islets from
patients with diabetes. By means of α-cell RNA sequencing analysis, Lawlor et al (2017)
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showed a higher Gcg: Stmn2 gene expression ratio in islets of people with type 2 diabetes
compared to healthy controls (52). Since there are many other metabolic disturbances in
diabetes as described above, those results, along with ours, suggest that Stmn2 gene and
protein expression levels within α-cells do not show parallel behavior with glucagon over
chronic disruptions in metabolism.
Since Stmn2 within the α-cell appears to persist within secretory granules in diabetes, and
does not show the same dynamics as glucagon in diabetes, we reasoned that changes in
its intracellular trafficking may be a mechanism of glucagon hypersecretion. In our
previous study, we showed that overexpression of Stmn2 in α-TC1-6 cells suppressed
glucagon secretion by increasing its trafficking through the endolysosomal pathway (20).
Conversely, knockdown of Stmn2 increased glucagon secretion and decreased its
localization in endosomes and lysosomes. In the present study, we explored the dynamics
of glucagon and Stmn2 trafficking in the endolysosomal pathway as a possible
mechanism of glucagon hypersecretion in diabetes.
The endolysosomal system is comprised of lysosomes, late endosomes, early endosomes
and recycling endosomes (53). In the context of dynamic movements of cargos within the
endolysosomal system, late endosome cargos can be transported to the lysosome
(anterograde) or the plasma membrane (retrograde). Retrograde transport can occur in
two ways: 1) to the early endosome, recycling endosome and then the plasma membrane,
or 2) to the Golgi apparatus and through the secretory pathway (54,55). The dramatic
decrease in localization of glucagon and Stmn2 in lysosomes and increased localization
of Stmn2 in the late endosomal compartment, together with Rab7, in diabetes suggest that
glucagon and Stmn2 are re-routed from anterograde transport to the lysosome to
retrograde transport to the late endosome and the secretory pathway. This pathway is
further confirmed by the lack of glucagon and Stmn2 localization in early endosomes and
recycling endosomes, suggesting that retrograde transport from the late endosome
towards the early endosome-recycling endosome is not prominent in α-cells. Therefore,
increased retrograde trafficking of glucagon from the late endosome to the secretory
pathway may be a potential new pathway of glucagon hypersecretion in diabetes.
Although a mechanism has not been investigated in this study, it is possible that Rab7, a
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member of the Rab family of GTPase endosomal trafficking proteins, interacts with the
retromer complex in this retrograde transport in α-cells (56–58). Retrograde transport of
proteins from endosomes to the TGN has been documented for some proteins such as the
acid hydrolase cathespsin D and its sorting receptor, mannose-6-phosphate receptor
(M6PR), transmembrane enzymes and SNAREs (59,60). It has been suggested that Rab7
may act as a master regulator of multiple endosomal processes, functioning in retrograde
transport throughout the process of endosome maturation(61) Our findings showing
higher fluorescence intensity of Rab7 together with increased co-localization with Stmn2
in diabetic α-cells suggests increased recruitment of Stmn2 a potential sorting protein,
into the late endosome to facilitate movement of glucagon towards TGN and secretory
pathway for glucagon hypersecretion.
It is well documented that Rab proteins can impact the regulated secretory pathway
through direct effects on secretory granules. The early endosomal protein Rab5 regulates
homotypic fusion of mast cell secretory granules prior to compound exocytosis (62) and
transports CD63 from early endosomes to secretory granules to promote granule
maturation (63). A more recent study has shown that trafficking proteins from early
endosomes are required for secretory granule maturation in Drosophila larval salivary
gland cells (64). However, our study did not reveal a role for early endosomes in
diabetes-induced glucagon hypersecretion; rather, we suggest that there is a possible role
for late endosomes in the transport of glucagon to the secretory pathway. Interestingly, it
has been found that, in pancreatic β-cells, there is an increase in insulin trafficking to the
lysosome in diabetic ob/ob mice (22), and a very recent study has determined a role for
the Rab7-interacting lysosomal protein RILP in the transport of insulin from secretory
granules to late endosomes and lysosomes for degradation in diabetes (65). Therefore, it
is tempting to speculate that, in diabetes, insulin is directed to lysosomes from granules
for degradation and glucagon is transported from late endosomes to granules for
enhanced secretion via the action of endosomal trafficking proteins.
In conclusion, our findings suggest that Stmn2 as an α-cell protein plays a potential role
in the abnormal intracellular glucagon trafficking in diabetes. We propose that there is a
switch from anterograde transport of glucagon and Stmn2 from endosomes to lysosomes,
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to retrograde transport of glucagon from late endosomes to the secretory pathway. These
findings suggest a potentially novel pathway that could account for the
hyperglucagonemia of diabetes.
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Chapter 5

5. Discussion and Future Directions
5.1 Glucagon interactome in secretory granules of α-cells
and its plasticity
It is well known that under normal physiological conditions, glucagon secretion is
suppressed by high glucose, GABA and insulin (1–5). However, chronic hyperglycemia
disrupts this fine regulation and results in elevated glucagon secretion (6–10). In Chapter
2, my results confirmed that chronic exposure of α-TC1-6 cells to high glucose increases
both glucagon production and secretion. My proteomics findings, together with related
functional studies, reflect a relationship between components of the glucagon interactome
and glucagon secretion from α-cells. Changes in the microenvironmental conditions of αcells alters the protein components of the glucagon interactome, which results in altered
glucagon secretion. Proteomic analysis also revealed that the glucagon interactome
contains two clusters of proteins: a histone core of proteins, previously unknown in αcell granules, and a cytoplasmic cluster of proteins.
The protein components of the cytoplasmic cluster were altered in response to the
paracrine inhibitors of glucagon secretion, GABA and insulin, and also to ambient
glucose levels. These alterations were accompanied by changes in glucagon secretion.
We propose that effects of either insulin or GABA, alone or in combination, on the α-cell
secretory phenotype could be governed through their effects on the glucagon interactome
within secretory granules.
Regarding the plasticity of cytoplasmic proteins within the glucagon interactome in
response to intrinsic or paracrine effectors, our proposed mechanism expands our lab’s
model for sorting proglucagon into the secretory granule via sorting signals (11) and
sorting receptors. To this end, several proteins were projected to have interactions with
glucagon and among them some proteins are predicted to directly interact with glucagon
in response to ambient glucose levels (5.5 mM or 25 mM) and presence of paracrine
208

effectors (GABA, INS or GABA+INS) (Figures 5- 1A-B). The formation of the
glucagon interactome may begin within the immature secretory granule, and based on the
“sorting by retention” theory, immature secretory granules transform into mature
secretory granules. The maturation process is accompanied by protein condensation in the
dense core portions of secretory granules, localization of integral proteins within the
membrane of secretory granule, acidification of granule contents, and removal of some of
their protein contents (12,13). This process could be accompanied by i) forming different
types of secretory granules, which bring about plasticity in secretory granules, and ii)
trafficking some proteins towards degradation machinery or exocytosis pathway.
Currently, there is no published document to show α-cell granule subtypes or glucagon
interactome in islets of animal models or humans to be able to make a matched
comparison. However, in a parallel comparison with secretory granules of β-cells (14),
some proteins of the glucagon interactome are well-known secretory granule proteins
such as carboxypeptidase E, PC2, chromogranin A, secretogranin family, GTP-binding
proteins, VAMP family, and Ras-related proteins of Rab family.
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B

Figure 5-1. Predicted proteins in the first shell of interacting proteins with
glucagon within the glucagon interactome. α-TC1-6 cells were cultured (A) in
25 mM glucose containing medium (HGM); or supplemented with GABA,
insulin (INS) or GABA+INS. (B) α-TC1-6 cells were cultured (A) in 5.5 mM
glucose containing medium (LGM); or supplemented with GABA, insulin
(INS) or GABA+INS.

Figure 5-2. Schematic structure of Stmn2 in comparison with other members
of the stathmin family. Both stathmin-1
(Stmn1) and stathmin-2 (Stmn2)
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contain a “stathmin-like domain” (SLD). This domain includes the following
subdomains: tubulin binding repeats (TBR1 and TBR2), “Proline rich

Treatment with insulin showed recruitment of ChgA into the first shell of the glucagon
interactome (Figure 5- 1B). This finding supports sorting receptor role of ChgA towards
secretory granule biogenesis in α-cells. Actually, special characteristics of ChgA in
terms of its aggregation in low pH, and high Ca2+microenvironment and also in response
to catecholamine makes it a good sorting receptor candidate(15). ChgA is the main
component of the secretory granules in neuroendocrine cells, and pancreatic α and β-cells
(16,17). Depletion of ChgA in neuroendocrine cell line PC12 suppressed secretory
granule biogenesis. In contrast, overexpression of ChgA in neuroendocrine cell line of
6T3 cells and in fibroblastic cell line of CV-1 cells, induced secretory granule biogenesis
(18). It was shown that ablation of ChgA in the mouse model reduced granule size and
number in the chromaffin cells of adrenal medulla (19). Anti-sense vector against ChgA
in the mouse model, reduced secretory granule numbers in the chromaffin cell (20). Our
lab already proposed that chromogranin A plays a potential sorting receptor for glucagon
in both α-TC1-6 cells and PC12 cells (11). Thus, finding potential interaction between
ChgA and Stmn2 could provide a novel protein network as a sorting receptor for granule
biogenesis.
My findings showed that GRP78 (Hspa5) is present in the interactome regardless of
glucose concentrations or presence of paracrine inhibitors, and co-localizes with and
interacts directly with glucagon. Interestingly, its depletion suppressed cell glucagon
content with no effect on glucagon secretion. This pattern reflects two potential roles for
GRP78; i) enhancing glucagon synthesis, and ii) reducing glucagon degradation.
Recently, it was shown that GRP78 is a component of the secretory granule in β-cells
(21), which provides further evidence on presence of GRP78 within secretory granules,
and its potential role in the secretory granule biogenesis, and trafficking. In terms of
interaction between GRP78 and ChgA, it was shown that GRP78 interacted with a ChgAderived peptide (pancreastatin) , which resulted in suppression of GRP78’s ATPase
activity. It was proposed that this interaction results in dysglycemia through increasing
hepatic glycogenolysis (22). However, underlying mechanism of interaction between
GRP78 and ChgA within the secretory granule of α-cells, and its physiological effect or
pathological consequences remain to be elucidated.
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My findings propose that plasticity in secretory granules of α-cells determine which
granules can dock and fuse with the plasma membrane. It was already discussed that
protein components of secretory granules play a vital role in the fusion and exocytosis of
secretory granules (23). To this end, it was shown that some select proteins of secretory
granules could be accelerator (such as Rabphilin3A) or inhibitor (such as Rab3A) for
docking machinery of secretory granules and exocytosis (24,25). In the context of the
pancreatic islet, it is well-known that all secretory granules are not functionally
equivalent. About 10% of the total granule population will dock to the plasma membrane,
and about 10% of those are in readily releasable pool (26,27). Granule properties are
likely governed by other parameters, such as homotypic fusion (28), membrane
composition (29) and composition of cargo proteins within the secretory granule. Since I
found that the granule cargo is remodeled in response to glucose and paracrine effectors,
it’s likely that the membrane components can also be remodeled to govern exocytosis.
The proteomics analysis has also revealed a cluster of histone proteins within the
glucagon interactome. Unlike the plasticity exhibited by the cytoplasmic core, the protein
components of the histone cluster appeared to have small changes in treatment groups.
The discovery of the histone cluster within α-cell secretory granules is novel, and
supported by the finding that the cytosolic fraction in pooled islets from multiple human
donors with 5 mM blood glucose had abundant amounts of the histone H2A (30). In this
respect, we showed the histone H2 as the most abundant histone in secretory granules
regardless of the prevailing glucose levels. We propose that the histone cluster within
secretory granules in α-cells is a conserved part of the glucagon proteome in which small
changes result in a significant effect on the α-cell response to different stimuli. As I have
already discussed, the presence of histone proteins within secretory granules could be an
adaptive mechanism in α-cells for responding to unfavorable microenvironmental
conditions (31–34).
One limitation of the study in Chapter 2 was the use of the murine pancreatic islet cell
line, α-TC1-6, for proteomics and glucagon secretion studies. Importantly, this welldifferentiated cell line keeps normal endocrine properties of α-cells. It was shown that αTC1 derived cell lines (α-TC1, α-TC1-6, α-TC1-9) correctly process proglucagon
213

towards production of matured glucagon and properly respond to stimuli especially in
high glucose condition (35). This cell line has been extensively used by our lab
(11,36,37) and others (38,39) for glucagon secretion studies and uncovering related
molecular aspects. As well, proteomic analysis of this cell line has been used to uncover
druggable targets in α-cells for clinical application (40) and its integrated proteomicsgenomics has been well demonstrated (41). On the other hand, preparing sufficient
amount of purified primary α-cells is a challenging subject, in a way that has been an
obstacle for doing research on α-cells. Thus, this cell line has afforded advantages to
perform molecular studies on several aspects of glucagon in a well-differentiated α-cell
model. However, I acknowledge that using mouse primary islets or human primary islets
would provide conditions closer to normal physiological conditions.

5.2
Stmn2 modulates glucagon secretion through the
endolysosomal system in non-diabetic α-cells
Stathmin-2 is a neuronal protein that possesses a stathmin-like domain (SLD) and an Nterminal extension (Figure 5- 2) (42). The former contains four conserved sites for
phosphorylation and the latter has three subdomains as follows; Golgi-specifying subdomain (n), membrane anchoring subdomain (m) and a variable subdomain (c). Membrane
anchoring is mediated by palmitoylation of two cysteine residues within “m” subdomain.
SLD is a conserved domain, which has four phosphorylation sites and two tubule binding
repeats. As a membrane-associated phosphoprotein it has been mostly found in cell
membranes of Golgi and some vesicles (such as endosomes) in neuronal cells (43–45); a
fact that has been recapitulated in current findings by showing localization of Stmn2 in the
cell membrane and cytoplasmic organelles, Golgi and secretory granules. In terms of
function, it has been shown that Stmn2 has a role in regulation of signal transduction,
microtubule dynamics, and protein transport and secretion (46,47).
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Figure 5-4. Schematic structure of Stmn2 in comparison with other members
of the stathmin family. Both stathmin-1 (Stmn1) and stathmin-2 (Stmn2)
contain a “stathmin-like domain” (SLD). This domain includes the following
subdomains: tubulin binding repeats (TBR1 and TBR2), “Proline rich
domain” (PRD), and N-terminal region of SLD (SLDN). Stmn2 contains an
extra domain of N-terminal extension. This domain includes conserved Golgispecifying subdomain “n”, conserved membrane anchoring subdomain “m”,
and poorly conserved subdomain “c”.

For the first time, my findings show the presence of Stmn2 within the α-cell secretory
Figure 5-5. Rab7 mediates late endosomal cargos towards lysosome (for
granule and its regulatory role in glucagon secretion. Co-presence of glucagon and Stmn2
degradation) or plasma membrane (for secretion). The Figure was extracted
within the secretory granule and their increased secretion in response to stimulation
from reference 48 according to the Creative Commons Attribution License
suggests α-cells use co-secreted secretory granule proteins as a strategy for regulation of
(http://creativecommons.org/Licenses/by/4.0/).Figure 5-6. Schematic structure
glucagon secretion from α-cells. In this respect, co-storage and co-secretion of glucagon
of Stmn2 in comparison with other members of the stathmin family. Both
and glutamate have been shown in α-TC1-6 cells, rat isolated islets and mouse islets
stathmin-1 (Stmn1) and stathmin-2 (Stmn2) contain a “stathmin-like
(23,48,49). It was shown that when α-cells are exposed to low glucose conditions, codomain” (SLD). This domain includes the following subdomains: tubulin
secreted glutamate plays an autocrine role in increasing glucagon secretion from α-cells
binding repeats (TBR1 and TBR2), “Proline rich domain” (PRD), and N(23). In addition, co-storage and co-secretion of glucagon with acetylcholine and a number
terminal region of SLD (SLDN). Stmn2 contains an extra domain of Nof proglucagon-derived factors (such as un-processed proglucagon, proglucagon 1-61 and
terminal extension. This domain includes conserved Golgi-specifying
miniglucagon) have been reported (50–52).
subdomain “n”, conserved membrane anchoring subdomain “m”, and poorly
conserved subdomain
Overexpression
of Stmn2 in“c”.
α-TC1-6 cells suppressed glucagon secretion and its depletion
brought about an increase in glucagon secretion, suggesting that Stmn2 may be a tonic
inhibitor of glucagon secretion. In a parallel study on β-cells, the concept of hormoneprotein co-storage and co-secretion has been already documented for insulin. To this end,
the regulatory role of insulin-interacting proteins [such as transmembrane protein 24
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(TMEM24) carboxypeptidase E or chromogranin A] on insulin secretion has been shown
in INS-1E cells, MIN6 cells and mouse pancreatic β cells (53–55). Furthermore, it was
shown that co-secretion of the co-stored proteins with insulin (53,56)could be a mechanism
to locally regulate insulin secretion from β-cells. For instance, ChgA or its cleaved product,
betagranin,

could inhibit glucose stimulated insulin secretion through binding KATP

channel and keeping it in an opened state, which prevents β-cell depolarization and insulin
secretion (56,57). I acknowledge that I used an immunostaining approach on fixed islets to
study the subcellular status of Stmn2. To this end, making a knock-in of fluorescent
reporter gene for Stmn2 in the mouse islet and its tracking using immunofluorescence
confocal microscopy would uncover more details about role of Stmn2 in glucagon
secretion in both normal and pathological condition.

5.3
Stmn2 plays a role in glucagon hypersecretion
through intracellular glucagon trafficking towards
endolysosomal system in diabetic α-cells
By tracking Stmn2 and glucagon, I have shown degradation of glucagon within the α-cell
and disturbance of this pathway in the diabetic condition. My findings proposed that under
normal physiological conditions, Stmn2 directs glucagon into the endolysosomal system
for degradation; however, in case of diabetes it takes a role in glucagon hypersecretion
from α-cells. To this end my findings propose that 1) there is a basal level of degradation
for glucagon within the endolysosomal system when there are coordinated levels of
glucagon and Stmn2; 2) this basal level of glucagon degradation will be compromised in
diabetes due to discordance between glucagon and Stmn2 levels; 3) the relatively lower
Stmn2 levels reduce trafficking of glucagon and Stmn2 towards lysosome; 4) As a
consequence, the levels of glucagon and Stmn2 within the late endosome will be increased;
5) in addition, there is an increased colocalization of Stmn2 and Rab7 within the late
endosome, and 6) these phenomena direct glucagon towards secretory pathway, which
results in higher glucagon secretion in diabetic α-cells. Thus, it can be proposed that Stmn2
could have a dual role in both the degradation and secretion of glucagon. In this context,
Rab7 may interact with Stmn2 in directing glucagon towards the secretory pathway. Of
note, such a dual role has been already proposed for Rab7 in β-cells (58). It has recently
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been shown that insulin is degraded within the endolysosomal system of β-cells, which is
mediated by interaction of Rab7 with Rab7 interacting lysosomal protein (RILP) (58). In
fact, this finding highlights a previously proposed model for Rab7-mediated late endosome
trafficking, in which Rab7 directs late endosome cargos towards perinuclear lysosomes for
degradation or the plasma membrane for secretion (59,60)(Figure 5- 3).

Late endosome or

Figure 5-7. Rab7 mediates late endosomal cargos towards lysosome (for
degradation) or plasma membrane (for secretion). The Figure was
extracted from reference 60 according to the Creative Commons
Attribution License (http://creativecommons.org/Licenses/by/4.0/).

5.4

Summary

My overall
that there
is a glucagon
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the secretory
Figure findings
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endosomal
re-routing
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and Stmn2
granule
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extracted from reference 48 according to the Creative Commons
Attribution License (http://creativecommons.org/Licenses/by/4.0/).

variability in blood glucose levels. Recruitment of Stmn2 within the interactome occurred
in the presence of glucagon secretion inhibitor, insulin, which was accompanied by
reduced fractional glucagon secretion and cell glucagon content. It seems that Stmn2
should be considered as a regulator of glucagon secretion with bimodality roles, in a
way that 1) directing glucagon towards endolysosomal system for degradation in normal
physiological condition when there is a balanced glucagon: Stmn2 ratio, and 2) mediating
glucagon hypersecretion in diabetic condition when the glucagon:Stmn2 ratio becomes
imbalanced. In this respect, I suggest that coordination of Stmn2 and Rab7 plays a role in
late endosomal re-routing of glucagon from lysosomal degradation towards secretory
pathway (Figure 5- 4). My findings reflect that reduction in Stmn2: glucagon ratio
increases glucagon secretion and an increase in this ratio suppresses glucagon secretion.
In fact, it seems that α-cell contains limiting amounts of Stmn2 in the diabetic condition
due to 1) lack of response in Stmn2 gene expression and Stmn2 synthesis to prevailing
glucose levels and 2) increased secretion of Stmn2 in diabetic condition. Thus, diabetic
hyperglucagonemia may occur through increased trafficking of glucagon to the secretory
pathway and decreased degradation through the lysosomal pathway mediated through an
association between Stmn2 and Rab7 within the late endosome.
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Figure 5-10. Late endosomal re-routing of glucagon and Stmn2 from lysosome
towards secretory pathway in diabetic α-cells. Lysosomal degradation of
glucagon and Stmn2 were suppressed. There is an enhanced Rab7 levels
within the late endosome of diabetic α-cells.

5.5

Future Directions

In my thesis, I revealed a mediating role for Stmn2 in glucagon degradation through the
endolysosomal system and its impairment in the diabetic condition. To further uncover
role of Stmn2 in glucagon hypersecretion from diabetic α-cells the following future
directions will be taken. By generating a transgenic mouse model with knock-out of
Stmn2 in α-cells (for instance, through tissue specific Cre/lox system), and following
glucagon secretion and intracellular glucagon trafficking in α-cells, it would complement
our findings on knock down of Stmn2 in α-TC1-6 cells. In this context, by generating
transgenic mouse model with knock-out of Rab7 in α-cells it would complement our
findings on potential role of Rab7 in glucagon secretion. In addition, by knock- in of a
fluorescent reporter gene for glucagon and inducing diabetes (through STZ injection) in
the abovementioned models it would be an approach to dynamically study role of Stmn2
and Rab7 in glucagon hypersecretion. In all of the abovementioned animal models,
performing glucose tolerance tests would provide more clinically related findings. As
well, generating Stmn2 knock-out in a type 2 diabetic model animal and following
glucagon intracellular tracking, glucagon secretion, and glucose tolerance tests would
extend our knowledge on role of Stmn2 in type 2 diabetes- related glucagon
hypersecretion. In addition, applying these approaches for testing potential role of other
uncovered proteins in my study (ChgA or GRP78; proteins in the first shell of interaction
with glucagon) could potentially introduce more candidate regulators for secretion of
glucagon. As well, one option for all of abovementioned models would be studying
related cell signaling pathways to Stmn2 through electrophysiological studies (patch
clamp studies) on single primary α-cells. This approach would be helpful to find a key
signaling pathway for Stmn2 and targeting its related elements for treatment of diabetes.
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By confirming current findings through these approaches, designing a pharmacological
agonist for Stmn2 would be a long-term goal to effectively reduce glucagon
hypersecretion in α-cells as a potential treatment for hyperglucagonemia of diabetes.
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